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Thesis Summary 
 
Oral drug delivery is considered the most popular route of delivery because of the ease of 
administration, availability of a wide range of dosage forms and the large surface area for drug 
absorption via the intestinal membrane. However, besides the unfavourable 
biopharmaceutical properties of the therapeutic agents, efflux transporters such as P-
glycoprotein (P-gp) and multiple resistance proteins (MRP) decrease the overall drug uptake by 
extruding the drug from the cells. Although, prodrugs have been investigated to improve drug 
partitioning by masking the polar groups covalently with pre-moieties promoting increased 
uptake, they present significant challenges including reduced solubility and increased toxicity.   
 
The current work investigates the use of amino acids as ion-pairs for three model drugs: 
indomethacin (weak acid), trimethoprim (weak base) and ciprofloxacin (zwitter ion) in an 
attempt to improve both solubility and uptake. Solubility was studied by salt formation while 
creating new routes for uptake across the membranes via amino acids transporter proteins or 
dipeptidyl transporters was the rationale to enhance absorption. New salts were prepared for 
the model drugs and the oppositely charged amino acids by freeze drying and they were 
characterised using FTIR, 1HNMR, DSC, SEM, pH solubility profile, solubility and dissolution. 
Permeability profiles were assessed using an in vitro cell based method; Caco-2 cells and the 
genetic changes occurring across the transporter genes and various pathways involved in the 
cellular activities were studied using DNA microarrays. 
 
Solubility data showed a significant increase in drug solubility upon preparing the new salts 
with the oppositely charged counter ions (ciprofloxacin glutamate salt exhibiting 2.9x103 fold 
enhancement when compared to the free drug). Moreover, permeability studies showed a 3 
fold increase in trimethoprim and indomethacin permeabilities upon ion-pairing with amino 
acids and more than 10 fold when the zwitter ionic drug was paired with glutamic acid. 
Microarray data revealed that trimethoprim was absorbed actively via OCTN1 transporters 
while MRP7 is the main transporter gene that mediates its efflux. The absorption of 
trimethoprim from trimethoprim glutamic acid ion-paired formulations was affected by the 
ratio of glutamic acid in the formulation which was inversely proportional to the degree of 
expression of OCTN1. Interestingly, ciprofloxacin glutamic acid ion-pairs were found to 
decrease the up-regulation of ciprofloxacin efflux proteins (P-gp and MRP4) and over-express 
two solute carrier transporters; (PEPT2 and SLCO1A2) suggesting that a high aqueous binding 
constant (K11aq) enables the ion-paired formulations to be absorbed as one entity. 
 
In conclusion, formation of ion-pairs with amino acids can influence in a positive way solubility, 
transfer and gene expression effects of drugs. 
 
Key words: Oral drug delivery, solubility, permeability, efflux transporters, ion-pairs, 
microarrays. 
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Abbreviation list  
IND Indomethacin  
TMP Trimethoprim 
CIP Ciprofloxacin 
An Absorption number  
Dn Low dissolution number  
APIs Active pharmaceutical agents  
GIT  Gastro Intestinal Tract  
Py Yield pressure  
pKa Dissociation constant 
ATP Adenosine triphosphate  
HUGO Human Genome Organisation  
ABC ATP-binding cassette  
SLC Solute carrier transporters  
P-gp P-glycoprotein  
NBD Nucleoside-binding domains  
MRP Multi-drug resistance associated protein 
ABCP/ ABCG2 Placenta specific ABC transporter  
LAT L-type amino acid transporter 
BCCT Betaine/Carnitine/Choline transporter 
AGCS Alanine/Glycine/Cation symporter 
PEG 400 Polyethylene glycol  
TEER Transepithelial electrical resistance  
ADMET Absorption, distribution, metabolism, excretion and 
toxicity  
SNP Single nucleotide polymorphism  
CGH Comparative genomic hybridization  
TMA Tissue microarrays 
D2O Deuterated water  
TGA Thermogravimetric analysis  
FT-IR Fourier Transform infra-red spectroscopy  
DCPD   Dicalcium phosphate dehydrate 
Fc          Crushing force 
ε            Porosity 
ρd           Bulk density 
ρt          True density 
σo                Zero porosity 
VMD     Volume median diameter 
Y          Yield strength 
PY         Yield pressure 
g  Gram  
HCl  Hydrochloric Acid  
HPLC  High Performance Liquid Chromatography  
hr  Hour  
kV  Kilovolt  
L  Litre  
log  Logarithm  
mA  Milliampere  
min  Minutes  
mg  Milligram  
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μg  Microgram  
Kg  Kilogram  
ANOVA  Analysis of variance  
DoE  Design of experiment  
DSC  Differential scanning calorimetry  
FDA  Food and Drug Administration  
PM        Phyical mixture between the drug and amino acid 
SM Salt mixture between the salt form of the drug and 
amino acid 
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1.1. Introduction 
Oral drug administration is considered the most popular route of delivery (Fig. 1.1.1) due to 
various factors including ease of administration, availability of large surface area for drug 
absorption and the wide range of dosage forms that can be designed to deliver active 
pharmaceutical ingredient/s  (Sastry, et al., 2000). Despite the several advantages, 
physiological barriers such as degradation in the acidic environment of the stomach, presence 
of luminal digestive enzymes and most importantly the biopharmaceutical properties of the 
drug molecule limit oral drug bioavailability (Hunter & Hirst, 1997). Biopharmaceutical 
properties have gained significant attention after the introduction of high throughput drug 
discovery programmes which generate large numbers of new chemical entities (NCE) with 
unfavourable properties primarily due to the use of lipophilic screens in generating lead 
candidates. Therefore, improving biopharmaceutical properties and developing new methods 
to accurately predict these properties have gained considerable attention within the 
pharmaceutical industry. 
 
 
 
 
 
 
 
Figure 1.1.8:- Contribution of various routes of administration in UK market (Aulton, M. E. 2002) 
 
1.2. Biopharmaceutical classification system 
Amidon et al. (1995)  recognised that the rate and extent of oral bioavailability is controlled by 
aqueous solubility and gastro-intestinal permeability which led to the development of  a 
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Biopharmaceutical Classification System (BCS) that categorizes all the drugs into four classes 
according to their permeability and solubility profile (table 1.1.1). 
 
In 2000, the BCS system was accepted by the FDA as a scientific model to waive the in vivo 
bioequivalence and bioavailability testing for class 1 drugs that exhibit rapid dissolution and 
permeability (FDA guidelines). The main objective of BCS is to predict in vivo pharmacokinetics 
of drugs by measuring permeability and solubility characteristics. According to the BCS, a 
highly soluble drug is a substance which at its highest dose strength is soluble in 250 mL or less 
of aqueous media over a pH range of 1-7.5 at 37 oC  while a highly permeable drug is a 
substance which exhibits an absorption profile of ≥ 90% of the total administered dose. 
 
Class I (high solubility/high permeability drugs): drugs in this class dissolve rapidly when 
administered and are transported rapidly across the gastrointestinal membrane. The rate 
limiting step to drug absorption is the drug dissolution or the gastric emptying rate (when the 
dissolution is very fast). 
Class II (low solubility/ high permeability drugs): drugs in this class are characterised by a high 
absorption number (An) and low dissolution number (Dn) and in-vivo drug dissolution is the 
rate limiting step. As the intestinal membrane and intestinal luminal contents vary along the 
intestine, the dissolution profile must be determined at 4-6 time points and at different 
physiological pH’s. Examples of class II drugs include griseofulvin, indomethacin and ibuprofen 
(Wu & Benet, 2005).  
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Figure 1.1.9:-  Classification of marked drugs and NCEs according to the Biopharmaceutical 
classification system (BCS) Aulton (2002). 
 
Class III (high solubility/low permeability drugs);  permeability is the rate limiting step in drug 
absorption. Therefore, it is important for class III drugs to be released rapidly from their 
formulations in order to maximise the residence time in the gastro-intestinal tract thereby 
improving their permeability. 
Class IV (low solubility/low permeability); drugs in this class are characterised by poor 
permeability and poor solubility and as a result have very poor oral bioavailability. Use of a 
prodrug is a common approach to overcome this problem. 
Table 1.1.12:- Biopharmaceutical classification system substrates adapted from Wu & Benet, (2005) 
 High solubility Low solubility 
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Class 1 
Acyclovir 
Amiloride S,I 
Amitryptyline S,I 
chloroquine S,I 
Diltiazem S,I 
Fluoxetine I 
Verpamil I 
 
Imipramine I 
Levofloxacin S 
Levodopa S 
Midazolam S,I 
Nifedipine S 
Quiniidine S,I 
Class 2 
Azithromycin S,I 
Carbamazepine S,I 
Ciprofloxacin S 
Cyclosporine S,I 
Indinavir S 
Indomethacin 
 
Erythromycin S,I 
Talinolol S 
Spiranolactone I 
Ketoconazole I 
Digoxin S 
Cisapride S 
Lo
w
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Class 3 
Acyclovir 
Amoxicillin S,I 
Atenolol 
Cimetidine S 
Cloxacillin 
Famotidine 
Folinic acid 
 
 
 
Penicillins 
Methotrexate 
Trimethoprim S 
Metoformin 
Pravastatin 
Tetracyclin 
 
Class 4 
Amphotercin B 
Colistin 
Ciprofloxacin S 
Hydrochlorothiazide 
Mebendazole 
Neomycin 
 
 
Methotrexate 
Furosamide 
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1.3. Factors affecting oral drug delivery 
1.3.1. Physiological factors in the gastrointestinal tract that affect drug bioavailability 
 
Gastrointestinal tract (GIT) physiology has a major effect on the bioavailability of active 
pharmaceutical ingredients (APIs). Physiological factors such as surface area, pH, gastric 
emptying rate, gastric motility and food are among the major factors influencing the rate and 
extent of drug bioavailability. 
The surface area available for oral drug absorption varies along the gastrointestinal tract as 
shown in table (1.1.2). The small intestine is composed of three regions: duodenum, jejunum 
and ileum which posses the largest surface area for absorption. Therefore, the majority of oral 
absorption occurs in the small intestine. On the other hand, the small surface area of the 
stomach and colon limits the absorption in these organs. 
 
Table 1.1.13:- Comparison of various physiological factors of the different regions of the 
gastrointestinal tract, which can affect the absorption of active drug ingredients. Adapted from 
Washington et al. 2001. 
Section Length  (m) Surface Area 
(m
2
) 
pH Residence Time 
Oesophagus 0.3 0.02 6.8 >30 seconds 
Stomach 0.2 0.2 1.8-2.5 1-5 hours 
Duodenum 0.3 0.02 5-6.5 >5 minutes 
Jejunum 3 100 6.9 1-2 hours 
Ileum 4 100 7.6 2-3 hours 
Colon 1.5 3 5.5-7.8 15-48 hours 
 
Another factor that influences oral bioavailability is the gastrointestinal pH. The pH of the 
gastrointestinal fluid varies from one region to another (between 1.8-7.8) along the GIT. 
Stomach has the most acidic environment (pH 1.8-2.5) because of the high concentration of 
hydrochloric acid secreted from the parietal cells of the stomach (Widmaier et al., 2011). The 
secretion of bicarbonate increases down the gastrointestinal tract and neutralizes the effect of 
hydrochloric acid and hence more alkaline conditions are observed along the small and large 
intestine (Aulton, 2002). pH influences ionisation and chemical stability of the therapeutic 
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agent depending on the acidity and basicity of the surrounding environment in the GIT (Aulton, 
2002). The rate at which an API leaves the stomach and reaches the duodenum is called the 
gastric emptying rate. As the small intestine is the major site for oral drug absorption, reducing 
the rate of gastric emptying will delay the availability of the active drug at the absorption site 
which in turn will delay the onset of therapeutic effect. Besides, the dosage forms are believed 
to affect the rate of gastric emptying as for instance solid dosage forms have a pronounced 
influence when compared to the aqueous solutions (Gidal, 2006). 
 
Intestinal motility is another physiological factor that affects drug bioavailability as it controls 
the residence time in the small intestine. Propulsive and mixing movements are the two types 
of motions encountered along the gastrointestinal tract. The propulsive movement is 
responsible for moving the materials through the GIT with slower propulsive movement 
increasing residence time in the small intestine. Mixing movements have a profound role in 
the fed state as it enables mixing the different food components which affect the residence 
time in the GIT and the dissolution rate of the drugs from solid dosage forms (Aulton, 2002). 
 
Food has a direct and indirect effect on oral absorption and bioavailability of active 
pharmaceutical agents. Food consumption could reduce the gastric emptying rate and in turn 
delay drug uptake. Food also could stimulate the secretion of gastric fluids and enzymes which 
might degrade certain active ingredients. Moreover, dietary components might complex with 
the active drug to form a resultant bigger complex with reduced absorption characteristics 
leading to decrease in bioavailability. For instance tetracycline antibiotics form a non-
absorbable complex with calcium (found in dairy products) which requires patient counseling 
to prevent reduced drug efficacy (Aulton, 2002). Similarly, the viscosity of gastrointestinal 
contents increases after food consumption which reduces drug dissolution and decreases oral 
bioavailability. 
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1.3.2. Effect of dosage form on drug bioavailability  
The pharmaceutical dosage form and its method of manufacture may have an impact on oral 
bioavailability of the therapeutic agents.  Maximum bioavailability is exhibited by aqueous 
dosage forms as the active pharmaceutical ingredients (APIs) are available in solution and 
ready for absorption into the systemic circulation. Nevertheless, it is not possible to formulate 
most APIs as oral solutions because of stability related issues and inherent properties of the 
drugs which affect their aqueous solubility. 
Aqueous suspensions are placed in the second position after solutions.  High bioavailability is 
achieved due to the larger surface area of drug presented to the gastrointestinal fluid which 
provides the necessary conditions for drug dissolution and absorption into the systemic 
circulation. There are various factors which affect drug release from aqueous suspensions 
including the crystalline form of the drug, particle size and effective surface area of the 
suspended drug particles, viscosity of the suspension in the gastrointestinal fluid and the 
inclusion of any surfactants (Aulton, 2002). 
 
Hard gelatin capsules are rated below suspensions and are a suitable delivery system for 
poorly soluble API as they provide large effective surface area for the drug in the 
gastrointestinal fluid. Hydrophilic diluents such as lactose are added into hard gelatin capsules 
in order to enhance dissolution of API. Other factors such as the nature and quantity of the 
diluents, surfactants or any added lubricants also determine the bioavailability of the drug. 
 
Among the dosage forms listed above, tablets are rated at the bottom of the table. 
Compression of the API with various pharmaceutical excipients into tablets results in a 
significant reduction in effective surface area of an active drug ingredient due to the 
manufacturing process. The reduction in the effective surface area has a negative impact on 
drug bioavailability as it becomes more difficult to produce a suspension of fine drug particles 
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from the compressed form. Before active ingredients undergo dissolution and become 
available for absorption from tablets, they undergo disintegration to form aggregates or 
granules followed by deaggregation to form suspension of drug particles. Tablet excipients and 
the manufacturing cycle have a significant impact on drug release from compressed 
formulations and affect bioavailability of the drug. 
 
Despite providing less bioavailability when compared against aqueous solution, suspensions 
and hard capsule dosage forms, tablets have achieved tremendous success since their 
introduction because of the various advantages they provide. Tablets can be easily handled, 
manufactured by various methods, produced at low cost, have more enhanced chemical, 
mechanical and microbiological stability than liquid formulations and can be modified to 
provide differing dissolution profiles. 
 
The tablet manufacturing cycle usually includes weighing, milling, granulation, blending, 
lubrication and compression. Direct compression is considered the simplest process in tablet 
manufacture as it requires no heat or moisture. However, the physical properties of the active 
ingredient and pharmaceutical excipients such as compactibility limit the use of direct 
compression especially for drugs of low potency where a high dose is required 
 
1.3.2.1. Excipients used in tablet manufacture 
Tablets contain a mixture of various excipients in addition to the active pharmaceutical 
ingredients (API). The inclusion of various excipients ensures the success of the tablet 
manufacturing process and the quality of the final product. Therefore, appropriate selection of 
the excipients including accurate concentrations is critical in the tableting process. Most 
commonly used excipients include fillers (diluents), binders, lubricants, glidants, disintegrants, 
colorants and flavouring modifiers. 
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1.3.2.1.1 Diluents 
Diluents/fillers are usually added into the tablet mix to bulk up the formulation for processing 
and handling. The diluents should have an acceptable taste, be chemically inert and non 
hygroscopic (Aulton, 2002). Lactose, sucrose, microcrystalline cellulose and glucose are among 
the commonly used diluents. Various grades of these fillers are commercially available and 
each grade has its characteristic physical properties which can be exploited depending on the 
requirements of the finished dosage form. For instance, fine grades of lactose are used for 
milling and wet granulation as they enhance the performance of milled excipients (Aulton,  
2002).  Lactose is widely used as a tablet filler because of its pleasant taste, its ability to 
dissolve readily in water and good compactability properties. It is available in both amorphous 
and crystalline form and the former is prepared by spray drying while the latter by 
precipitation.  
Microcrystalline cellulose, also known as Avicel is a widely used filler. Avicel is a depolymerised 
cellulose prepared by treating cellulose with mineral acids. Besides, being used as filler, it is 
used as a binder and disintegrant in tablet manufacture (Aulton,  2002). 
 
1.3.2.1.2. Binder 
In order to improve cohesive and adhesive forces between different ingredients within the 
powder mixture and to ensure the formulation of an intact tablet, a binder (adhesive) is added 
to the formulation mixture. The binder should be able to cohere various excipients without 
impairing the disintegration and dissolution properties of the tablets. Sucrose, gelatine and 
starch are the most commonly used binders in the concentration range between 2- 10% w/w 
(Aulton, 2002). 
1.3.2.1.3. Disintegrants 
A disintegrant is usually added to tablets to overcome the impaired cohesion during the 
compression process and in turn facilitate tablet disintegration. Disintegration takes place in 
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two stages; during the first step the liquid wets the solid surface of the tablet and penetrates 
through the tablet pores, which results in the second phase of tablet disaggregation. Various 
mechanisms of disintegration have been proposed including wicking, enhanced wettability and 
swelling (Alderborn, 2002). 
 
1.3.2.1.4. Lubricants 
High friction between the tablet and die wall emerges as a result of the high compression force 
applied during tablet compaction. This high friction results in a series of problems such as 
capping and even tablet fragmentation. Incorporation of a lubricant in the tablet mix forms an 
intermediate film of low shear strength between the die wall and the tablet interface which 
facilitates tablet ejection and reduces tablet deformation (Alderborn , 2002). 
Magnesium stearate is the most widely used lubricant at a concentration range between 0.25- 
0.5% and sometimes up to 1%. Nevertheless, using lubricants can have negative effects on 
tablet manufacture. Lubricants can interfere with the bonding properties of the binder which 
could impair tablet hardness. Moreover, the majority of the used lubricants are hydrophobic in 
nature, thus they retard tablet disintegration and dissolution.  
 
1.3.2.1.5. Glidants 
Glidants may be required in tablet manufacture especially when high production speed is 
employed. Glidants are fine particles which are mixed with the powder in the dry state before 
compression. Collidal silica, talc and starch are examples of the glidants. 
 
 
1.3.2.2. Tablet characterisation 
Directly compressed tablets are prepared by applying high pressure onto a bed of powder 
which results in the formation of new bonds between particles or granules forming a coherent 
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compact. Both the manufacturing process and the properties of used materials affect the 
characteristics of the resultant tablets e.g. disintegration time, mechanical strength and drug 
release profile.  
 
1.3.2.3. Tablet preparation 
During powder compression, the bulk volume of the powder decreases as the air between the 
particles is displaced. Reduction in the amount of air enables the particles to get closer to each 
other and promotes bond formation by an exothermic process (Rowling et al., 1995; Coherin 
Beach and Hollenbelk, 1985). 
 
Joiris et al. (1998) presented insights into the commonly applied terminology in tablet 
preparation. Compressibility was defined as the ability of the material to undergo a volume 
reduction upon exposure to pressure. Plotting tablet porosity against compaction pressure 
produces a compressibility profile of the material. Similarly, compactability describes the 
entire process, and was defined as the ability of material to produce tablets with sufficient 
hardness after densification. Compactability can be represented by plotting tablet tensile 
strength against porosity. Finally, the ability of materials to form a tablet of specified 
mechanical strength under the effect of compaction force was known as tabletability. 
 
When compressing a powder bed at low compaction pressure, the particles rearrange 
themselves to form a closely packed structure. As the compression pressure increases further, 
the particles fail to undergo further rearrangement and volume reduction is achieved by elastic 
and plastic deformation or fragmentation of the particles (Train, 1956; Duberg & Nystrom, 
1986). 
Plastic deformation results in permanent change of particle shape as it is an irreversible 
process, while elastic deformation is a reversible process and particles can resume their 
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original shape. Brittle particles which cannot undergo plastic or elastic deformation break 
down into smaller units (fragmentation).  
 
 
 
 
 
 
 
 
Figure 1.1.10:- Diagram showing various types of deformation occurring during powder compaction. 
 
 
Both mechanical properties and mechanism of volume reduction affect the degree of volume 
reduction. For instance, brittle particles which fragment extensively produce tablets with high 
porosity as it creates more bonding points which prevent further volume reduction. However, 
ductile materials produce tablets with relatively low porosity as a high degree of plasticity 
enables particles to move close to each other and results in less a porous structure. 
 
To describe the volume reduction behaviour of a powder, various mathematical equations 
were developed including the Heckel, Kawakita and Cooper-Eaton equations. These equations 
evaluate the effect of applied pressure on the porosity changes of the tablets. 
The Heckel analysis (Heckel, 1961a; Heckel, 1961b) is considered one of the most valuable 
methods to describe powder behaviour during compaction.  In the Heckel equation, the 
material constant K measures material plasticity and can be calculated from the slope of the 
linear portion of Heckel plot. The reciprocal of the material constant is known as the yield 
Elastic  
deformation 
Plastic  
deformation 
Fragmentation 
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compression 
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compression 
After 
compression 
 41
pressure (Py). Initial filling of the die and rearrangements of the particles are represented by 
constant A. 
 
AKPD +=− ))1/(1ln(  
Where D is the tablet relative density at pressure P, K is a material constant 
 
Two methods can be used for Heckel analysis; the in-die and out-of-die method. For the in-die 
method (at-pressure) the relative density is calculated at the applied load. Despite being 
suitable for materials that have difficulties in forming intact compacts (due to capping), the 
elastic deformation affects the K values and hence the Py value is the apparent mean yield 
pressure. 
The out-of-die method (zero-pressure) measures the relative density after tablet ejection from 
the die. Therefore, materials are pressed at different compression forces to construct a plot 
between D and P. The only drawback for the out-of-die method is the laborious and time 
consuming experimental set up (York, 1979; Duberg & Nystrom, 1986). 
 
1.3.2.4. Bonding mechanisms 
The five main types of bonding mechanisms include formation of solid bridges, bonding due to 
movable liquids, non-freely movable binder bridges, shape-related bonding and attraction 
between solid particles. During powder compaction, it is believed that the bonding is restricted 
to formation of solid bridges, intermolecular forces and shape related bonding (mechanical 
interlocking) (Alderborn, 2002). 
Solid bridges are formed in materials with mobility in the contact area. The movement is either 
due to the dissolved state under the effect of multi molecular solvent sorption layer or from 
the fused state under the effect of heat. The strength of the formed solid bridges depends on 
the internal strength of the particles and separation of the resultant aggregates is irreversible. 
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On the other hand, mechanical interlocking occurs when materials are able to hook and twist 
together. This kind of bonding depends on the shape and surface features of the particles and 
is predominant in needle shaped fibres and irregular particles that have a higher tendency to 
twist and hook during compaction.  
 
1.3.3 Effect biopharmaceutical drug properties on oral bioavailability 
Biopharmaceutical properties such as aqueous solubility and drug permeability across the 
intestinal membrane are believed to be the main determinants of oral drug bioavailability. 
 
1.3.3.1 Solubility 
Both aqueous solubility and dissolution are important factors which affect bioavailability as 
insoluble drug candidates which show poor solubility during their transit of the GIT are 
eliminated without entering the systemic circulation (Aungst, 1993). Currently, there is a 
general consensus in the pharmaceutical industry that the majority of new drug candidates are 
poorly water soluble (Lipinski et al., 1997; Lipinski, 2000) with intrinsic solubility values of less 
than 1 μg/mL (Li et al., 2005). Various physical techniques such as particle size reduction, 
complexation with cyclodextrins or surfactants and dispersing a drug into a carrier have been 
adapted in order to improve drug solubility. Chemically modified drugs (salts and prodrugs) 
have also been shown to enhance solubility. 
1.3.3.1.1 Physical modification to improve drug solubility. 
Many studies have demonstrated that particle size reduction can increase the rate of 
dissolution and oral bioavailability of poorly soluble drugs such as progesterone (Hargrove et 
al., 1989), estradiol and estrone (Englund and Johansson, 1981), oxfendazole (Shastri et al., 
1980) proquazone (Nimmerfall and Rosenthaler, 1980) and nitrofurantoin (Watari et al., 1983). 
Size reduction results in increasing the specific surface area and consequently the dissolution 
rate (Noyes and Whitney, 1897). However, agglomeration could take place upon milling 
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especially with hydrophobic drugs such as aspirin and phenobarbitone. The formed aggregates 
decrease the effective surface area and reduce the bioavailability. Ball milling, micronization 
(using impact mills and fluid energy mills) and spray drying are commonly used techniques in 
size reduction. 
Solid dispersion formation is another technique for improving drug solubility. The first 
generation of solid dispersion was first described in the early sixties by Sekiguchi & Obi (1961) 
when it was observed that formation of eutectic mixtures improved drug bioavailability by 
reducing the drug particle size and improving its wettability in the eutectic mixture. This was 
followed by the application of urea as a water soluble carrier for poorly soluble drugs such as 
chloramphenicol (Sekiguchi & Obi, 1964) and sulfathiazole (Sekiguchi & Obi, 1961). In the mid 
sixties, Goldberg et al., (1966) demonstrated that crystalline carriers such as mannitol and 
crystalline sugars release the drug as microcrystals which possess higher solubility. 
Studies conducted by Simonelli et al., (1969); Chiou & Riegelman (1969) found that solid 
dispersions using crystalline carriers are thermodynamically stable and less effective. 
Therefore, the use of new amorphous carriers such as polymers was investigated and was later 
referred to as second generation solid dispersions. Synthetic polymer carriers such as 
povidone, polyethyleneglycol or natural polymers such as cellulose derivatives (Vasconecelos 
et al., 2007) were investigated in the formation of solid dispersion compacts (Van Drooge et 
al., 2006). 
Recently, it has been suggested that inclusion of carriers with surface activity or self 
emulsifying properties could have a greater impact on the dissolution profile of poorly soluble 
drugs. Consequently, the third generation of solid dispersions were formulated which included 
surfactants like intutec SPI and inulin (Van Drooge et al., 2006).  
Inclusion complexes (host-guest complexes) were found to exert a profound effect on the 
physicochemical properties of their guest molecules since the guest molecules are caged and 
locked inside the host cavity. These properties include; taste masking, controlled drug release, 
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control of sublimation and volatility, stabilization of labile guest and importantly enhancing the 
solubility of highly insoluble guests (Del Valle, 2004). Cyclodextrins are commonly used as 
hosts due to their ability to form inclusion complexes with a wide range of guest molecules 
including gaseous, liquid and solid compounds. Cyclodextrins are cyclic oligosaccharides 
consisting of eight, seven and six α (1, 4) linked glycosyl units to form α, β, γ-cyclodextrins 
respectively. There are two key factors which determine the ability of cyclodextrins to form 
the inclusion complex; steric factors which depend on the relative size of guest molecules or 
functional groups within the guest molecules and secondly, the thermodynamic interaction 
between the  different components (cyclodextrin, solvent, guest) (Del Valle, 2004). 
1.3.3.1.2. Chemical modifications to improve drug solubility 
Various approaches have been investigated to improve drug properties without altering 
therapeutic activity. Chemical based approaches which work on the principle of drug 
derivatization were very effective in improving drug efficacy. A commonly used chemical 
approach which utilises reversible derivatives is the synthesis of a prodrug. Prodrugs 
(proagents) were first discussed by Albert in the late 1950s and the technique gained 
significant attention in 1975 as a tool to optimise and enhance the clinical application of drugs 
(Amidon, 2000). The theory behind prodrug synthesis is based on the addition of a functional 
group on to the structure of the poorly water soluble drug to enhance its solubility. This 
functional group is modified chemically or enzymatically in-vivo to release the parent drug.  A 
commonly used functional moiety is a phosphate group by linking directly or through a linker 
to the parent drug (Stella, 1996). The main advantage of using a phosphate group is its good 
chemical stability and rapid quantitative in-vivo cleavage by alkaline phosphatase (Burstein et 
al., 1999). Stella et al., (2005) utilised phosphate group to prepare a phosphoryloxymethyl 
ether prodrug of propofol (general anaesthesia) which is believed to be pain free and avoids 
any hyperlipidemia problems when prepared in a purely aqueous vehicle. The Hemi-succinate 
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group is another promoiety which was used to prepare prodrugs of chloroamphenicol, 
prednisone and methylprednisone (Kauffman et al., 1981).  
 
During the last few decades amino acids have been investigated widely as promoieties to 
improve the aqueous solubility of poorly soluble amine and alcohol based drugs (Kovach et al., 
1975; Amidon et al., 1980; Aggarwal et al., 1990; Upshall et al., 1990). In 1995 Pochopin et al., 
investigated the solubility and stability of dapsone upon conjugation with alanine, lysine, 
leucine, glycine and phenylalanine. The study concluded that all the amino acid prodrugs 
showed at least a 2 fold increase in solubility. The lysine prodrug exhibited the highest 
solubility (greater than 65 mg/mL) which was attributed to its γ–amine which becomes 
protonated at physiological pH (Pochopin et al., 1995). Another successful study was carried 
out by Hatchinson et al., (2002) which included conjugating benzothiazoles with lysine and 
alanine that converts the highly lipophilic benzothiazoles into water soluble prodrugs. 
 
1.3.3.1.2.1. Salt formation 
As discussed above, most of the NCE’s possess poor mechanical and physicochemical 
properties which present significant formulation challenges (Forbes et al, 1995). Salt formation 
is considered a potential solution to optimise properties for drug candidates which have 
ionisable groups. Both the physicochemical characteristics and biological performance of the 
drug differ considerably for the salt form when compared to the free drug (Bighley et al., 
1996). However, the selection of counter ions (salt forming ions) is carried out empirically 
based on a range of criteria including ease of crystallization, percentage yield, hygroscopicity 
and flowability (Berge et al., 1977). 
Many studies have investigated the relationship between salt properties and the counter ions 
used. Yet, to date no successful predictive tool for estimating the effect of the salt former on 
the behaviour of the parent compound has been reported. Stahl & Wermuth, (2002) suggested 
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that the dissociation constant (pKa) is the most important property of the drug that influences 
salt formation and the selection of the counter ion is based on the difference in pKa between 
the parent molecule and the counter ion (minimum difference between the salt former and 
counter ion should be 3 pKa units).  
Salt formers are divided into different categories according to their functionality and purpose. 
Table 1.1.3 summarises some of the commonly used potential salt formers. 
Table 1.1.14:- Classification of common pharmaceutical salts (adapted from Bastin et al., 2000). 
Salt class examples 
 Anions 
inorganic acids hydrochloride, hydrobromide, sulfate, nitrate, 
phosphate 
sulfonic acids mesylate, esylate, isethionate tosylate, napsylate, 
besylateg 
carboxylic acids acetate, propionate, maleate, benzoate, salicylate, 
fumarate 
anionic amino acids      glutamate, aspartate 
hydroxyacids Citrate, lactate, succinate, tartrate, glycollate 
fatty acids       hexanoate, octanoate, decanoate, oleate, stearate 
insoluble salts     pamoate (embonate), polystyrene sulfonate 
(resinate) 
 Cations 
organic amines      triethylamine, ethanolamine, triethanolamine, 
meglumine, ethylenediamine, choline 
insoluble salts     procaine, benzathine 
metallic sodium, potassium, calcium, magnesium, zinc 
cationic amino acids      arginine, lysine, histidine 
 
Hydrochloride is one of the popular salt formers used for weakly basic drugs because of its low 
pKa value. However, hydrochloride salts could salt out and in turn reduce the optimal 
solubility, causing high acidity in the formulations and greater corrosion risk (Bastin et al., 
2000). Due to the limitation on the use of inorganic ions, alternative counter ions have been 
explored lately. Pellegate, (1993) investigated lysine, ornithine and arginine to prepare novel 
salts of furosemide. The prepared salts exhibited very high solubility up to 560 mg/mL for the 
lysinate salt which was much higher than furosemide itself and even its sodium counterpart. In 
another study, L-arginine was used to solubilise ionosine and lysine was tested for salt 
formation with ibuprofen (Tung et al., 1991) 
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1.3.3.2. Permeability 
Oral drug bioavailability is an important parameter for new drug candidates under the drug 
discovery investigation programme. Once the new drug candidate is identified based on its 
pharmacological response, the following critical stage is to investigate its in vitro permeability. 
Further development is unlikely to take place if the drug is found to have poor permeability or 
absorption and as a result a great deal of interest is dedicated to study and enhance drug 
permeability (Egan and Lauri., 2002). 
 
1.3.3.2.1. Anatomy and physiology of the small intestine. 
The human small intestine ranges between 2-6 m in length and is divided mainly into three 
parts; duodenum, jejunum and ileum. Around 90% of the gastrointestinal tract absorption 
takes place in the small intestine. The intestinal surface has a unique structure which makes it 
suitable for absorption. The surface is covered by villi and microvilli which increase the 
intestinal surface area by 30 and 600 fold respectively (Balimane, et al., 2000). 
The main role of the small intestine is to serve as a site of absorption for nutrients. It also 
works as a barrier which prevents the entry of any foreign substance or digestive enzymes. The 
absorptive cells or enterocytes are the most common epithelial cells which are differentiated 
into apical and basolateral membrane and separated by tight junctions (Balimane, et al., 2000). 
1.3.3.2.2. Mechanisms and transport routes of drug absorption in the gastrointestinal tract        
 
After the drug enters into the solution form that is suitable for absorption across the 
gastrointestinal membrane, a number of transport routes are available for drug permeation 
from the apical to the basolateral side. The major routes of drug uptake include transcellular, 
paracellular, efflux and metabolism based drug absorption as illustrated in Figure 1.1.4. 
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Figure 1.1.11:- Structure of intestinal wall showing the various mechanisms of oral absorption, 
adapted from Hamalain & Frostell-Karlsson, (2004). 
 
The majority of the therapeutic agents are absorbed through the transcellular route by passive 
diffusion through the lipid membranes of the intestinal mucosa. Drug molecules with smaller 
molecular mass (<500 Daltons) capable of forming hydrogen bonds and exhibiting high 
lipophilicity move from regions of high concentration to lower concentration i.e. down the 
concentration gradient before entering into the blood circulation.  
 
Another known passive diffusion mechanism for drug uptake is through the paracellular route. 
Drug candidates reach the basolateral side by travelling through the water filled pores 
between the tight junctions of the adjacent epithelial cells. Molecules transported via this 
route should be polar with a molecular weight less than 250g/mol (Dressman et al., 2010). 
Drugs can also be transported against their concentration gradient via a transporter route 
known as active transport. Adenosine triphosphate (ATP) provides the energy required for 
absorption by the active transporters  which involves binding of the drug with the carrier that 
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results in conformational changes in the cellular membrane and helps in the transport of the 
drug into cell lumen (Dressman et al., 2010). 
Large drug molecules such as antibodies, hormones and proteins which cannot bind to 
transporter carriers or enter the cells via transcellular or paracellular routes get absorbed via 
endocytosis. The drug molecule is enclosed by the lipid membrane on the apical side to form a 
vesicle which travels across the cell and exits by fusing with the lipid membrane on the 
basolateral side (Dressman et al., 2010).  
 
1.3.3.2.3. Carrier mediated transporters 
 
The majority of the previous studies investigating drug absorption across the intestinal 
membrane suggested that drug transportation occurs predominantly via paracellular transport 
and passive transcellular mechanisms (Stenberg et al., 2000) in which the lipid solubility of the 
drug is the critical determinant. However, water soluble compounds such as amino acids, 
sugars, monocarboxylic acids, organic cations and anions, phosphates and water-soluble 
vitamins were found to cross cell membranes via specialized carrier mediated transporter (Ling 
and Thompson, 1974) 
 
Human gene sequence analysis has demonstrated the presence of 406 genes which encode for 
ion channels and 883 genes which encode for transporters (350 of which encode for 
intracellular transporters). The Human Genome Organisation (HUGO) has approved 52 ATP-
binding cassette (ABC) genes and 229 solute carrier transporters (SLC). More than 200 of these 
genes have been cloned and characterised including peptide transporters, amino acid 
transporters and neurotransmitter transporters (Shin et al., 2003) 
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Membrane transporter proteins are classified into channels and carrier mediated transporters. 
Carriers are further classified into facilitated diffusion, primary and secondary active 
transporters according to the energy requirements (Stenberg et al., 2000). 
 
Primary active transporters extrude the substrates from the cell against its concentration 
gradient utilising energy derived from the conversion of ATP into ADP by ATPase. On the other 
hand, secondary active transporters (solute carrier transporters) utilize the energy generated 
by ion pumps (Na+/K+ ATPase) during transportation of Na+ and Ca+2 ions across the 
membrane.  
 Membrane Transporters  
1.3.3.2.3.1. ATP-binding cassette Transporters (ABC) 
 ABC transporters were first discovered as drug-resistance proteins (Gottesman et al., 2002) 
and a correlation between expression of ABC transporters and cancer drug resistance has been 
known for more than 25 years (Huang and Sadee, 2006). A diverse number of substrates are 
transported across the cell membrane by ABC transporters. To date, around 52 ABC 
transporter genes have been identified and grouped according to their structural homology 
into seven groups (from A to G).  ABC transporters are classified according to their predicted 
two-dimensional structure into four classes (Figure 1.1.5). The first class was defined after the 
discovery of P-glycoprotein (P-gp) in 1976 (Juliano & Ling, 1976). 
Transporters in the first class consist of two identical halves and each half contains 6 putative 
transmembrane segments and two cytoplasmic nucleoside-binding domains (NBD); these two 
domains bind and enable the hydrolysis of ATP and N-glycosylation occurs in the first 
extracellular loop of P-gp. The second class has a similar structure to that of the first and the 
only difference is the N-glycosylation site as it takes place in the fourth extracellular loop. This 
class includes transporters such as MRP4 and MRP5 (mammalian). The third class has 
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additional 5 putative transmembrane segments towards the N-terminus. Additional 
glycosylation takes place on the new extracellular loop. Recently, a new ABC transporter 
known as BCRP was discovered which was found to have a single intracellular ATP binding site 
at N-terminus, followed by 6-putative transmembrane segments with N-glycosylation on the 
last extracellular loop. Due to its unique conformation and arrangement in the plasma 
membrane,  BCRP is also known as a half-transporter (Figure. 1.1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.12:- Structure of ABC transporters which confer drug resistance adapted from Mohammed et 
al., 2012. 
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1.3.3.2.3.1.1. P-glycoprotein. 
P-gp is also known as ABCB1 or MDR1 and is the first and most characterised ABC transporter. 
P-gp is expressed in the blood brain barrier, apical membranes of excretory cells such as 
hepatocytes and the epithelial cells in kidney proximal tubules and luminal membrane of the 
small intestine (Giacomini et al., 2010). The mRNA levels of P-gp increase longitudinally along 
the intestine with the lowest level in the stomach and highest levels in the colon (Wacher et 
al., 1998). P-gp drew great attention when it was found to interact with multiple anticancer 
drugs and mediated the efflux of a wide range of therapeutic drugs across biological 
membranes. Polyaromatic hydrophobic drugs with positive or neutral charges are common 
substrates for P-gp (Huang and Sadee, 2006). Not only conventional anti-cancer drugs (e.g. 
methotrexate), but newly developed drugs such as geldanamycin (Huang et al., 2004) and 
gleevec (Mahon et al., 2003) were found to be effluxed by P-gp. Talinolol (intermediate 
lipophilic B-blocker) is an extensively studied P-gp substrate. Although the metabolic clearance 
of talinolol is negligible and the drug is excreted unchanged in faeces and urine, talinolol oral 
bioavailability is just over 50% which suggests that the drug is not completely absorbed from 
the gastro-intestinal tract (GIT). Despite the acceptable physico chemical properties and in 
vitro permeability profile of talinolol, the basolateral to apical flux was greater by 10 fold 
compared to apical to basal flux (Wetterich et al., 1996). The efflux pattern was reduced upon 
inclusion of P-gp inhibitors such as verapamil providing further evidence of the efflux 
mechanism of talinolol. P-gp knockout mice were used in a study carried out by Schinkel et al 
to evaluate the role of P-gp in limiting the oral bioavailability of its substrates (Schinkel et al., 
1997). The results showed that the wild type mice had an oral bioavailability of less than 5% 
for UK-22,671 (new compound) while P-gp knockout mice resulted in a higher bioavailability 
(22%).  
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In order to improve the permeability of P-gp substrates, its activity is inhibited or modulated 
through the use of drugs or chemicals. P-gp modulation is achieved either indirectly, by 
inhibiting; the hydrolysis of ATP, binding to ATP or directly through interaction with P-gp 
binding sites. The indirect method is not feasible as the chemical agent could adversely affect 
other ATPases. Pharmacokinetic interactions of P-gp substrates were reported and the number 
is on the rise as, for instance cardiac patients who are on digitoxin and quinidine could show 
digitoxin toxicity as the plasma concentration of digitoxin (which has a narrow therapeutic 
window) increases by at least three fold (Shin et al., 2003). P-gp substrates and inhibitors are 
summarised in Table 1.1.4. 
 
Since P-gp is not expressed in all multi-drug resistance cells, research groups have explored 
other efflux transporters which resulted in the discovery of a protein referred as multi-drug 
resistance associated protein1 (MRP1). MRP1 (ABCB1) was found to confer resistance to 
anionic and neutral hydrophobic natural products such as vinca alkaloids and anthracyclines 
(Kruh and Belinsky 2003). Glutathione is a MRP1 substrate and is believed to play a major role 
in MRP1 activity (Leslie et al., 2001). Despite showing potential in vitro, isoxazoles (MRP1 
inhibitors) exhibit limited in vivo effects due to their side effects and low bioavailability. 
Further investigation of MRP homologues led to the discovery of eight new members of MRP 
sub families including MRP-2 to MRP9 (Huang and Sadee, 2006). 
 
Another cancer resistance protein that has been investigated is ABCG2 known as placenta 
specific ABC transporter (ABCP). ABCG2 mediates the transportation of negatively and 
positively charged hydrophobic molecules such as topotecan, flavopiridol, mitoxantrone, 
methotrexate and rhodamine (Doyle & Ross 2003). Interestingly, ABCG2 was found to exhibit 
polymorphism which in turn affects its interaction with the substrates. For instance, ABCG2 
shows more resistance to mitoxantrone and anthracyclines upon its mutation. Yet, mutated 
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ABCG2 fails to transport methotrexate (Volk & Schneider 2003). Table 1.1.4 summarises other 
members of the ABC transporter family which have been shown to confer drug resistance. 
Table 1.1.15:- Location and functions of ABC transporters (Huang and Sadee, 2006). 
1.3.3.2.3.2. Solute carrier transporter (SLC) 
Solute carrier transporters are another super family of membrane transporters. 
Approximately, 300 SLCs genes have been cloned and clustered into 43 families. SLCs mediate 
the transportation of hydrophilic moieties such as sugars, organic cations, anions, phosphates, 
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metals, monocarboxylic acids, water soluble vitamins and drugs with structures that resemble 
natural substrates (Huang and Sadee, 2006). 
 Folate transporter (SLC19 family) was the first reported SLCs to be studied in conjunction with 
anti-cancer drugs. Resistance to antifolate drugs such as methotrexate was reported in vitro in 
cancer cells; these cells have showed loss of SLC19A1 activity due to mutation. Also, the 
expression of SLC19A3 was found to be down regulated in breast cancer cells and as a result 
these cells were resistant to doxorubicin (Liu et al., 2003). 
 
Nucleoside transportation also takes place through SLCs mainly via the SLC28 family; 
concentrative CNTs and SLC29 family. The former is distributed in tissues such as renal and 
intestinal epithelia, liver and macrophages (Huang and Sadee, 2006). SLC28 consists of three 
members (SLC28A1-A3) which transport Na+ concentration dependant synthetic and natural 
nucleoside analogues and take part in synthesizing nucleic acid through salvage pathways 
(Rauchwerger et al., 2000). On the other hand, SLC29 consists of four members SLC29A1-A4 
which are distributed widely in mammalian cells and tissues. Similar to SLC28, they take part in 
cellular transport of nucleosides and nucleoside salvage. 
  
Interestingly, SLC29A1 down regulation confers resistance to nucleoside drugs by effluxing the 
drug, while SLC28 proteins mediate drug influx (Baldwin et al., 2004). Therefore nucleoside 
drug resistance could be overcome by using SLC29A inhibitors which do not affect SLC28. 
 
Amino acids are essential for mammalian cells and tissues as they serve as building blocks for 
glutathione and protein synthesis and also are essential in energy metabolism. Amino acids are 
transported through SLC carriers and are subdivided into small families according to their 
substrate selectivity and Na+ dependence (Amo et al., 2008). The L-type amino acid 
transporter; LAT1 (SLC7A5) was first cloned by Kanani et al. in 1998 which was followed by the 
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discovery of LAT2 in the subsequent year by  Segawa et al., (1999). Previous studies have 
demonstrated that SLC7A5 plays a major role in transporting aromatic, branched, long chain 
and essential amino acids. As such these transporters were found to be highly expressed in 
rapidly growing cells such as tumors (Huang and Sadee, 2006). LAT1 is distributed mainly in 
dividing/growing cells such as the brain, placenta and tumors. However, LAT2 is distributed in 
colon, intestine and kidney (Amo et al., 2008). 
 
Interestingly, amino acids have a full transporter system in prokaryotes as well. For instance, 
Pseudomonas aeruginosa has a branched chain amino acid cation symporter (LIVCS) family 
which transport branched chain amino acids. Similarly, the BCCT (betaine/carnitine/choline 
transporter) family was found in Gram negative bacteria. BCCT functions as a membrane 
transporter of amino acids with quaternary amino groups. Amino acid transporters were also 
found in Gram positive bacteria such as AGCS (alanine/glycine/cation symporter) which 
transport glycine and alanine in symport with monovalent cations like H+/Na+ (Reizer et al., 
1994) Eukaryotes also have a full amino acid transporter system. Solute:Sodium Symporter 
(SSS family) transports exist in bacteria, archaea and animals as well (Saier,M.H., 2000).  
Further examples of SLCs are summarised in Table 1.1.5. 
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Table 1.1.16:- functions of SLC transporters (Huang and Sadee, 2006). 
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1.3.3.2.4. Techniques for improving drug permeability 
 
Prodrug synthesis has been studied to improve both drug solubility and permeability. The pre 
moieties mask any polar groups on the compounds which results in drug partitioning across 
the membranes to increase its absorption. One of the most commonly employed groups of 
compounds is carboxylic acid esters and amino acids. Amino acid ester prodrugs of nucleosides 
were found to improve their permeability as for instance valacyclovir which is 5-L-valyl ester of 
acyclovir was shown to exhibit 3 to 5 fold increase in systemic bioavailability when compared 
to the parent drug (Weller et al., 1993). These results could be attributed to the enhanced 
intestinal absorption of L-amino acid nucleosides prodrugs via PEPT1 transporters as suggested 
by Han et al., (1998). Despite being successful as a permeability enhancer, most of the 
prepared prodrugs have low solubility which self limits their use as bioavailability enhancing 
strategy (Majumdar et al., 2004). 
 
Other studies suggested that ion-pairing (neutral species formed by electrostatic attraction 
between oppositely charged ions in solution) can be used to improve drug permeability. The 
interaction between the two opposite charges results in burying of the charge in the drug 
molecule and hence alters its physical properties. A study conducted by Irwin et al., (1969) 
demonstrated that the rate and efficacy of an ionic drug isopropamide was improved upon 
ion-pairing with an exogenous counter ion such as trichloroacetate. However, the mechanism 
of ion-pairing is still not clear and the permeability increase could be attributed to the direct 
effect of the counter ion i.e. binding to mucosal membrane, lowering the interfacial tension of  
the gut wall and causing mucosal erosion (Quintanar-Guerrero et al., 1997).  
Interestingly, ion-pairing of methotrexate with L-arginine was found to enhance the nasal 
permeability of the drug 24 times when compared to the drug alone (Ivaturi and Kim., 2009).  
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Other approaches used to improve drug permeability include; use of polymers which could 
disturb the epithelial cell tight junctions (Kotze et al., 1998), the use of microspheres and 
nanoparticles (Hodges et al., 1995) and membrane fluidizing agents (Manganaro, 1997). 
Since carrier mediated transport is believed to play a more important role than previously 
appreciated, research emphasis has shifted to blocking multi drug resistance (MDR) 
transporters using pharmacological reversal agents such as verapamil, quinidine, cyclosporine 
and valspodar (Donnenberg & Donnenberg, 2005). 
Interestingly, some studies have demonstrated that various formulation excipients can inhibit 
the efflux function of P-gp and in turn improve the overall intestinal absorption. In 2002, 
Hugger et al. suggested that Pluronic P85 and Polyethylene glycol [PEG 400] have a direct 
effect on P-gp function and also could work indirectly by changing the Caco-2 monolayer 
membrane fluidity or buffer osmolarity. Another study conducted by Rege et al., (2002) 
suggested that Tween 80 and Cremophor EL increase apical-basolateral permeability and 
decreased basolateral to apical permeability of a P-gp substrate (rhodamine 123). Other 
excipients such as Labrasol, Acconon E, Miglyol, Solutol HS 15, sucrose monolaurate, 
polysorbate 20, TPGS and polysorbate 80 were also found to decrease P-gp efflux function 
(Cornaire et al., 2004). 
 
1.3.3.2.5. Method for assessing drug permeability 
Human intestine is not only the site for drug absorption but also functions as a barrier (physical 
and biochemical) for drug uptake for orally administrated drugs. The tight junctions between 
the enterocytes in the intestine and the hydrophobic nature of the cell membranes represent 
the physical barrier that the drug faces, while the degradation enzymes and the efflux 
transporter proteins account for the biochemical barriers in the intestine. 
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Various methods have been proposed to assess the permeability function of the 
intestinal membrane including in vivo, in vitro and in silico analysis. In vivo models use 
living animals or humans in order to track the permeability of the therapeutic agents 
while the in vitro models mimic in vivo conditions in order to estimate the permeability 
of oral drugs (Worth & Balls, 2002). Nevertheless, in vivo and in vitro correlation analysis 
is important to ensure the validity of data produced by in vitro experimentation.  
 
1.3.3.2.5.1. In vitro Assessment of Permeability 
In vitro models include a variety of different methods including physicochemical assays, 
membrane based assays, cell based assays and excised tissue assays. 
1.3.3.2.5.1.1. Physiochemical Assessment of Permeability 
The most common physicochemical descriptor used to predict drug absorption across the 
intestinal membrane is the octanol/water partition coefficient (log P). There are numerous 
methods to measure the log P values including the shake-flask method, slow stirring method, 
methanol-water gradient and micellar/microemulsion method. Table (1.1.6) summarises the 
advantages and disadvantages of the various method used in determining the log P. 
 
 
 
 
 
 
 
 
 
 61
Table 1.1.17:- Various methods used in determining the log P values.  
Method Advantage Disadvantage Reference 
Direct   
Shake-flask Most realistic 
method, reliable 
Time consuming, requires high 
quantity of product used, 
formation of octanol emulsions in 
water, not reliable for highly 
lipophilic compounds 
OECD (1995) 
Slow stirring method Avoid the formation 
of emulsions, 
reliable 
Time consuming, quantity of 
product used 
Brooke et al. 
(1986) and de 
Bruijn 
et al. (1989) 
Chromatographic methods   
Classical HPLC 
approach 
Quick and cheap, 
does not require 
chemical 
quantification 
Different retention mechanisms; 
has poor reproducibility; just work 
between pH 2-7.5 
Finizio et al. 
(1997), 
Micellar and 
microemulsion 
electrokinetic 
chromatography 
Quick and not 
expensive 
Requires the establishment of 
solvation parameter model 
Poole and Poole 
(2003) 
Methanol–water 
gradient 
and a short 
octadecylpoly( 
vinyl alcohol) 
column 
Good correlation 
with shakeflask 
method 
 Donovan and 
Pescatore (2002) 
Others   
Filter probe method Rapid; well adapted 
to construct a 
logD/pH profile 
Expensive, hard to set up Leo (2000) 
 
1.3.3.2.5.1.2. Excised Tissue Permeability Assays 
Excised tissues for instance intestinal segments, intestinal rings and mucosal sheets can be 
used to assess drug permeability. Intestinal segments are isolated and everted prior to filling 
by a small volume of the buffer solution free from the drug. The two ends of the segment are 
tied off and immersed in an Erlenmeyer flask that contains large volume of the buffer solution 
with the drug of interest solubilised in it. The flask is continuously supplied with oxygen and 
agitated and samples from the buffer solution inside the segment are taken to assess drug 
permeability.  
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1.3.3.2.5.1.3. Cell Based and Membrane Based Permeability Assays 
 
One of the major drawbacks of using excised tissues for assessing oral absorption is the 
technical difficulties it poses which resulted in the introduction of the different cell lines. 
Human cell lines such as intestinal adenocarcinoma cell lines (Caco-2), HT29 (Huet et al., 1987) 
and T84 (Dias and Yatscoff 1994) and animal cell lines like MDCK (Madin Darby Canine Kidney), 
CHO (Chinese Hamster Ovary) (Tavelin et al., 1999) have been used widely in laboratories 
around the world to assess oral permeability. 
Caco-2 monolayers were first isolated from a colon adenocarcinoma of a 72-year-old patient 
(Fogh et al. 1977). Upon culturing, Caco-2 differentiates continuously and produces the 
structural and functional patterns of enterocytes (Pinto et al. 1983). Caco-2 cells can reach 
confluency after 3-6 days and become completely differentiated within 20 days (Pinto et al. 
1983). After differentiation, the cells express alkaline phosphatase, sucrase isomaltase and 
aminopeptidase which are characteristic for enterocyte brush border microvilli. 
The barrier function of the differentiated Caco-2 monolayers is judged by the transepithelial 
electrical resistance (TEER) values which range between 200-600 Ωcm
2
. Caco-2 monolayers 
have been extensively used to study passive paracellular permeability (Artursson et al. 1993; 
Artursson et al. 1996), passive transcellular absorption (Artursson 1990), carrier mediated 
uptake of B-lactam antibiotics (Inui et al. 1992), amino acids (Thwaites et al. 1995), amino acids 
analogue (Hu and Borchardt 1990) and efflux transport (Eneroth et al. 2001, Tran et al. 2002). 
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Table 1.1.18:- Some of the transporter proteins expressed in Caco-2 monlayers 
Membrane 
transporter 
Location Substrate Inhibitor Reference 
P-gp 
(MDR1) 
apical Talinolol 
Digoxin 
Verapamil 
Guinidine 
Verapamil 
Augustijns and 
Mols, 2004 
Greiner et al. 1999 
Collett et al. 2005 
MRP1 basolateral Methotrexate 
Estradiolglucor. 
Probenecid 
MK571 
Endres et al. 2006 
MRP2 apical Grepafloxacin 
Vinblastine 
MK571, Furosemide 
Indomethacin 
Lowes and 
Endres et al. 2006 
MRP3 basolateral Methotrexate 
Estradiolglucor. 
Hydroxycotinine O-
glucuronide 
Endres et al. 2006 
Létourneau 2005 
MRP4 apical Estradiolglucor. Probenecid Endres et al. 2006 
MRP5 basolateral Methotrexate Probenecid, MK571 Pratt et al. 2006 
MRP6 basolateral Mercaptopurine Probenecid, 
Indomethacin 
Endres et al. 2006 
Boraldi et al. 2004 
MCT1 apical Salicylic acid 
Ketoprofen 
Fluorescein 
L-lactic acid 
Konishi et al. 2002 
Choi et al. 2005 
OATP-B apical Estrone-3-
sulphate 
Pravastatin 
Pravastatin Ito et al. 2005 
Kobayashi et al. 
2003 
BCRP apical Topotecan GF120918 Jonker et al. 2000 
hPepT1 apical Cefixime 
Valacyclovir 
Gly-Sar 
Nifedipine 
cephalosporines 
Duverne et al. 
1992, 
Behrens et al. 2004 
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Table 1.1.19:-Summary table of in vitro permeability models and their advantages and limitations 
(Worth & Balls 2002). 
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1.3.3.2.5.2. In vivo Assessment of Permeability  
 
The majority of the in vivo studies (Table 1.1.9) use animals as models to predict oral 
absorption in humans. The main advantage of conducting in vivo studies is that it provides the 
all the necessary biological parameters that could influence drug absorption and as such an 
accurate full picture of permeability assay can be obtained. Summary of the various models 
that are available are presented below. 
Table 1.1.20:- Summary table for in vivo permeability models (Worth & Balls  2002). 
 
 
1.3.3.2.5.3. In silico Assessment of Permeability 
 
Due to the increase in the development of NCE over the last couple of decades, there has been 
a growing demand to predict drug performance at an early stage of development phase which 
has seen the emergence of predictive in silico techniques to estimate drug absorption, 
distribution, metabolism, excretion and toxicity (ADMET). In silico models comprise of a group 
of mathematical models which examine compound descriptors such as hydrogen bonding, 
molecular size and lipophilicity and estimate the biological activity based on their 
physicochemical properties.  
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The advantage of using in silico models is that they do not require access to the actual 
compound and produce results faster which means that the permeability studies of a 
compound could be predicted even before the synthesis of the compound. However, the 
major limitation of applying in silico models is that the obtained results account for passive 
transcellular permeability and do not take into account other routes such as active transport 
and efflux. 
Table (1.1.10) provides a summary of the major physiochemical characteristics used in 
predictive absorption models. 
 
 
 
in silico
 
Figure 1.1.13:- Comparison of how much research has been performed using, in silico, in vitro and in 
vivo techniques during the last decade (2001- 2010) Mohammed et al., 2012. 
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Table 1.1.21:- Summary table for in silico Permeability models (Stenberg et al., 2000) 
1.4. Microarrays 
 
Carrier transporter proteins have broad substrate specificity and various drugs from different 
pharmacological classes interact during the process of permeation. Moreover, there could be a 
partial overlap between these transporters’ substrates and as a result the pharmacodynamics 
and pharmacokinetics of a drug can be affected by more than one efflux protein (Taipalensuu 
et al., 2001). Thus, a systematic/holistic investigation of the efflux proteins is vital to get a 
broad picture of carrier expression profiles that affect drug/formulation permeability. 
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Interestingly, many physiological changes that take place at the cellular level are reflective of 
their level of gene expression. Genes are up or down regulated under different physiological 
conditions such as disease state, drug metabolism, exposure to toxins and response to 
treatment. This has paved the way for modern biomedical research that prompted the 
biologist to develop gene expression matrices that would allow identification of specific gene 
sets involved in a defined process, disease condition or cellular differentiation. Analysis of gene 
expression at m-RNA levels was first discussed by Alwine et al. (1977) using Northern blotting 
but was limited to the study of small sets of genes. The second major development by Liang 
and Pardee (1992) was differential displaying technology which succeeded in measuring 
multiple differences of gene expression in parallel. Yet, this method was qualitative and 
screening was dependent on the length of mRNA rather than its identity. The introduction of 
microarrays in 1995 revolutionised the research arena relying on gene expression profiling.  
The technique addressed the various limitations in studying gene expression and was 
associated with high sensitivity and throughput. Microarrays allow for the use of low amounts 
of starting material and the small size of the arrays improves the sensitivity and enables the 
screening of vast number of genes simultaneously (Hal et al., 2000).  
 
A microarray is defined as a collection of microscopic spots orderly arranged onto the surface 
of a solid support. It is a modern technique comprising of thousands of genes automatically 
spotted on specially treated glass slides. Spots or probes are designed in such a way that each 
probe binds to a specific fluorescently labeled nucleic acid (target) during the hybridization 
reaction. The binding between probe and target is analyzed via measuring the emitted 
fluorescence by the hybridized target during scanning. The principle difference between 
conventional hybridization and a microarray is the capability of arrays to monitor multiple 
genes on a single array which results in simultaneous profiling of genes in an organism.  
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1.4.1. Types of microarrays 
 
Microarrays are arrangements of samples or probes in specific order onto a matrix. According 
to the probe used, microarrays are broadly divided into two types; nucleic acid and tissue 
microarrays. 
Nucleic acid microarrays are prepared by spotting nucleotide probes onto a support matrix and 
base-pairing principles are used to bind the complementary targets (Southern et al., 1999). 
Glass slides are commonly used as a support matrix for the microships, however materials such 
as nylon, silicon and nitrocellulose membranes have also been used. The probes used for 
nucleotide microarrays could be DNA, cDNA or oligonucleotides which are printed onto the 
slides via robotics or could be built in directly onto the array by inkjet techniques or 
photolithography (Lockhart et al., 1996). 
cDNA microarray is an example of transcriptomic arrays which enables large scale comparison 
of the whole genome of two samples. RNA is extracted from the test sample followed by 
reverse transcription to get cDNA that is labelled by fluorochrome. Both the normal (control) 
and target samples are mixed and incubated with the cDNA microarray and the slide is 
analysed using image analysis systems. The obtained data represent the transcriptional affinity 
for the whole genomes on the grid. The large amount of data obtained makes it impossible to 
point the genes that characterise the molecular pathobiology of certain disease; hence data 
processing is considered the bottleneck of microarray technologies.  
 
Another category of nucleotide microarrays is single nucleotide polymorphism (SNP) 
microarray which is a genomic array that detects polymorphism or mutation that might occur 
in a population. SNPs usually take place in non-coding regions of the DNA and occur 
throughout the genome. The main advantage of using SNPs is to determine disease 
susceptibility and therefore tailoring the efficiency of drug therapy for an individual which is 
also known as personalized medicine. It might be in the near future when physicians can 
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screen patients for susceptibility to certain disease by analyzing their DNA for specific SNPs 
profiles. 
A third category of nucleotide microarrays is comparative genomic hybridization (CGH) 
microarray which identifies genomic losses and gains in certain diseases. Most of the solid 
tumours are characterised by genetic instabilities which cause chromosomal re-arrangements. 
Until recently, it was difficult to characterise solid tumours by using chromosomal re-
arrangements because of the high chromosomal instability. Studies using CGH have shown 
that solid tumours undergo frequent losses and gains and different tumour types have distinct 
CGH patterns. Nevertheless, the lack of spatial resolution of CGH arrays makes it difficult to 
conclude that different tumour types or tumours at different stages of evolution have distinct 
pattern of gains and losses. 
The final type of microarray is called tissue microarrays (TMA). A number of novel 
markers have been identified recently by molecular biologists. These markers are 
believed to have prognostic, diagnostic and therapeutic significance especially in the 
field of cancer. The introduction of TMA enables rapid and cost effective validation of 
these markers rather than the use of conventional histo pathological techniques.  
1.4.2. Procedure for setting up Microarray studies 
 
The microarray experiment starts with isolation of the RNA from both the control sample and 
the treated sample (test sample). The cDNA probes are prepared separately through reverse 
transcription which are labelled using fluorescence dyes; Cy3 (control sample) and Cy5 (test 
sample). The labelled probes are mixed together and hybridized for 17 hours on the array slide 
which is followed by washing and imaging of fluorescence to record the different levels of 
expression of genes.  
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Figure 1.1.14:- Schematic representation of the procedures followed to setup microarrays studies. 
Samples (control and test samples) are labeled with different fluorescent dyes (Cy3 and Cy5) and 
competitively hybridized to the same array. Final imaging requires a fluorescent scanner that can 
excite and detect at multiple wavelengths. 
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2.1. Aims and Objectives 
Despite the several advantages of oral drug delivery, the unfavourable biopharmaceutical 
properties of drugs (i.e. low solubility and low permeability) decrease drug bioavailability 
across the oral route. Although prodrugs have been formulated to alter the biopharmaceutical 
properties, they present significant challenges including the requirement for complete drug 
profiling, potential toxicity and stability issues. On the other hand, ion-pairs could be a 
potential solution to address both solubility as well as permeability.  
 
 The overarching aim of this thesis is to study the application of charged amino acids as both 
solubility as well as permeability enhancing agents through formation of ion-pair complexes. 
The content in this thesis investigates and addresses for the first time both solubility and drug 
uptake through the inclusion of a single agent i.e. amino acids.  For this purpose, three model 
drugs were selected; indomethacin (weak acid, BCS II), trimethoprim (weak base, BCS III/IV) 
and ciprofloxacin (zwitter ion, BCS IV). All the selected drugs carry charges so that they could 
bind electrostatically with the oppositely charged counter ions. In addition, trimethoprim and 
ciprofloxacin are known to be substrates to efflux transporter proteins and possess limited 
permeability. The objectives of this thesis include: 
1. Preparation of physical mixtures and salts for the different model drugs using 
oppositely charged amino acids to evaluate their influence upon changes in 
concentration, structure and physico-chemical properties. 
2. Systematic investigation of multi-functionality of amino acids in dosage form 
preparation to determine their suitability in translation of results into clinic. 
3. Evaluating the permeability of model drugs across Caco2 monolayers and identifying 
the genomic signature for drug transport of model drugs in the presence of oppositely 
charged counter ions. 
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3.1. Salt preparation and characterisation for indomethacin using 
cationic amino acids 
 
3.1.1. Introduction 
 
Both solubility and permeability are considered key determinants for drug bioavailability. 
Lately, the number of poorly soluble drugs has increased greatly especially after the 
introduction of combinatorial chemistry and high throughput screening to the drug discovery 
cycle and around one third of these new compounds have aqueous solubility less than 20 
µg/mL (Li et al., 2005). Therefore, formulating oral dosage forms of these poorly soluble drugs 
becomes a great challenge for the formulation pharmacist (Leuner and Dressman, 2000). 
Salt formation is a commonly used technique to modify the characteristics of new chemical 
entities (NCE) in order to overcome the undesirable characteristics of the parent drug 
(Anderson and Conradi, 1985). Both the physicochemical characteristics and biological 
performance of the drug differs dramatically from the salt form (Bighley et al., 1996). Most of 
the salt forming agents are selected empirically; many issues such as ease of crystallization, 
percentage yield, hygroscopicity and flowability are considered prior to selecting the salt 
former (Berge et al., 1977). Many studies tried to investigate the relationship between the salt 
properties and the counter ions used. Yet, until now no successful way of predicting the effect 
of salt former on the behaviour of the parent compound has been reported. Stahl & Wermuth 
suggested that the dissociation constant (pKa) is the most important piece of information to 
gather about NCE (Stahl and Wermuth, 2002), then a number of counter ions can be selected 
to form a stable form (minimum difference between the salt former and counter ion should be 
3 pKa units). After selecting a number of potential counter ions, further physicochemical tests 
should be carried out to evaluate the crystallinity, polymorphism and melting point. Amino 
acids have shown great success as potential salt formers: Pellegate (1993) utilised lysine, 
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ornithine and arginine to prepare novel salts of furosamide (Pellegata R., 1993). The prepared 
salts exhibited very high solubility up to 560 mg/mL for the lysinate salt which was much 
higher than furosemide itself and even its sodium salt. Another study conducted by Fujisawa et 
al have prepared new cephalosporin salts with arginine and lysine, the prepared amino acid 
salts were claimed to be less painful when administered parentally (Fujisawa et al., 1976). 
Other studies have succeeded to prepare novel salts of arginine with acidic drugs such as 
benzoquinolizine-2-carboxylic acids (Deshpande et al., 2007) and inosine (Kurauchi et al., 
2004). While lysine managed to form new salts with ibuprofen (Tung et al., 1991) and 4-
diphenylacetic acid (Giuseppe, 1989). 
On the other hand, poor permeability of NCE makes the drug unsuitable for further 
development and great efforts are exerted to avoid getting a potent non-absorbed drug (Egan 
and Georgio, 2002). It is strongly believed that nutrient transporters play a major role in 
transporting nutrients as well as various therapeutic agents (Oh et al., 1999). Interestingly, 
amino acids succeeded in improving the drug permeability of poorly permeable drugs such as 
gemcitabine and other anticancer agents by ester linkage and mediate the transportation 
through hPEPT1 transporters (Song et al., 2004).  Moreover, amino acids have been used in the 
past to improve aqueous solubility of alcohol and amine drugs through prodrug formation 
(Aggarwal et al., 1990; Upshall et al., 1990). Therefore, amino acids were chosen in the current 
study to improve the solubility of a BCS II model drug through a salt formation technique as 
the first stage prior to investigating the effect of using these amino acids to improve drug 
permeability via amino acids mediated transporter and ion-pairing mechanisms.  
Indomethacin (IND) was selected as a model drug for this study as it has an acidic carboxyl 
group which acts as a potential salt former, moreover its transportation is mediated by P-
glycoprotein transporter. According to the Biopharmaceutical classification system (BCS), IND 
is classified as a poorly soluble highly permeable drug (i.e Class II). IND is a non-steroidal anti-
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inflammatory drug (NSAID) which is widely used to reduce pain associated with rheumatoid 
arthritis, osteoarthritis, bursitis and headache (Sweetman, 2005).  
 
3.1.2. Materials and methods 
3.1.2.1 Materials 
Indomethacin (TLC ≥ 99%), L-Arginine (non-animal source), L-Histidine (Reagent plus ™, L-
Lysine and Potassium bromide (99% FT-IR grade) all were purchased from Sigma Aldrich, UK. 
D2O (99.9% min) was purchased from Coss scientific instrument Ltd, DMSO-D6 (98.8% min) 
was purchased from MERCK (Darmstadt, Germany). 
 
3.1.2.2 Methods 
3.1.2.2.1 Analytical technique 
The amount of indomethacin (IND) dissolved in the solution samples was quantified by HPLC 
using a Dionex 1100 system with autosampler (AS50), gradient pump (GP50), UV detector 
(UVD 170U) and RP-C18 analytical column (Phenomenex 110A, 150x4.6 mm, 5µm). The 
analysis method was adapted from Song et al., (2004). IND was eluted using acetonitrile (60%) 
and 0.1 M acetic acid (40%) as a mobile phase and pumped at 1.0 mL/min flow rate. UV 
detector was adjusted at λmax of 248 nm (predetermined using Unicam UV-Visible 
Spectrophotometer). The retention time was 6.5±0.12 min and a rectilinear calibration curve 
was established at concentration range between 10-500µg/mL with 0.99 correlation 
coefficient (For more details see appendix 1). 
 
3.1.2.2.2 Phase solubility diagram 
Phase solubility diagram was established by measuring the saturated solubility of IND free acid 
with various concentrations of basic amino acids (L-arginine,L-lysine and L-histidine). Excess 
IND was added into screw-capped tubes containing serial dilutions of the amino acids solutions 
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and agitated at room temperature (Stuart SB 162 stirrer) for 24 h. After equilibrium the 
supernatant was filtered through 0.45 µm filters and analysed by HPLC to determine 
indomethacin concentration. The pH of amino acid solutions was monitored using Xisherbrand  
Hydrus 500 pH meter. 
 
3.1.2.2.3 Salt preparation 
Equimolar amounts of IND and the free amino acid (L-arginine, L-lysine, L-histidine) were 
solubilised in water and the solutions were mixed and stirred until equilibration then filtered. 
The filtrate was transferred into vials and freeze dried for 48 h using Modulyo freeze dryer at -
40oC shelf temperature and under vacuum created by an E2M5 Edwards pump then samples 
were collected and kept at 40oC oven for 4h using Gallenkamp vacuum oven. 
Despite the low yield of the freeze drying technique, it was preferred over the salt preparation 
method adapted by Anderson & Conradi using organic solvent (Berge, 1977). Lyophilized 
products are highly pure and devoid of the formation of any solvates. Generally, salts prepared 
by an organic solvent method do not behave well in an aqueous environment as they could 
convert to the free acid or base, exhibit low solubility and stability and their use becomes 
limited (Chauhan et al., 2004). 
3.1.2.2.4 Thermogravimetric analysis (TGA) 
Moisture content and decomposition temperature of indomethacin and its prepared salts 
were determined using a thermogravimetric analyser (Pyris 1 TGA, Perkin Elmer). 5-10 mg of 
samples were added to an open pan and analysed at temperature range 30-300 oC at 10 oC/min 
scanning rate and under nitrogen stream. The resultant thermograms were analysed using 
Pyris Manager Software (version 5.00.02) 
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3.1.2.2.5 Differential scanning calorimetry 
Differential scanning calorimeter (Pyris Diamond DSC) was used to investigate the melting 
point and the crystallization exotherms of the prepared salts.  Approximately, 2-5 mg of the 
salts were weighed and transferred to an aluminium sample pan (50 µL capacity) then a  
pierced aluminium top was crimpled in place in order to seal the pan. Intra cooler 2P system 
was used to initially cool the samples to 50 oC and then the sample was heated to 300 oC at a 
rate of 10 oC/min. Nitrogen was used as a purge gas at a flow rate of 20 mL/min, Indium and 
Zinc were used to calibrate the heat flow and melting point onset (156.6 oC for Indium and 
419.47 oC for Zinc). The obtained thermograms were analysed using Pyris Manager Software 
(version 5.00.02). The experiment was performed in triplicate and an empty aluminium pan, 
sealed in the same way of the samples, was used as a reference cell for all the measurements. 
 
3.1.2.2.6 FT-infrared (IR) spectroscopy 
FTIR absorbance spectra of IND and its salts were obtained with Nicolet IR 200 spectrometer 
(Thermo electron corporation) using KBr discs technique. Crystalline KBr was dried at 65oC over 
night before use. Samples were prepared by mixing IND or its salts with dry KBr at 1:100 (w/w) 
ratio and pressed at 8 tones for 5 min (using Specac tablet presser) to form KBr discs. 64 scans 
were done over wavelength 4000- 400 cm-1 for each sample. EZ OMNNIC 7.0 software was 
used to interpret the IR spectrum. 
3.1.2.2.7 
1
HNMR 
Samples were analysed with Bruker Avance DPX-250 NMR (at 250.1 MHz) and Bruker Topspin 
software was used to analyse the data. Approximately, 1-2 mg of the salts were dissolved in 1 
mL of deuterated water (D2O) and placed in sample capillary vial up to 5-10 cm height.  
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3.1.2.2.8. pH solubility profile 
pH solubility studies were determined by using the Ledwidge & Corrigan method (Ledwidge 
and  Corrigan, 1998). Saturated solutions of the salts and acids were prepared by dissolving an 
excess of the drug in deionised water. The solutions were agitated constantly using (Stuart SB 
162) stirrer at ambient temperature. pH was adjusted to values below and above these of the 
saturation solutions by adding HCl or the appropriate base (L-arginine). After 2 hours intervals 
an aliquot was withdrawn and filtered through 0.45 µm filter, then analysed using HPLC (see 
section 3.1.2.2.1) 
 
3.1.2.2.9. Solubility studies 
Solubility studies were carried out using Hugchi and Connor’s method (Higuchi and  Connors, 
1965) excess amount of IND or its salts are added to capped test tubes with 5 mL of deionised 
water and stirred for 24 hours at room temperature until equilibrium is reached. Subsequently, 
the suspension is filtrated through 0.45μm syringe filters and suitably diluted and the 
concentration was measured by HPLC. 
 
3.1.2.2.10. Conventional tablet preparation and dissolution studies 
Conventional tablets weighing 500 mg and containing 50 mg of IND or equivalent amounts of 
the prepared salts were prepared for dissolution studies. Starch was used as a tablet binder 
and anhydrous lactose was used as a diluent in 1: 8 ratio respectively. All the excipients were 
geometrically mixed with the active ingredients and 500 mg were weighed and compressed 
using a Specac tablet presser at 8 tones pressure for 10 minutes. 
USP II paddle method (ERWEKA DT-600) was used to perform the in vitro dissolution studies. 
The prepared tablets were placed into dissolution vessels containing 900 mL of phosphate 
buffer (pH 7.2) and the dissolution medium was maintained at 37oC±0.5oC and stirred at 50 
rpm. 5mL of samples were collected at a predetermined time intervals (1, 5, 10, 20, 30, 45, 60 
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and 90 min) then filtered through 0.45 μm Millipore filters. The dissolution media was replaced 
by 5mL of fresh dissolution fluid in order to maintain a constant volume. After proper dilution 
samples were analysed by HPLC as mentioned above. 
 
3.1.3. Results and discussion 
3.1.3.1 Phase solubility diagram 
 Before preparing IND salts, a phase solubility diagram was first constructed between IND and 
three basic amino acids namely; L-arginine, L-lysine and L-histidine. The phase solubility 
diagram gives preliminary data about the ability of the counter ions to dissociate IND free acid 
and also provides data about the extent of improvement of solubility upon using these counter 
ions. 
The results showed that increasing the basic amino acid concentrations resulted in improving 
IND solubility significantly (Fig. 3.1.1). Such an increase in solubility could be attributed to the 
ability of the amino acids to increase pH of the medium upon increasing their concentration 
which in turn enables the dissociation of IND free acid (ionised form) resulting in an increase in 
solubility. 
L-arginine has a basic side chain with a pKa of 12.48 for –NH2 group; this value is much higher 
than the pKa of IND (pKa= 4.5). This in turn results in IND free acid giving up its proton to –NH2 
group to form –NH3
+ cation and hence IND acts as a strong acid in L-arginine solution. Since a 
linear relationship between IND solubility and L-arginine concentration was observed (R2= 
0.998), therefore it is believed that IND is 100% dissociated in arginine solution. Hence an 
electrostatic interaction is possible between the two ionised species to form a salt. 
Although the pKa of the –NH2 side chain of L-lysine (pKa= 10.53) is lower than that of arginine, 
the solubility of IND in L-lysine was significantly higher and this could be possibly because of 
self-association between IND and lysine which inhibits the rate of nucleation of the final salt 
(Ledwidge and Corrigan., 1998; Serajuddin and Mufson, 1985; Serajuddin and Jarowski, 1985). 
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Such self-association was not observed in IND-arginine salt probably because of the large 
numbers of H-donor groups in arginine and the very low number of H-acceptor groups, 
therefore the possibility of arginine self-association is low and instead arginine would interact 
intermolecularly with the H-acceptor groups of IND. However, lysine has 2 H-donor groups and 
one H-acceptor group and there would be a high probability of intermolecular interaction 
between lysine molecules and hence a higher chance for IND to self-associate and to inhibit 
the nucleation rate.  
On the other hand, the basic amino group of L-hisitidine has a pKa of 6 (slightly higher than 
IND) which possibly results in weaker degree of dissociation of indomethacin in histidine (Fig. 
3.1.1). As a consequence, only a small ratio of IND exists in the ionised form (i.e. IND acts as a 
week acid in histidine solution) and results in poor yield of the salt. 
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Figure 3.1.15:- Phase solubility diagram between IND, L-arginine, L-lysine and L-histidine. The figure 
also shows pH measurements of various concentrations of the amino acids (n=3). 
 
3.1.3.2 Characterisation of the salt form 
After evaluating the degree of dissociation of IND with the various basic amino acids, three 
salts were prepared by lyophilisation and further characterised by Fourier transform infra-red, 
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differential scanning calorimetry, thermo-gravimetric analysis and 1H nuclear magnetic 
resonance. 
3.1.3.2.1 Differential scanning calorimetry and Thermo-gravimetric analysis 
Fig 3.1.2 shows the DSC and TGA scans of IND and its prepared salts. IND showed an 
endothermic peak at 162.67 oC, corresponding to its melting point (onset 161.07 oC). The IND 
melting enthalpy of fusion was very high (1133.69 J/g) reflecting the strong crystal lattice of 
the drug. Interestingly, thermal characterisation of IND-arginine salt revealed that the 
prepared salt was in the amorphous form as DSC data have shown a crystallization exotherm 
at 118.93 oC where the amorphous form starts to crystallize and these formed crystals 
exhibited melting at 209.73 oC. Similarly, the IND-lysinine salt was found to exist in an 
amorphous form and showed a weak crystallization exotherm at a lower temperature 79 oC 
followed by a melt at 223.26 oC. Interestingly, after 2-week of storage under ambient 
conditions; IND-lysine crystallization exotherm disappeared which possibly suggests that the 
salt converted from the amorphous form into the crystalline form upon storage and this could 
be attributed to the relatively low crystallization temperature. However the arginine salt 
remained in its amorphous form under similar conditions. 
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Figure 3.1.16 :- DSC and TGA scans for  IND free acid,  IND-Hisidatine,  IND-Lysinate salt, and  IND-
Arginate salt. 2- 5 mg of the sample was heated to 300
o
C at rate of 10 
o
C/min (n=3) 
 
On the other hand, L-histidine did not form a salt with IND and DSC shows a melt at 249.05 oC 
which degrades before complete melting. A similar peak was obtained upon thermal analysis 
of L-histidine free base. This result suggest that there was no salt formation and these results 
were further confirmed with FT-IR and 1HNMR studies (sections 3.1.3.2.2 & 3.1.3.2.3) 
 
TGA scans revealed that the prepared salts degrade a few degrees above their melt and the % 
weight loss increased greatly after the decomposition point due to the volatility of the 
degradation products. The moisture content was very low in all the prepared salts and 
maximum moisture of 1.2% was found for IND-lysine salt (Fig. 3.1.2). 
 
3.1.3.2.2 Fourier Transform infra-red spectroscopy (FT-IR) 
FT-IR spectra were used to characterize the possibility of interaction between IND and the 
amino acids counter ions. Using FT-IR, the IND salt formation could be established by (1) 
Absence of non-hydrogen bonded carboxylic acid peak νC=O at 1717 cm-1 (Silverstein and 
Webster., 1998). (2) Appearance of absorption bands at 3350-3150 cm-1 corresponding to NH3
+ 
stretching of amino acids salts (Socrates, 1994). 
 
 
 
 
 
 
 
 
 
                                                 
 
 85
indomethacin
 0
 20
 40
%
T
IND-arginine
 40
 60
 80
 100
%
T
IND-lysine
 50
 100
%
T
IND-histidine
 0
 50
 100
%
T
 500    1000   1500   2000   2500   3000   3500  
Wavenumbers (cm-1)
IND-arginate 
IND-lysinate
IND-histidate 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.17 :-  (A) The characteristic FT-IR absorption bands of IND, IND-arginate, IND-lysinate and 
IND-histidate (from top to bottom), (B)  chemical structure of indomethacin. 
 
 
IND FT-IR spectra (Fig. 3.1.3A)  showed characteristic absorption bands at 3021 cm-1 which can 
be assigned for C-H aliphatic chains, 1717 cm-1 corresponding to carbonyl stretching of the acid  
ν (C14=O) and at 1691 cm-1 for bezoyl C10=O as previously described by (Tong and Zografi, 
2001).  Interestingly, upon adding L-arginine to IND free acid, the absorption band of non-
hydrogen bonded C14=O was eliminated, possibly due to proton loss and involvement of the 
carboxylic group in the salt formation with the basic amino group of the amino acid. While, the 
benzoyl carbonyl stretches at around 1691 cm-1 shifted slightly  to 1675 cm-1 for both arginate 
and lysinate salt. Such a shift could be attributed to the effect of the local dielectric constant 
change between the ionised form and non-ionised form of IND (Tong and Zografi, 2001). On 
the other hand, both benzoyl and carbonyl stretching for IND free acid ν(C=O) were absent in 
IND-histidine and an absorption band was observed at 1635 cm-1 which corresponds to 
carboxylic νC=O of histidine (Petrosyan, 2007). These results suggest that histidine could not 
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form a salt with IND and this could be attributed to the low dissociation ability of IND in 
histidine solution as discussed above for the phase solubility diagram. 
 
 
Table 3.1.22: Major band (peak) positions and assignments for IND and its salts in the region of 4000-
400 cm-1 
compound Infrared (cm-1) Assignment 
IND 3371 
3021 
1717 
1691 
C-H aliphatic 
OH group 
Asymmetric acid  νC=O  
Benzoyl (amide) νC=O  
IND-arginate 3381 
3089 
1675 
1584 
N-H stretching 
C-H alphatic 
Benzoyl (amide) νC=O 
Asymmetric COO- 
IND-histidine 3418 
3009, 2881 
1635 
N-H stretching 
C-H alphatic 
Carboxylic νC=O of histidine 
IND-lysinate 3417 
2932 
1675 
1590 
N-H stretching 
C-H alphatic 
Benzoyl (amide) νC=O 
Asymmetric COO- 
 
3.1.3.2.3 
1
HNMR 
 
1HNMR spectroscopy was also used to confirm the salt formation and determine the molar 
ratio of interaction between IND free acid and the anionic amino acids by counting the 
hydrogen integrals. DMSO was used to dissolve IND while, deuterated water (D2O) was used to 
solubilise the salts. 
Fig 3.1.4 shows the 1HNMR of IND free acid, at 7.6 ppm frequency the 4H of IND halogenated 
aromatic ring which appeared as multiplet. While, the hydrogens of the methoxy aromatic 
ring; C7(1H) doublet, C9 (1H) doublet and C6 (1H) singlet appeared at 6.9, 6.94 and 7.04 ppm 
respectively. (3H) of the methoxy group (OC17H3) appeared as singlet at 3.6 ppm, while (3H) of 
methyl group (C12H3) appeared as singlet at lower frequency (2.21 ppm) as it is less shielded.  
Similar results were reported by Chauhan et al., (2004). The total integrated H count for IND 
was 15 (Fig. 3.1.4). 
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Figure 3.1.18:- 
1
HNMR spectra of  indomethacin free acid in DMSO 
 
IND-arginine salt showed a slight chemical shift (δ) for IND bands and 7H assignments 
appeared between 1.44 to 3.00 ppm which represent C33H2, C
32H2, C
31H2 and C
29H groups of 
the aliphatic chain of L-arginine. The total integration of (H) was 22, which confirms the 
formation of IND-arginate salt with 1:1 molecular ratio as the new 7H assignments correspond 
to one arginine molecule (Fig. 3.1.5). 
Interestingly, DMSO dissolved IND and IND-arginine salt and (H) atom of IND carboxylic OH 
group appeared at 12.38 ppm and disappeared in IND-arginine salt (data not shown) which 
further confirms the loss of carboxylic proton as previously discussed in FT-IR section. 
Similarly, the 1HNMR data for IND-lysine salt (Fig. 3.1.6) showed the appearance of new 9H 
assignments corresponding to C32H2 (multiplet), C
33H2 (triplicate), C34H2 (triplicate), C
31H2 and 
C29H1 (triplicate) at 1.31, 1.55, 1.72, 2.84, 3.57 ppm respectively. The formed lysine salt was in 
the 1:1 ratio.  However, IND-histidine samples revealed histidine characteristic bands with the 
absence of IND bands (Fig. 3.1.7) and this could be attributed to very low dissociation of IND 
and its inability to form a salt with histidine.  
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Figure 3.1.19:-  
1
HNMR spectra for IND-arginine salt dissolved in D2O. 
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Figure 3.1.20:- 
1
HNMR spectra for IND-lysine salt dissolved in D2O. 
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Figure 3.1.21:- 1HNMR spectra for IND-histidine dissolved in D2O. 
 
 
 
3.1.3.3. Aqueous solubility determination. 
 
IND aqueous solubility is a prerequisite for its dissolution rate as compounds with aqueous 
solubility lower than 100μg/mL cause dissolution limitations to drug absorption (El-Badry et al., 
2009). IND is practically insoluble at acidic pH (0.33 μg/mL at pH 4.5) and slightly soluble at pH 
7; 40 μg/mL (Chauhan et al., 2004). IND aqueous solubility was 0.244 μg/mL at pH 4.95 while 
the IND-arginine salt exhibited the highest solubility among the prepared salts and improved 
the solubility by 104 fold to 34.8mg/mL. IND-lysine increased the solubility by 2x103 fold 
corresponding to 7.8 mg/mL. The high solubility exerted by arginate salt could be attributed to 
its stable amorphous form and in turn low energy is required to solubilise the salt. On the 
other hand, lysinate salt was in the crystalline form requiring higher energy to disrupt the 
crystal structure and in turn resulting in lower solubility values. 
 
3.1.3.4. Dissolution study. 
 
In vitro drug release profile of IND free acid and its salt are shown in Fig. 3.1.8. The prepared 
salts showed greater dissolution rates than the free acid. 
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The highest dissolution rate was exhibited by the IND-arginine salt and 69.4±5.02% of IND was 
released within the first 10 min and up to 94.3±2.9 % after 30 min, followed by IND-lysinate 
salt which released 59.88±5.6% and 88.4±0.42 % of the drug after 10 and 30 min respectively. 
Nevertheless, only 37.9±12.4% of IND was released from the free acid formulation during the 
first 10 min and 93.2±1.8% in 60 min. 
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Figure 3.1.22:-  Dissolution profile for IND free acids and its salts in phosphate buffer pH 7.2. Data are 
mean± SD (n=3). 
 
It is obvious that changing the salt form has an influence on the dissolution rate despite using 
similar bulk pH (phosphate buffer pH 7.2) for all the studied samples. Such changes in the 
dissolution profile could be attributed to the ability of IND-arginine and IND-lysine salts to 
exert a self-buffering action, yielding different pH values at the dissolving surface in the 
diffusion layer (Forbes et al., 1995). It is possible that the IND-arginine salt has a high buffering 
capacity and produces higher pH at the diffusion layer and in turn higher dissolution rate. 
Moreover, the arginine salt was in the amorphous form and it is well-known that the 
amorphous form represents the ideal case for faster dissolution (Hancock and Zografi, 1997). 
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Despite the high solubility exhibited by IND L-arginine and IND L-lysine salts, a slight 
improvement in dissolution rate was observed and this could be attributed to the different 
micro-environmental pH surrounding the surface of the formulation in the solubility and 
dissolution studies where deionised water and phosphate buffer were used respectively. These 
results come in line with Stahl et al findings which conclude that the aqueous solubility may 
not always be a good indicator which form would have the optimum dissolution rate and the 
dissolution profile of the salt could be higher, equal or even lower than the free form of the 
drug depending on the micro-environmental pH surrounding the surface of the formulation 
(Stahl and Wermuth, 2002). 
3.1.3.5. pH- solubility profile. 
 
 
Classical pH-solubility profile of weak acids consists of two main regions; region I and region II. 
The excess solid in equilibrium with saturated solution in region I represent the free acid and 
the total solubility is described by Kramer and Flynn equations (Kramer and Flynn, 1972). 
)1]([)(,
3
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K
HApHpHacidS aT  
                                          )101]([ PkapHAH −+=    Equation 3.1.1 
Where S is the total solubility at given pH, [HA] is the intrinsic solubility of free acid, Ka is the 
acid dissolution constant. 
On the other hand, the excess solid in equilibrium with the saturated solubility in region II 
represents the salt and the total solubility is described by  
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Where [A-] is the saturation solubility of the salt, Ksp is the solubility product of the salt. 
For weekly acidic drugs when pH less than pKa by 2 units, the solubility is practically 
independent on the pH and remains constant at the intrinsic solubility (So). At pH >pKa the log 
solubility increases linearly with pH (i.e solubility increases exponentially with pH). 
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Figure 3.1.23:- pH solubility profile of indomethacin free acid (circles) titrated with L-arginine at 
ambient conditions.Point a represents the saturation solubility of the free acid. The theoretical curve 
(dotted lines) was fitted using Eq 3.1.1. 
 
pH solubility profile of indomethacin is presented in figure (3.1.9) and follows equation (3.1.2) 
with R2= 0.94. Indomethacin acid has a solubility of 0.24 µg/mL at pH 4.95 in water (point a) 
reducing the pH to 2 using 0.1N HCl gave an estimation of 0.09 µg/mL for intrinsic solubility 
[HA]. Indomethacin solubility increased exponentially with pH upon titrating with L-arginine 
free base reaching a maximum solubility of 2837.8 µg/mL at pH 8.6 (point b) and this was 
attributed to the formation of IND-arginate salt which has higher solubility. 
 Excess IND-arginate salt was dissolved in water with saturation solubility 34833.22 µg/mL at 
pH 8.45, addition of 0.1 N HCl to this saturated solution dropped the solubility to 0.55µg/mL at 
pH 2.25 due to the precipitation of indomethacin as a free acid, these results comes in line 
with Ledwidge and  Corrigan (1998).  
a 
b 
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3.1.4. Conclusion 
 
 The ability of basic amino acids to forms salts with indomethacin was evaluated in this study. 
Both L-arginine and L-lysine dissociate IND and then interacted electrostatically to form two 
novel salts. However, IND failed to dissociate in L-histidine solution. These results were further 
confirmed by FT-IR and 1HNMR. The two prepared salts showed very high solubility and 
dissolution profile when compared with the free acid.  Na, K and Li IND salts have been 
previously prepared, however using amino acids as counter ions will provide number of 
advantages such as suitability with hypertensive patients and painfulness injection. Future 
work will investigate the effect of using these amino acid salts on the drug permeability across 
Caco-2 cells. 
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Prediction of compaction properties of binary mixtures of indomethacin 
and indomethacin-arginine with arginine 
3.2.1. Introduction 
 
Salt formation studies have shown 104 fold increase in IND solubility. However, the high 
dissociation of the salt form could deteriorate the drug ability to partition across the intestinal 
membrane. Adding excess of the counter ion would act as a common ion and could reduce IND 
dissociation by shifting equilibrium towards the undissociated form. To put this into a practical 
solution, the current study aims at investigating the feasibility of using arginine as a tablet filler 
and upon reaching the absorption site the tablet will disintegrate and an excess of arginine will 
be available around the drug and might be able to keep the salt form undissociated for 
absorption. 
 
Tablets are the most commonly used dosage form nowadays. Many components are involved 
during the tablet manufacture in order to improve the quality of the product. The compaction 
of all the ingredients into one tablet is a complex process. The main reason behind such 
complexity is the involvement of various physical characteristics of each pharmaceutical 
powder during the compaction process. Therefore, most of the scientific research was devoted 
to studying the compaction behavior of individual powders. 
Compaction behavior of binary mixtures was investigated by many studies (Sheikh-Salem and 
Fell., 1981; Humber-Droz et al., 1983; Van Veen et al., 2000; Zheng et al., 1995; Ramaswamy et 
al., 1970; Jetzer, 1986; Ilkka and Paronen, 1993; Fell J., 1996). However, no simple relationship 
was observed between the properties of tablets prepared from binary mixtures to tablets 
prepared of single components. Three relationships have been discussed in the literature; 
linear, positive and negative relationships. The study carried out by Newton et al., (1977) 
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found that tablets prepared of dicalcium phosphate dihydrate (DCPD) and phenacetin had a 
higher tensile strength than tablets prepared from either individual alone (Newton et al., 
1977). The study suggested that the positive relationship is probably because the bonds 
formed between DCPD-phenacetin are stronger than the bonds between individual materials 
(Newton et al., 1977). Similar results were later found by Cook and Summers (Cook and 
Summers, 1985) when DCPD was co-compressed with aspirin. Although porosity, punch force 
and elastic recovery showed a linear relationship, the tensile strength of the prepared tablets 
showed a positive relationship (Cook and Summers, 1985). Linear relationship was reported by 
Newton et al., (1977) and Fell (1996) for different types of lactose. Such a good correlation was 
attributed to the similarity in the compaction properties and the bonding mechanisms of the 
two components. On the other hand, mixtures of brittle lactose and plastic sodium chloride 
had negative relationship. This was attributed to the ability of lactose to undergo brittle 
fracture resulting in higher proportion of lactose-lactose bonding which is believed to be 
weaker than that of sodium chloride (Sheikh-Salem and Fell, 1981). 
Despite the large number of studies conducted on binary mixtures only a few studies managed 
to propose a model to predict the mechanical properties of compacted mixtures (Leuenberger, 
1985; Van Veen et al., 2004). Percolation theory is widely used to explain the change of 
properties exhibited by binary mixtures. For instance, in binary mixture of materials A and B if 
powder B exists in a small fraction it will form isolated inclusions and form a dispersed phase. 
While the A powder will form the continuous phase. Because of the localized tension caused 
by the presence of a small amount of B, the behavior of powder A will change. Increasing the 
amount of B in the mixture will result in aggregate formation and at certain point in the 
concentration increasing of B, a network of B particles appears and this concentration 
represents the percolation threshold. Furthermore, during the compaction of A and B three 
kinds of interactions can take place: (1) A prefer bonding with A and B bonds preferentially 
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with B, or (2) the affinity of A-A or B-B bonding is similar to the affinity of A-B bonding or (3) A 
bonds preferentially with B.  
Indomethacin (IND) is a non-steroidal anti-inflammatory drug (NSAID) which is widely used to 
reduce pain associated with rheumatoid arthritis, osteoarthritis, bursitis and headache 
(Sweetman, 2005). The compaction properties of IND solid dispersion with crosspovidone was 
evaluated by (Shibata et al., 2005), and the study found that better tablets are obtained upon 
using microcrystalline cellulose and magnesium stearate. While the studies conducted by 
Tahvanainena et al (2012) found that IND can form good tablets with acceptable tensile 
strength upon loading with thermally oxidized mesoporous silicone microparticles 
(Tahvanainena et al., 2012), these tablets were found to have higher dissolution and 
permeability profile than the free IND. Although many studies evaluated the compaction 
properties of formulations containing IND, none of them investigated the densification 
mechanism of this anionic drug alone.  
Most of the active pharmaceutical ingredients (API) have poor compaction properties 
therefore pharmaceutical excipients such as tablets fillers, binders and disintegrants are 
incorporated in the formulation in order to improve the properties of the manufactured 
tablets. The first aim of this work is to characterise the compaction properties of three 
individual powders namely; IND, as a module drug and IND arginine salt (as its salt form) and 
arginine (as a tablet filler for the free drug and the salt form), The second stage of this work 
will utilize Response Surface Modeling (RSM) to predict the characteristics of binary mixtures 
between the free drug and arginine (PMs) and the IND salt form with arginine (SMs) and 
compare the predicted results against the experimental data.   
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3.2.2. Materials and methods 
3.2.2.1. Materials 
Indomethacin (TLC ≥ 99%), L-Arginine (non-animal source) and magnesium stearate were 
purchased from Sigma Aldrich (Dorset, UK). Ethanol was purchased from Fisher Scientific 
(Loughborough, U.K.) 
3.2.2.2. Methods 
3.2.2.2.1. Physical mixtures (PMs) and salt preparations. 
 
PMs of IND with various molar ratios of arginine were prepared by weighing accurate amount 
of TMP and mixed by KitchenAid (Michigan, USA) at mixing speed of 3 for 5 minutes with the 
various ratios of of arginine. IND arginine salt was prepared using the ElShaer et al method 
(2011). Equimolar amounts of IND and the free amino acid were solubilised in water and the 
solutions were mixed and stirred until equilibration then filtered. The filtrate was transferred 
into vials and freeze dried for 48h using  a Modulyo freeze dryer at -40oC shelf temperature 
and under vacuum created by (E2M5 Edwards pump) then samples were collected and kept at 
40oC for 4h using a Gallenkamp vacuum oven. Salt excess amino acid mixtures (SMs) were 
prepared by the same way as PMs. 
3.2.2.2.2. Tap density and Powder flow (Hausner’s ratio and Carr’s index) 
 
USP I apparatus (Sortax tap density tester) was used to measure the true density of the 
powders. 15 gm of the powders was weighed and poured into a 100 mL measuring cylinder 
and the initial volume of the powder was recorded as zero tap (bulk volume). The machine was 
allowed to vibrate at 50, 100, 150, 200 and 250 taps and the final volume after each tapping 
was recorded.  
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Carr’s compressibility index was used to study the flow characteristics of the powders and was 
calculated from equation (3.2.1). 
100' ×
−
=
t
pt
sCarr
ρ
ρρ
 Equation 3.2.4 
 
While the Hausner ratio was used to evaluate the ease of powder flow and equation 
(3.2.2) was used to work it out. 
p
tHausner
ρ
ρ
=   Equation 3.2.5 
Where ρt is the tapped density and ρp is the poured density. 
 
Table 3.2.23:- Flowability based on Hausner ratio, Carr’s Index and angle of repose according to BP 
guidelines (British Pharmacopoeia 2011). 
 
3.2.2.2.3. Particle Size Distribution Analysis (Sieve method) 
 
A set of sieves (Retsch AS 200) of diameter 710 µm, 355 µm, 250 µm, 125 µm, 90 µm, 75 µm 
and 63µm arranged in a decreasing order of their diameter were used to measure the 
powders’ particle size distribution. 15 gm of the powders were accurately weighed and placed 
on the top sieve and then allowed to shake for 12 minutes at amplitude of 60. The powder 
retained in each pan was weighed and the cumulative weight undersize was calculated and 
plotted against sieve diameter. This test was not carried out for the salts and their mixtures 
because of the small sample sizes  
 
 
Haunser Ratio 
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3.2.2.2.4. Tablet preparation 
 
Tabets of IND, its arginine salt and physical mixtures with excess of the amino acid counter ions 
at (1:1), (1:2), (1:4) and (1:8) molar ratios were prepared to study tableting properties. The 
powders were compacted using an uniaxial hydraulic press (Specac tablet presser) and split die 
which prevents mechanical failure by allowing triaxial decompression. Magnesium stearate in 
ethanol (5% w/v) was used to lubricate the die walls and punch surfaces. Powders were 
compressed at 5, 10, 20, 30, 40 and 60 kN and at dwell time of 30 sec.  
The prepared tablets were cylindrical with a diameter of 13 mm and weight of around 500 mg. 
Tablets were left in desiccators for 24 h prior to performing any mechanical testing. 
 
Tablet characterization 
3.2.2.2.5. Tensile strength measurements 
 
The force required to crush the prepared tablets was measured using a tablet hardness 
apparatus (Schleungier 4M, Thun, Switzerland). The measured force was used to determine 
the tablet tensile strength using equation (3.2.3). 
dt
Fc
pi
σ
2
=      Equation 3.2.6 
Where σ is the tablet tensile strength, Fc is the crushing force required to break the tablet, d is 
the tablet diameter and t is the tablet thickness. All measurements were done in triplicate. 
3.2.2.2.6. Heckel analysis 
The Heckel equation (3.2.4) was used to analyze tablets’ compression data (Heckel, 1961a). 
AKPD +=− ))1/(1ln(   Equation 3.2.7 
Where D is the tablet relative density at pressure P, K is a material constant (slope of the 
straight line portion of Heckel plot) and is 1/3 of the yield strength. 1/K value is used to express 
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the mean yield pressure. A is a function of the initial bulk volume and is calculated from the 
intercept of the straight line of the Heckel plot. 
3.2.2.2.7. Apparent, bulk particle density and porosity measurements 
 
Bulk density was determined by using 10 ml cylinder to measure the volume (V) of a pre-
weighed sample. Apparent particle density was measured using a helium pycnometer 
(Multipycnometer Quantachrome Instruments, Hampshire, UK). Both bulk and true density 
values were used to determine the powder porosity according to equation (3.2.5). 
)/1(100 td ρρε −=    Equation 3.2.8 
Where ε is the porosity and ρd is the bulk density and ρt is the true density. All the 
measurements were done in triplicate. 
3.2.2.2.8. Disintegration time studies 
 
Disintegration time is the time required for tablets to disintegrate completely without leaving 
any solid residue. In vitro disintegration time was evaluated using US pharmacopoeia 
monograph (<701> disintegration). Erweka ZT3, Appartebau, GMBH was used in this study as a 
disintegration apparatus and distilled water (800 ml) as disintegration medium; the 
disintegration medium temperature was maintained at 37 °C by thermostat. Six tablets were 
placed in the basket rack assembly and covered by a transparent plastic disk. The 
disintegration time was taken as the time required for tablets to disintegrate completely 
without leaving any solid residue. All the measurements are carried out in triplicate and 
presented as (mean ± standard deviation). 
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3.2.2.2.9. Design of the experiment 
 
MODDE software version 8 (Umetrics inc., USA) was used to design the statistical experiment 
for this study. Three levels full factorial design response surface modelling (RSM) with total 
runs of 24 of which three replicated centre points was selected for this study. 
The effect of two independent variables; compaction force (F) and arginine percentage (R) on 
three dependant variables (responses); porosity (P), tensile strength (S) and disintegration time 
(T) was studied. 
 
3.2.3. Results and discussion 
3.2.3.1. Powder characterisation 
 
Physical mixtures (PMs) of IND and arginine and salt mixtures (SMs) of IND salt and arginine 
were prepared in ratios of 1:1, 1:2, 1:4 and 1:8. The prepared PMs, SMs and individual 
powders of IND and arginine were characterised in terms of particle size distribution, 
flowability, bulk, true, tapped density and porosity. 
 
3.2.3.1.1. Particle size analysis 
 
Particle size analysis showed that IND:arginine 1:1 PM has the most uniform particle size 
distribution with its median of around 175 µm. Around 90% of 1:8 and 1:4 physical mixtures 
had particle size <350 µm. whilst the 1:2 and 1:1 ratios had 70% and 30% of the particles <350 
µm respectively. Particle size distribution of IND and arginine was comparable as 60% of IND 
molecules having a particle size <350 µm, and 70% of arginine particles having a particle size 
<350 µm (Fig. 3.2.1). 
The particle size analysis suggests that the IND dry powder and 1:2 physical mixture should 
have good flowability because of their large particle size. Whilst particles with particle size 
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lower than 100 µm are cohesive and flow problems occur (Staniforth, 2007). Therefore, it was 
interesting to carry out flowability studies for the individual powders and the physical mixture. 
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Figure 3.2.24– Particle size analysis of Indomethacin, L-Arginine and physical mixtures (n=3). 
 
3.2.3.1.2. Flowability studies. 
 
In this study the flow properties for IND, its salt, PMs and SMs were evaluated using angle of 
repose (Table 3.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 103
Table 3.2.24– Hausner Ratio, Carr’s Index and angle of repose for Indomethacin, L-Arginine and their 
PMs and SMs. 
Formulation Angle of 
Repose (Mean 
± SD, n=3) 
Hausner Ratio Carr’s Index Formulation Angle of 
Repose (Mean 
± SD, n=3) 
IND 36.89 ± 3.28 3.54 71.77   
L-Arginine 29.4 ± 0.84 2.70 63.00 IND arg Salt 36.00 ± 1.92 
PM 1:1 42.82 ± 0.07 3.11 67.88 SM 1:1 37.06 ± 3.56 
PM 1:2 41.44 ± 3.20 2.94 66.03 SM 1:2 24.83 ± 0.86 
PM 1:4 33.86 ± 4.30 3.36 70.23 SM 1:4 25.40 ± 0.37 
PM 1:8 29.85 ± 2.40 3.44 70.92 SM 1:8 26.60 ± 2.31 
 
Angle of repose measurements showed that IND has fair flowability (angle of repose= 36.89 ± 
3.28), whilst, arginine had excellent flowability (angle of repose= 29.4 ± 0.84). Although SEM 
images show large particle size of IND (Fig. 3.2.2), the drug showed fair flowability 
characteristics and this may be attributed to the positive surface charge carried by IND. This 
positive charge increases the adhesiveness to the surfaces and in turn deteriorates the flow of 
the powder as suggested by Soppelaa et al., (2010). On the other hand, SEM has shown 
elongated rods for arginine with rough surface which are believed to be the reason behind the 
good flowability of this amino acid. 
 Interestingly, the flow properties dropped (p<0.05) upon mixing IND and arginine at 1:1 and 
1:2 ratios. This is possibly because of significantly electrostatic interactions forming between 
the negative and positive charge on IND and arginine respectively which results in increasing 
the co-adhesion between the two binary mixtures. Beyond these two ratios increasing arginine 
concentration resulted in increasing the overall negative charge on the mixture and hence the 
flowability of the powder mixture (Table 3.2.2) improved from passable at 1:1 and 1:2 ratios 
into excellent flowability (29.85 ± 2.40) at 1:8 ratio. 
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Figure 3.2.25:- SEM images for (A) IND and (B) ar ginine, (C) IND arginine salt. 
 
On the other hand, flow properties for all the powders were found to be poor upon using the 
Hausner ratio and Carr’s index methods (Table 3.2.2). Such variation between the two 
methods is possibly because the Hausner ratio and Carr’s index are one-point determinations 
that do not take into account the ease or speed with which consolidation of the powder occurs 
(Staniforth, 2007). Materials with high index which are supposed to have low flowability were 
found to consolidate quickly and hence had more uniform filling on tablet machines. The study 
conducted by Li et al found a similar trend in that powders which showed good flowability 
according to Hausner ratio exhibited poor flowability when tested using the bin-flow test and 
vice versa (Li et al., 2004). 
 
 The flowability characters of IND arginine salt and SMs were studied as well by measuring the 
angle of repose of the powders. Haunser ratio and Carr’s index were not carried out because of 
the low amount of the salt obtained via freeze drying. 
A B 
C 
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Although IND arginine salt has zero net charge on its surface, yet its flowability (AOR= 36.00 ± 
1.92) was similar to that of IND free acid. The poor flowability of the salt form is possibly 
because of the agglomerate like structure of its particles formed during its freeze drying as 
suggested by Soppelaa et al., (2010) and Alhusban et al., (2011). In contrast to the PMs, salt 
binary mixtures showed increase in the flowability characteristics as the amount of arginine 
increased in the mixture (Table 3.2.2) probably because no co-adhesion occurs between the 
cationic arginine as the salt carries no charges on its surface. Hence, increasing the ratio of the 
amino acid in the mixture resulted in increasing the negative charge and enhancement of 
flowability.  
 
Table 3.2.25:- Weight, volume Bulk Density, True Density and Porosity of IND, arginine and their PMs 
Formulation Weight 
(g) 
(M± SD, n=3) 
Volume 
(cm
3
) 
(Mean ± SD, 
n=3) 
Bulk Density 
(g/cm
3
) 
(Mean ± SD, 
n=3) 
True Density 
(g/cm
3
) 
(Mean ± SD, 
n=3) 
Porosity 
(Mean ± SD, 
n=3) 
IND 1.01 ± 0.01 2.43 ± 0.15 0.41 ± 0.03 1.44 ± 0.04 0.71 ± 0.02 
L-Arginine 1.01 ± 1.01 2.10 ± 0.10 0.48 ± 0.02 1.50 ± 0.31 0.67 ± 0.09 
PM 1:1 1.01 ± 0.00 2.67 ± 0.06 0.38 ± 0.01 1.58 ± 0.14 0.76 ± 0.02 
PM 1:2 1.01 ± 0.01 2.60 ± 0.10 0.39 ± 0.02 1.52 ± 0.34 0.74 ± 0.06 
PM 1:4 1.01 ± 0.00 2.23 ± 0.15 0.45 ± 0.03 1.54 ± 0.21 0.70 ± 0.06 
PM 1:8 1.01 ± 0.00 2.30 ± 0.10 0.44 ± 0.02 1.50 ± 0.14 0.71 ± 0.03 
 
3.2.3.1.3. Porosity studies 
 
Bulk density, true density and porosity were measured for the individual powders and physical 
mixture and are summarised in Table (3.2.3). IND bulk density was found to be 0.41 ± 0.03 
whilst that of arginine was 0.48 ± 0.02. Upon preparing physical mixtures of IND and arginine, 
the bulk density dropped significantly (p<0.01) to 0.38 ± 0.01 which is lower than that of IND 
and arginine alone. A similar trend was observed in ElShaer et al (in press) studies with 
TMP/aspartic acid physical mixture (chapter 4.2) and as suggested, it may be because of the 
overall reduction of the repulsion force between similar by charged molecules in the same 
powder with such reduction caused by the addition of counter ions which carry opposite 
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charge (ElShaer et al., 2012). Nevertheless, the true density and powder porosity were the 
same for all the formulations and no significant difference was found between any of them 
(Table 3.2.3). 
 
Table 3.2.26:- Weight, volume, bulk density, true density and porosity of IND salt and the SMs 
Formulation Weight (g) 
(M±SD, n=3) 
Volume (cm
3
) 
(M±SD, n=3) 
Bulk Density 
(g/cm
3
) 
(M±SD, n=3) 
True Density 
(g/cm
3
) 
(M±SD, n=3) 
Porosity 
(M±SD, n=3) 
IND arg Salt 0.50 ± 0.00 3.07 ± 0.06 0.16 ± 0.00 2.13 ± 0.06 0.92 ± 0.00 
SM 1:1 0.50 ± 0.00 1.80 ± 0.01 0.28 ± 0.02 1.80 ± 0.05 0.85 ± 0.01 
SM 1:2 0.50 ± 0.00 1.77 ± 0.06 0.28 ± 0.01 1.96 ± 0.05 0.86 ± 0.01 
SM 1:4 0.50 ± 0.00 1.50 ± 0.10 0.33 ± 0.02 2.08 ± 0.12 0.84 ± 0.00 
SM 1:8 0.50 ± 0.00 1.53 ± 0.32 0.34 ± 0.06 1.95 ± 0.02 0.83 ± 0.02 
 
Analysis of bulk density for SM suggested that an increase in bulk density decreases the 
porosity although statistically there was no difference found between any of the formulations 
in bulk density, true density and porosity data shown in Table 3.2.4 (p>0.05).  
Powder characterisation has shown better bulk densities and porosity for the salt form and the 
SMs when compared to the free drug and its PMs which could be attributed to the way the salt 
form was prepared as the lyophilized salt would have a highly porous structure and in turn 
higher bulk density (Alhusban et al., 2011). 
3.2.3.2. Densification properties of individual powders 
 
After the full powder characterisation, the compaction properties of each individual powder 
were studied in order to understand their densification mechanisms prior to conducting the 
RSM and experimental studies for the binary mixtures. 
The reduction of the material volume that accompanies an applied pressure is known as 
compressibility (Joiris et al., 1998). The compressibility behaviour of pharmaceutical powders is 
evaluated by plotting the tablet porosity against the compaction force (Joiris et al., 1998). For a 
pharmaceutical powder to form a strong compact, the material should be highly compressible, 
i.e. have smaller porosity upon compression in order to enable particles to get closer to each 
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other and increase the bonding area between the particles. Fig. 3.2.3 shows the 
compressibility profile of the three individual powders; IND, arginine and IND arginine salt. 
Generally, increasing the compression force resulted in a decrease in the tablets’ porosity. The 
highest compressibility profile was exhibited by the salt. Probably because of the highly porous 
structure of the salt form obtained during the freeze drying cycle which might have resulted in 
poor packing due to cohesiveness of the powder as reflected by its flowability. The high 
compressibility profile of the salt form would enable the formation of strong tablets because of 
the high interparticulate bonding area created upon densification of this highly compressible 
powder. On the other hand, IND free acid showed the lowest compressibility profile as the 
tablet porosity was 0.52±0.01 at 5 kN and slight dropped to 0.46 upon doubling the 
compression force then no significant (P>0.05) change was observed even at the very high 
compression forces. Arginine compressibility was between that of the free acid and the salt 
form (Fig. 3.2.3). 
In order to understand the densification mechanism of the individual powders, Heckel analysis 
was carried out. 
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Figure 3.2.26:-  Plots of tablet porosity against compaction pressure, showing the compressibility of 
IND, arginine, IND arginine salt (n= 3). 
 
It is known that the plastic properties of pharmaceutical powders play an important role during 
the densification of the powder. Therefore, Heckel analysis was carried out and both the yield 
strength and yield pressure were calculated using Heckel equation (Equation 3.2.4) and 
summarised in Table (3.2.5). Heckel graphs for the powders showed initial curvature 
representing the particle fragmentation and rearrangement in the die. This is followed by a 
linear relationship between compaction force and -ln porosity, the slope of which indicates the 
degree of plastic deformation and consequently yield strength (Staniforth, 2007). Heckel 
analysis showed that IND arginine salt and arginine have yield strengths of 43.85 and 28.01 
respectively. Which reflects the high plasticity of the two powders especially arginine. 
Nevertheless, the analysis showed a very low plastic characteristics and high elastic 
deformation of IND that take place during compaction as the yield strength was found to be 
208.33.  The high elastic behaviour of IND affected the integrity of its prepared tablets and 
problems such as capping, lamination and breakage were observed.  
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Table 3.2.27:-  Summary of Heckel analysis and tensile strength at zero porosity (σ0) for IND, arginine, 
IND arginine salt, PMs and SMs. 
Formulation σ0 Yield 
pressure 
Yield 
strength 
Formulation σ0 Yield 
pressure 
Yield 
strength 
IND 1.13 625 208.3333 Salt 3.35 131.5789 43.85965 
Arginine 381 84.03361 28.0112 SM 1:1 4.12 208.3333 69.44444 
PM 1:1 1289.9 185.1852 61.7 SM 1:2 29.33 166.6667 55.55556 
PM 1:2 223.9 72.46377 24.15459 SM 1:4 147.12 188.6792 62.89308 
PM 1:4 217.65 62.5 20.83333 SM 1:8 588.54 109.8901 36.63004 
PM 1:8 n/d 107.5269 35.84229     
 
The ability of pharmaceutical powders to form a strong tablet during densification is known as 
compactability and can be represented by plotting the tensile strength against porosity. 
The compactability profile of IND, IND arginine salt and arginine were studied and are 
summarised in Fig. 3.2.4. As suggested by Ryshkewitch, (1953) an exponential correlation 
between tablets tensile strength and porosity was observed for both arginine and the IND 
arginine salt, i.e. increasing the tablet porosity resulted in an exponential decrease in the 
tablets’ tensile strength. However for unknown reasons IND showed a weak correlation (Fig. 
3.2.4). The highest compactability was exhibited by arginine and because the compactability 
reflects the strength of bond formation, this suggests that strong bonds are formed during the 
densification of arginine. In contrast to IND which showed the lowest compactability 
indicating, the weak bond formation under the compaction. In order to calculate the tablets’ 
tensile strength at zero porosity the Ryshkewitch equation (Equation 3.2.6) was used and 
results are summarised in (Table 3.2.5). 
εσσ be−= 0   Equation 3.2.9 
 
Where σ is the tensile strength σ0 is the tensile strength at zero porosity, ε is the porosity and b 
is a constant. 
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Figure 3.2.27:- Plots of tablet tensile strength against porosity, showing the Compactability of IND, 
arginine, IND arginine salt (n= 3). 
 
 
Another property is tabletability which is known as the ability of powder to form a tablet of 
specific strength while exposed to compaction pressure. The tabletability profile of a 
pharmaceutical powder can be expressed by plotting tablet tensile strength against 
compaction force (Sun and Grant, 2001). Both powder compressibility, which affects the 
bonding area and compactability properties of the powder which reflects the strength of bond 
formation determine the tabletability characteristics of the pharmaceutical powder. Figure 
3.2.5 shows that increasing the compaction force results in increasing the tensile strength for 
the tablets. IND powder showed the lowest tensile strength (0.21±0.05) at 60 kN. This result 
was expected as Heckel analysis revealed the high elasticity of IND while the compactability 
data showed weak bond formation. On the other hand, the cationic amino acid tablets showed 
the highest tensile strength and IND arginine salt tablets had good tabletability. Although the 
salt form showed better compressibility, its tabletability was not as great as the arginine. This 
assumes that compactability of the powder is the main determinant of the compacts strength.  
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Figure 3.2.28:- Plots of tablet tensile strength against compaction pressure, showing the tabletability 
of IND, arginine, IND arginine salt (n= 3). 
 
 
The ability of the tablets to disintegrate in water was evaluated and the disintegration results 
revealed that increasing the compaction force deteriorates the tablets’ disintegration time. 
Although compressibility data revealed the high porosity of IND, the free acidic drug showed a 
very poor disintegration and the drug failed to disintegrate even after 20 minutes (Fig 3.2.6). 
The high lipophilicity of IND could be the reason behind its poor disintegration. Hansch and Leo 
reported the log P value of IND to be 3.8 (Hansch and Leo, 1979) which reflects its low 
hydrophilicty, low wettability (Fukami et al., 2005) and hence the extended disintegration 
time.  
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Figure 3.2.29:- Disintegration time for IND, arginine and IND arginine salt (n=3) (¥; tablets failed to 
disintegrate within 20 minutes), (*** p<0.001). 
 
However, arginine tablets showed very rapid disintegration time (25.3±2 s) for tablets 
compressed at 30 kN despite having high tensile strength (1.23±0.09). Probably because of the 
high hydrophilicity of arginine as it has low log P value of 0.69 (Kennedy et al., 2000) and 
therefore high wettability and fast disintegration. Although the salt form was found to be 
highly hydrophilic (ElShaer et al., 2011), the disintegration time was not as low as that of 
arginine and this might be attributed to the very low porosity of the salt tablets as suggested 
by the compressibility data. Low porosity results in poor water penetration into the tablets and 
hence a longer disintegration time is required. 
3.2.3.3 Comparison between the predicted and experimental data for binary mixtures 
3.2.3.3.1. Compressibility characterisation of the binary mixtures 
 
The characterisation of the individual powders showed that arginine has very high bonding 
capacities and its tablets disintegrate quickly. This means that incorporating the amino acid 
into the formulations, should improve the tablets’ characteristics. Moreover, studies carried 
out in our lab showed that adding arginine to the formulation improves anionic drugs 
dissolution and absorption through intestinal membranes (data discussed in the next chapter). 
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Therefore, an experimental design was used to predict the effect of incorporating arginine to 
IND, which showed very poor compaction and disintegration characteristics, and IND arginine 
salt in an attempt to fit a model that could predict the compaction properties of the binary 
mixtures and compare it against the experimental data.  
The compaction force is an important factor that affects the porosity and tensile strength of 
the tablets. Hence the compaction force (F) was selected as an independent variable and 
compaction force was changed between 5-60 kN. The arginine ratio (R) –ranging between 0-
100%- in the binary mixture was the second variable and was selected for the reasons 
mentioned above. The effect of these two independent variables on tablet porosity (P), tensile 
strength (S) and disintegration time (T) was studied using response surface modelling (RSM). 
RSM was preferred over screening modelling because the aim of the study is to predict effect 
of both the compaction force and arginine ratio on the tablets characteristics. A full factorial 
design with each factor varied at three levels was selected, and the model was fitted to the 
multiple linear regression (MLR) because the total number of responses was not more than 3. 
The significance of the quadratic model (linear, interactive and polynomial) on the dependent 
variables was carried out using analysis of variance (ANOVA) and the quantitative effects of the 
independent variables on the responses was considered significant at a 95% confidence level 
(p< 0.05). A high degree of reproducibility was obtained for most of the responses (Fig. 3.2.7), 
which suggest that the three responses are strongly dependent on the two independent 
variables. 
                                                 
 
 114
0
0.2
0.4
0.6
0.8
1
1.2
Porosity  Tensile strength  Disintegration time
R
ep
ro
du
ci
bi
lit
y 
(r2
)
IND/arginine PM INDsalt/arginine SM
 
Figure 3.2.30:- Reproducibility of the results for all three responses which represents the variation of 
the response under the same conditions (pure error) compared with the total variation of the 
response.  
 
Table (3.2.6) summarise the effect of each independent factor on the responses; the sign of 
the effect represents the trend while the values indicate the magnitude of this effect. The data 
show that both the compaction force (F) and arginine ratio (R) have a significant (P< 0.001) 
influence on IND tablet porosity. Figure (3.2.8A) shows that increasing the compaction force 
and arginine ratio causes a decrease in the tablets porosity. Nevertheless, the effect of 
compaction force (0.16) was twice that of arginine ratio (0.08). Interestingly the interactive 
term FR was found to have an antagonistic effect as the magnitude of decrease in the tablet 
porosity (P) was less than the effect of each single term.  
Table 3.2.6:- The quantitative factor affecting tablets porosity and their associated p value for the 
responses. 
 Porosity 
term IND IND arginine salt 
 Effect p value Effect p value 
F -0.1598 <0.001 -0.3045 <0.001 
R -0.07805 0.001176 -0.0175 0.578895 
F2 0.154053 <0.001 0.25403 <0.001 
R2 -0.02275 0.46393 0.2332 <0.001 
FR -0.06226 0.0217 0.06554 0.100594 
 
Looking at IND-arginine salt/arginine binary mixtures (Fig. 3.2.8B, Table 3.2.6) showed that 
only the compaction force influences the porosity of the tablets (0.3), while incorporating 
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arginine had no significant effect on the porosity (p>0.05). This is probably because of the high 
compressibility of the salt form which was found to be higher than the cationic amino acid and 
hence masked the effect of arginine which appeared to be significant upon mixing with low 
compressible IND.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.31:- Surface response plot showing the effect of compaction force and arginine ratio on 
tablets porosity for (A) IND/arginine binary mixtures, (B) IND salt/arginine binary mixtures 
 
The MLR was used to fit the mathematical equation and the response surface plots (3D) which 
could be used to predict the tablet porosity by inputting the experimental conditions using the 
two independent variables; F and R. 
The mathematical expression for working out the porosity of IND/arginine binary mixtures is 
equation (3.2.7) 
FRFRFPInd 062.015.0078.0159.0343.0 2 −+−−=         Equation 3.2.10 
PorosityPorosity
A B 
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While that for the salt form is expressed in equation (3.2.8) 
22 23.025.03.015.0 RFFPSalt ++−=      Equation 3.2.11 
 
Where PInd is the porosity for IND/arginine PMs, PSalt the porosity of IND salt/arginine SMs, F is 
the compaction force and R is arginine percentage in the binary mixture. 
 
The compressibility profile for IND and the salt with various ratios of arginine was studied in 
order to compare the experimental findings against the predicted data (Table 3.2. 6). 
Figure (3.2.9A) shows the compressibility profile for IND/arginine binary mixtures. Similar to 
the individual powders, increasing the compaction force resulted in decreasing the tablet 
porosity. The highest compressibility was exhibited by arginine> PM 1:4> PM 1:2> PM 1:1> IND 
Heckel analysis (Table 3.2.5) showed that PM 1:4 has the highest plasticity as its yield strength 
was found to be (20.83) and the elasticity of IND (yield strength of 208.33) dropped 
significantly upon incorporating arginine into the formulations (yield strength of 61.7 at PM 
1:1). These results confirm the quadratic model findings which suggested the significant role of 
adding arginine on the tablet porosities.  
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Figure 3.2.32:-  Plots of tablet porosity against compaction pressure, (A) Compressibility of IND, L-
arginine and PM’s and (B) Compressibility of IND salt and SM’s (n=mean±SD and n=3). 
 
On the other hand, studying the compressibility profile for IND salt/arginine mixtures (SMs) 
showed that only SM at 1:1 (50 % arginine) ratio had higher compressibility than the salt form 
while other has not been significantly affected when adding the amino acid. Moreover, Heckel 
analysis revealed that there is no big difference between the yield strength of the salt form 
and the salt mixtures with arginine (Table. 3.2.5) which reflects the low changes in the 
compressibility profile upon incorporating arginine. The porosity for most of the ratios 
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dropped significantly upon increasing the compaction pressure which suggests that the 
compaction force is the main determinant of the compressibility profile for the SMs. These 
results go in line with the RSM model. 
 
3.2.3.3.2. Tabletabiliy characterisation 
 
In order to predict the ability of arginine binary mixtures with IND and the salt to form a tablet 
of specific strength while exposed to compaction pressure (tabletability), RSM was carried out 
and figures (3.2.10A) and (3.2.10B) were generated for IND/arginine PMs and salt/arginine 
SMs respectively.  
Tensile strength was the second response evaluated in this study and the predicted data 
showed that IND tablets tensile strength was significantly (P< 0.001) increased upon increasing 
both the compaction force (F), arginine ratio (R) and their interactive term (FR). The 
compaction force (F) and arginine ratio (R) were found to have the same magnitude of effect 
on the tablets’ tensile strength; 1.73 and 1.79 respectively (Table 3.2.7). 
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Figure 3.2.33:- Surface response plot showing the effect of compaction force and arginine ratio on 
tablets tensile strength for (A) IND/arginine binary mixtures and (B) IND salt/arginine binary mixtures. 
 
Interestingly, combining both factors (FR) during the preparation of the tablets was found to 
have a synergistic effect (2.032) on the tablets’ strength. This effect could be explained by the 
ability of arginine to improve the compressibility of IND tablets which in turn improves the 
interparticulate bonding area. Besides, its ability to enhance the bond formation during 
densification as reflected by the compactability studies. Because both compressibility and 
compactability are pre-determinant of tablet strength, hence an increase in the tensile 
strength was observed. Moreover, this synergistic effect could reflect strong bonding between 
IND and arginine which achieved highest value at 50% of arginine (PM 1:1) as suggested by the 
high (σ0) value as early suggested by Sheikh-Salem and Fell., (1981). None of the polynomial 
terms (F2 or R2) were found to be effective (p>0.05) on the tablets hardness. 
Tensile strength
Tensile strength
A B 
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Table 3.2.28:- The quantitative factor affecting tablets tensile strength and their associated p value for 
the responses. 
 Tensile strength 
term IND IND arginine salt 
 Effect p value Effect p value 
F 1.73733 <0.001 1.938 <0.001 
R 1.79459 <0.001 1.0815 0.02527 
F2 -0.4075 0.289239 -0.2607 0.702288 
R2 0.28075 0.45716 0.72462 0.28989 
FR 2.0324 <0.001 1.711 0.00544 
 
Similarly, incorporating arginine to the salt formulations showed similar trends and the tablets’ 
tensile strength was increased upon increasing the compaction force and arginine ratio. 
Nevertheless, the compaction force was the main determinant of the tablets’ hardness for the 
SMs as the magnitude of effect exhibited by the compaction force (F) was twice (1.938) that of 
arginine ratio (1.08) (R). Moreover, the interactive term (FR) was found to antagonise the 
effect of compaction force as combining the two factors was found to be less effective (1.71) 
than the compaction force alone (1.94). Mathematical equations (3.2.9 and 3.2.10) and 
response surface plots were generated after the model was fitted to MLR, and could be used 
to predict the tablets tensile strength if the compaction force and arginine ratio are known. 
FRRFS Ind 03.279.173.1022.1 +++=   Equation 3.2.12 
 
FRRFSSalt 711.108.1938.1083.1 +++=   Equation 3.2.13 
 
Where Sind is the tensile strength for IND/arginine PMs, Ssalt is the tensile strength for IND 
salt/arginine SMs, F is the compaction force and R is the arginine percentage. 
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Figure 3.2.34:-  :-  Plots of tablet tensile strength against compaction pressure showing (A) 
Tabletability of IND, ARG and PM’s, (B) Tabletability IND salt and SM’s (n=3). 
 
 Experimental studies of the effect of compaction force and arginine ratios on the tensile 
strength for PMs and SMs were studied and summarised in Fig. 3.2.11. 
Similar to individual powders, a linear relationship was observed between the tablets tensile 
strength and compaction force, i.e. increasing the compaction force resulted in increasing the 
tensile strength for all the formulations. The highest tabletability was shown by arginine> PM 
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1:2≈ PM 1:4> PM1:8 >PM 1:1. While IND free acid which showed the lowest tabletability 
properties among the PMs (Fig. 3.2.11A). The compressibility and compactability similarities 
between 1:2 and 1:4 PMs might be behind their similar tabletability. 
Fig. 3.2.11B shows the tabletability profile of the SMs, again it was clear that increasing the 
compaction force increased the tablet tensile strength. However, SM at 1:2 showed a drop in 
the tablets’ strength at very high compaction force (Fig. 3.2.11B) which could be because of 
the over-compaction. 
The highest tabletability was exhibited by arginine> SM 1:8> SM 1:4 > SM 1:1≈ SM 1:2:> salt. 
The practical data shows clearly that the compaction force has a strong effect on the tablet 
strength for both the IND and the salt mixture as suggested by the RSM model. Furthermore, 
the effect of arginine ratio in salt binary mixture is believed to go in line with the data 
suggested by the model. Nevertheless, IND/arginine physical mixtures data has not 
demonstrated similar trend and the effect of arginine ratio on the tablet hardness of the PM 
was not clear. 
 
3.2.3.3.3. Disintegration studies 
 
Disintegration time was the last response to be evaluated in this study. The significant terms 
which were found to affect the disintegration time for IND/arginine PMs tablets were 
identified as compaction force (F), arginine ratio (R), the interactive term (FR) and the 
polynomial term of arginine ratio (R2). Increasing the compaction force (F) was found to 
increase the disintegration time by a magnitude of (262.16) while increasing the ratio of 
arginine in the mixtures were found to decrease the time required for the tablets to 
disintegrate significantly (p< 0.001) and even by higher magnitude when compared to the 
compaction force (F). Although the arginine ratio had higher impact on the disintegration time 
than the compaction force, the interactive term (FR) was found to delay the tablets 
disintegration for the PMs. 
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Table 3.2.29:- The quantitative factor affecting tablets disintegration time and their associated p value 
for the responses. 
 Disintegration time 
term IND IND arginine salt 
 Effect p value Effect p value 
F 262.167 <0.001  509.167 <0.001 
R -1069.51 <0.001 -513.834 <0.001 
F2 -43.4425 0.57141 -162.128 0.0259 
R2 250.25 0.00352729 -127 0.0706917 
FR 170.137 0.0119061 -192.515 0.00218 
 
 
On the other hand, RSM showed that both the compaction force and the arginine ratio have 
similar magnitude of effect on the disintegration time of salt/ arginine SMs. Nevertheless, the 
compaction force (F) was found to increase the disintegration time while the arginine ratio was 
found to speed up the tablets’ disintegration (Table 3.2.8). The interactive term (FR) was found 
to decrease the disintegration time for the SMs.  
Equations (3.2.11) and (3.2.12) can be used to describe the effect of the two independent 
factor; compaction force and arginine ratio on the effect of disintegration time for PMs and 
SMs, respectively. 
FRRRFTInd 17025.25051.106916.262055.556 2 ++−+=     Equation 3.2.14 
FRFRFTSalt 5.19212.16283.51316.509647.504 2 −−−+=   Equation 3.2.15 
 
Where Tind is the disintegration time for IND/arginine PMs, Tsalt is the disintegration time for 
IND salt/arginine SMs, F is the compaction force and R is the arginine ratio. The three 
dimensional surface plots were generated using the software and simulates the effect of 
compaction force and arginine ratio, individually and simultaneously, on the disintegration 
time for the PM (Fig. 12A) and SMs (Fig. 3.2.12B). 
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Figure 3.2.35:- Surface response plot showing the effect of compaction force and arginine ratio on 
tablets disintegration time for (A) IND/arginine binary mixtures and (B) IND salt/arginine binary 
mixtures 
 
 
The experimental data for the effect of compaction force and arginine ratio on the 
disintegration time for the PMs and SMs are summarised in Figures 3.2.13A and 3.2.13B 
respectively. 
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Figure 3.2.36:- (A) Disintegration time for IND, ARG and PM’s (B) Disintegration time for IND salt and 
SM’s 
 
 
The addition of arginine to IND tablets was found to drop the disintegration time significantly 
(Fig. 3.2.13A). It usually takes more than 20 minutes for IND tablets (compressed at 5 kN) to 
disintegrate and upon adding 50% arginine (PM 1:1) to the formulations the disintegration 
time was dropped to 195±117 sec. Moreover, increasing the ratio of arginine in the 
formulation was found to significantly decrease the disintegration time (Fig 3.2.13A). The 
effect of compaction force (F) on the disintegration time was significant upon applying low 
0
100
200
300
400
500
600
700
800
900
1000
1100
1200
1300
1 2 3 4 5 6
Compaction Force (kN)
Di
si
n
te
gr
at
io
n
 
Ti
m
e 
(S
ec
s)
IND 1:1 1:2 1:4 1:8 L-Arginine
5               10                   20                 30                      40                 0 
A 
0
100
200
300
400
500
600
700
800
900
1000
5 10 20 30 40 60
Compaction Force (kN)
Di
si
n
te
gr
at
io
n
 
tim
e 
(S
ec
s)
IND:ARG Salt 1:1 1:2 1:4 1:8 L-Arginine
B 
                                                 
 
 126
forces and up to 30 kN. Beyond 30 kN the effect of force was insignificant. These data comes 
on line with the RSM findings which suggested that the arginine percentage is the more 
determinant as it has higher magnitude than that of the compaction force (Table 3.2.8). 
Studying the disintegration profile of IND arginine salt and SMs showed a similar profile to that 
of the PMs. Generally, increasing the compression force resulted in increasing the 
disintegration time (Fig. 3.2.13B). At most of the compression forces, the disintegration time 
was decreased in the order IND salt>1:1SM>1:2SM>1:4SM>1:8SM i.e. as the L-arginine ratio 
increase. Interestingly, the disintegration time of the SM 1:1 was faster than the salt form 
although the former had lower porosity than the latter as early observed in (Fig. 3.2.9B). This 
suggests that the incorporation of arginine in the formulation has a great impact on the 
disintegration time as suggested by the RSM. 
The correlation between the predicted values and the actual values of tablets’ porosity, tensile 
strength and disintegration times were compared (Fig. 3.2.14). A strong correlation (R2= 0.89) 
was observed between the predicted and actual values for tablets’ porosity. While weak 
correlation was observed for that of tablets’ tensile strength and disintegration time R2= 0.77 
and 0.61 respectively. This suggest that RSM can be used to predict tablets’ porosity for binary 
mixtures but not tablets’ tensile strength or disintegration time probably other factors may be 
involved during the process of tablet disintegration and tabletability. 
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Figure 3.2.37:- Correlations between actual and theoretical values for measuring (A) tablets’ porosity, 
(B) tablets’ tensile strength and (C) tablets’ disintegration time. 
3.2.3. Conclusion 
Individual powder characterisation showed good flowability properties of arginine as it had 
low angle of repose of (29.4 ± 0.84) mainly because of its large particle size and rough surface 
of its particles. Moreover, the tablet characterisation showed that arginine could be used 
successfully as a tablet filler, binder and disintegrant because of it’s good compressibility, 
compactability and low disintegration time.  RSM showed that both compaction force and 
arginine ratio could have a significant impact on tablets’ porosity, tensile strength and 
disintegration time. Nevertheless, RSM could not be used to predict the tensile strength and 
disintegration time of the tablets probably because of the involvement of other factors such as 
the type of forces formed at various ratios of the binary mixtures. 
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The effect of ion-pairing indomethacin with arginine/lysine on its permeability 
profile across Caco-2 cells 
 
3.3.1. Introduction 
Indomethacin (IND) is a non steroidal anti-inflammatory drug which is used for the treatment 
of rheumatoid arthritis. IND was first introduced in 1962 as a treatment for inflammation. IND 
is a weakly acidic drug (pKa= 4.5) and has poor solubility because of its hydrophobic nature (log 
P=3.1). Nevertheless, IND diffuses quickly and is completely absorbed through the intestinal 
membrane after oral ingestion and can therefore be classified as a class II drug under the 
biopharmaceutical classification system (BCS).  
pH partitioning theory for charged drug candidates states that  lipid membrane bilayers only 
allow the absorption of unionised (molecular form) drug candidates while the charged species 
do not pass through the membrane (Shore et al., 1957) . However, investigations over the last 
couple of decades on oral drug absorption have demonstrated the role of other factors in drug 
absorption. Daniel et al. (1985) and McEwain and Lucas (1990) suggested that the acidic 
microclimate of the drug at the surface of the epithelium has an effect on the passive uptake 
of uncharged weakly acidic drugs which was known as pH shift (Winne, 1977). Although 
passive diffusion is the main mechanism of absorption for majority of drugs, carrier mediated 
transporters, found in mucosal and serosal membranes can be involved in the transport of 
acidic drugs. Tsuji et al., (1994) investigated the mechanism of absorption of monocarboxylic 
acid drugs through various ion channel transporter systems. The results showed that carboxylic 
acid drugs were primarily carried across the intestinal cells through H+ gradient dependant 
transporter systems when compared to Na+ dependent carrier systems. Although the study by 
Tsuji et al., (1994) identified the role of a specific carrier system in the transport of acidic 
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drugs, the contribution of active influx to net transport of the drug was not clear suggesting 
the wider role of alternative/complimentary carrier systems in the absorption of weakly acidic 
drugs. The next set of studies published by Ganapathy et al., in 1995 identified H+ coupled 
oligopeptide transporters (PEPT)-1 (SLC15A1) expressed in human small intestine and was 
shown to mediate the absorption of anionic angiotensin converting enzyme inhibitors and B-
lactam antibiotics. Similarly, monocarboxylic acid transporter (MCT)-1 also known as SLC16A1 
was believed to play an essential role in the rapid transport of monocarboxylates.  Recent 
studies by Kobayashi et al., 2003 identified another super family of organic anion transporting 
polypeptide (OATP)-B expressed in the apical membrane of the small intestine with a specific 
role for the transport of anionic molecules across the gut.  
The current investigation focuses on the permeability profile of the weakly acidic model drug 
indomethacin (IND). IND was selected for this study as it is metabolically stable at intestinal pH 
and  previous studies from our lab (ElShaer et al., 2011) showed a substantial improvement in 
solubility and dissolution upon addition of cationic amino acids (lysine and arginine). The 
primary hypothesis of this study was to explore the role of ion-pairing IND with cationic amino 
acids (arginine and lysine) on drug uptake across Caco-2 cells. Arginine and lysine were 
selected for this study because they carry positive charge upon ionisation which could interact 
electrostatically with the anionic carboxylic group of IND to form ion-pairs. Moreover, arginine 
and lysine have a full transporter system on the epithelial cells hence an alternative 
transporter system would be created for IND and higher absorption profile could be achieved. 
Solute carrier transporter SLC3A1 (b0,+) is the major transporter of the cationic amino acids and 
expressed mainly in the apical membrane of the small intestine (Broer, 2008). 
 
Caco-2 cells are human colorectal carcinoma cell lines and posses microvillus structure, 
hydrolysis enzymes and carrier mediated transporters and have been used to evaluate parallel 
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transport routes including passive and active transport (Dantzig & Bergin, 1990; Hilgers et al., 
1990; Chen et al., 1994). 
 
3.3.2. Materials and methods 
3.3.2.1. Materials 
Indomethacin (TLC ≥ 99%), L-Arginine (non-animal source), L-Lysine, 1-octanol (ACS 
spectrophotometric grade ≥ 99%) and ninhydrin reagent (2% solution) were purchased from 
Sigma Aldrich, UK. 
Acetonitrile, glacial acetic acid and absolute ethanol were purchased from Fisher Scientific UK. 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), Nonessential amino 
acids (NEAA), 1% pencillin-strepotomycin, 2mM glutamine and Hank’s balanced salt solution 
(HBSS) were purchased from Bio Sera, UK. 1% Trypsin–EDTA was obtained from Gibco Lab. UK. 
3.3.2.2. Methods 
3.3.2.2.1. Preparation of pre-saturated solution of 1-octanol and de-ionised water. 
1000 ml of de-ionised water was added to 4 mL of 1-octanol. The mixture was shaken for few 
minutes and left overnight. The de-ionised water was separated from 1-octanol using 1000 mL 
separating funnel. 
 
3.3.2.2.2. Octanol- water partitioning experiment  
500 µg of IND was added to 100 mL octanol-saturated deionised water with molar excess of 
arginine/lysine (in ratios 1:1, 1:2, 1:4 and 1:8). 5 mL of the aqueous phase was allowed to 
equilibrate with 5mL of octanol at room temperature and stirred for 24 hours using a magnetic 
stirrer. The two phases were then separated by centrifugation and IND concentration [INDt]Aq 
in the aqueous phase was measured using HPLC. Mass balance was used to calculated IND 
concentration in octanol phase [INDt]Oct using equation (3.3.1). 
[INDt]Oct = total drug put into the system- [INDt]Aq   Equation 3.3.16 
                                                 
 
 132
The apparent distribution coefficient DA could be calculated using equation (3.3.2) 
DA= [INDt]Oct/[INDt]Aq     Equation 3.3.17 
 
3.3.2.2.3. HPLC method to study the concentration of indoemthacin 
The amount of indomethacin (IND) dissolved in the solution samples was quantified by HPLC 
using a Dionex 1100 system with autosampler (AS50), gradient pump (GP50), UV detector 
(UVD 170U) and RP-C18 analytical column (Phenomenex 110A, 150x4.6 mm, 5µm). The 
analysis method was adapted from Song et al., (2004). IND was eluted using acetonitrile (60%) 
and 0.1 M acetic acid (40%) as a mobile phase and pumped at 1.0 mL/min flow rate. UV 
detector was adjusted at λmax of 248 nm (predetermined using Unicam UV-Visible 
Spectrophotometer). The retention time was 5.09±0.02 min and a rectilinear calibration curve 
was established at concentration range between 1-500µg/mL with 0.99 correlation coefficient. 
3.3.2.2.4. Ninhydrin analysis 
Ruhemann (1911) found that reacting ninhydrin with alanine under condensation of ammonia 
with hydrantoin (reduced form of ninhydrin) produced a blue coloured compound 
(diketohydrindylidene diketohydrindamine) known as Ruhemann purple (Fig. 3.3.1). 
Ruhemann found that the colour is produced upon reacting ninhydrin reagent with any acidic 
compounds that has α-NH2 side chain e.g amino acids, proteins and peptides. Therefore this 
method was used to determine the concentration of compounds containing α-NH2 photo-
metrically. 
 
The concentrations of arginine and lysine in octanol/water partitioning studies were quantified 
using the ninhydrin method. In order to construct a calibration curve, serial dilutions of the 
amino acids were prepared and 1 mL of the prepared samples was mixed with 0.5 mL of 
ninhydrin reagent and vortexed for 20 seconds. The samples were heated in a pre-warmed 
water bath at 80 oC  for 20 minutes. The samples were removed from the water bath and left 
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to cool. The intensity of the coloured Ruhemann purple was analysed using a UV 
spectrophotometry at a wavelength of 560 nm. 
Calibration curves were constructed with regression coefficient of 0.99 and 0.94 for arginine 
and lysine respectively. After constructing the calibration curves, the concentrations of the 
amino acids in the aqueous layer were determined using the linear curve equations (3.3.3) and 
(3.3.4) for arginine and lysine respectively. 
Y=0.421x    Equation 3.3.18 
Y=0.0481x   Equation 3.3.19 
 
NH
NH
NH2
NH2
+
O OH
O
OH
OH
O
N
O
O O
O
Ruhemann's Purple
L-arginine
O
OH
OH
O
Ninhydrin
O
H
OH
O
OH2 +
Reduction
Oxidative 
deamination 
Hydrindantin
NH
O
NH2
NH2
+
OHO
+NH3
CO2
NH
O
NH2
NH2
+
+
Decarboxylation
80 oC
Imino acidKeto acid
Hydrolysis
Direct 
combination
80 oC
 
Figure 3.3.38:- Schematic representation of ninhydrin reaction. 
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3.3.2.2.5. Procedure for Caco-2 cell culture 
Caco-2 cells at passage 48 were gifted from Huddersfield University and used at passages 50-
80. Cells were allowed to grow in 75cm² T-flasks and maintained using Dublecco’s modified 
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 0.5% pencillin-streptomycin, 2mM 
glutamine and 1% nonessential amino acids (NEAA). Culture medium was changed every 2 to 3 
days and cells were grown at a temperature of 37°C and 5% CO2.  The cells were passaged by 5 
mL trypsin-EDTA when they reach 90% confluence. Transepithelial transport assay was carried 
out using Khan et al., (2011) methods, 2 x 105cells/cm² were seeded on polycarbonate-coated 
membranes (6-well transwell plates, 24mm, 4.7cm²) and were allowed to grow for 21 days and 
the media in both apical and basal compartments were changed every 2-3 days. Transepithelial 
electrical resistance (TEER) was measured at the start and end of every study. 
 
3.3.2.2.6. Indomethacin permeability study 
Caco-2 monolayers were used 19-21 days after seeding. Apical to basolateral permeability of 
IND and IND PM formulations was assessed. The transwells were rinsed and incubated for 15 
minutes with drug-free transport medium (Hanks balanced salt solution; HBSS). Following 
incubation, HBSS was removed and 1.5 mL of the medium containing IND alone (500 µg/mL) 
and IND with various molar ratios of the cationic amino acids (1:1, 1:2, 1:4 and 1:8) were 
introduced to the apical side. Sample aliquots (300μL) were taken from the basolateral side at 
given time intervals (0, 5, 10, 15, 20, 30, 60 and 90 minutes). After each sampling, an equal 
volume of fresh transport buffer (pre-warmed at 37°C) was added to the receiver 
compartment (basal side) and kept the cells at a temperature of 37°C and 5% CO2 during 
experiment. Samples were subsequently analyzed by HPLC. In order to confirm the mass 
balance, samples were taken from both apical and basolateral compartments at the last time 
point (90 mins). All experiments were performed at 37°C (n = 5).  
Apparent permeability coefficient Papp (cm/s) was calculated using (equation 3.3.5) 
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0/1/ ACdtdQPapp ×=    Equation 3.3.20 
 
Where dQ/dt is the rate of appearance of the drugs on the basolateral side (nmol s-1), Co is the 
initial concentration on the apical side and A is the surface area of the monolayer (4.7 cm2). 
The data presented was validated using HPLC measurement of drug transfer during the 
process of permeability.  
3.3.2.2.7. Recovery 
The amounts of IND recovered from both apical and basolateral compartments at the end of 
the experiment were calculated using equation (3.3.6) and results are summarised in tablet 
(3.3.1).  
Recovery (%)
100
min0
min90min90 ×
×
×+×
=
DD
DDRR
VC
VCVC
          
Equation 3.3.21
 
 
Low recovery data are attributed to entrapment of the compounds into the cell monolayers or 
adsorption to the device surface which in turn results in error calculating the transport rate 
(Aungst et al., 2000) 
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3.3.3. Results and discussion 
Partitioning studies 
3.3.3.1. Octanol-Water partitioning.  
As mentioned above, the majority of the acidic drugs are transported mainly by passive 
diffusion. The surface area of brush border membranes is more than 1000 fold larger than the 
surface area available for paracellular transport (Pappenheimer, 1987) which leaves the 
passive transcellular route as the main mechanism of absorption for most of the drugs. Many 
studies were carried out to predict passive absorption across intestinal membrane based on 
various physico-chemical properties of the drugs. Various properties such as desolvation 
energy (Burton, 1992), hydrogen bonding capacity (Young, 1988; Conradi, 1991), molecular 
surface area (Barlow, 1994), surface activity (Seelig, 1994) and octanol/water partitioning 
coefficient (Martin, 1981) were studied to correlate drug absorption across cell membranes. 
Although using a single physico-chemical property to predict the permeability properties of 
drug molecule was an easy and simple tool to investigate, the outcomes showed a reasonable 
correlation to transcellular passive drug absorption.  
 
The most widely used predictor for drug absorption is the octanol/water partitioning (log P). As 
octanol has lipophilicity that resembles that of cell membranes, log P values are used to 
predict the capacity of drug molecules to partition into cell membrane.  
Our earlier work utilized hydrophilic amino acids as ion-pairs with the lipophilic IND to improve 
its solubility and dissolution profile.  As suggested by the pH partitioning theory, lipid 
membrane bilayers only allow the absorption of uncharged drug species while the charged 
species do not pass through the membrane (Shore et al., 1957). In our current study, it was 
expected that the ion-paired IND amino acid (salt form) (AB) would ionise in the aqueous 
medium into its respective ionic species (A-) and (B+) raising that prospect of 
unfavourable/poor transcellular absorption of the drug. Having studied the fundamental 
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principle of ionisation (Fig. 3.3.2), we decided to add excess of the basic counter ion (arginine 
and lysine amino acids in this study) to shift the equilibrium of salt ionisation towards the non-
ionised form of the salt (Fig. 3.3.2). Therefore, excess of the cationic amino acids were ion-
paired with the salt forms. 
 
AB                           A- +  B+ 
BOH                       OH- + B+ 
Figure 3.3.39:- schematic representation of the ionization of the salt form and the effect of adding 
excess of the basic counter ion on the ionisation equilibrium. 
 
The goal of this current study was to investigate whether incorporating hydrophilic amino acids 
at various molar ratios with the prepared salt forms, have an effect on the permeability profile 
of IND . 
Assuming that ion-pair formation between IND (acidic drug) and the basic amino acids 
(arginine/ lysine) in octanol-water mixture, at equilibrium conditions, there would be 
formation and destruction of ion-pairing and partitioning process between octanol-water. 
Miller, (2009) and Connors, (1987) and Grant and Higuchi (1990) defined the association 
constant for ion-pair formation in the aqueous phase K11aq in equation (3.3.7). 
aqaq
aq
aq BA
AB
K ][][
][
11 =      
Equation 3.3.22 
 
Where [A]aq, [B]aq and [AB]aq are the concentrations of the acidic drug IND, basic counter and 
the ion-pair in the aqueous phase respectively. 
The total amount of IND in octanol would exist only as an ion-pair which means that [At]oct  
equals [AB]oct and the apparent octanol aqueous distribution coefficient of IND can be 
calculated from equation (3.3.8). 
aqaq
oct
A ABA
AB
D ][][
][
+
=
  
Equation 3.3.23 
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Where [A]aq represents the concentration of IND free drug in the aqueous phase and [At]aq is 
the total concentration of IND in the aqueous phase [At]aq= [A]aq+[AB]aq.  
 The intrinsic partition coefficient of the ion-pair in octanol-water, PAB is defined as the ratio 
between the ion-pair concentration in octanol to its concentration in water equation (3.3.9). 
aq
oct
AB AB
AB
P ][
][
=
 
Equation 3.3.24 
Upon combining equations (3.3.7)(3.3.8) and (3.3.9), a common equation is obtained.  
ABaqABaqA PBPKD
1
][
11
11
+=
 
Equation 3.3.25
 
The concentration of IND was determined using the HPLC method while the concentration of 
the cationic amino acids in the aqueous phase was calculated using the ninhydrin test. Upon 
plotting the double reciprocal of the apparent octanol-water distribution coefficient of IND as 
a function of the basic amino acid concentration (i.e plotting 1/DA Vs 1/[B]aq), both K11aq  and 
PAB can be calculated from the double reciprocal curves or the curve equations. 
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Figure 3.3.40:- IND concentrations in aqueous and octanol layers and its corresponding Log P values at 
various concentrations of arginine. 
 
The partitioning behaviour of IND at various molar ratios of arginine were studied and 
summarised in Fig. (3.3.3). The experimental data showed that IND has a log P value of 3 which 
is in line with the literature findings (Siissalo et al., 2010). Such high log P value reflects the 
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hydrophobic nature of IND which in turn deteriorates its solubility. The ratio of the cationic 
amino acid counter ions was increased while IND concentration was held constant. Increasing 
the concentration of arginine in the formulations was found to increase the aqueous solubility 
of IND and reduce its partitioning in the lipophilic layer. IND log P value dropped significantly 
by 1.5 units upon adding arginine at 1:1 ratio. Further increase in arginine concentration 
resulted in a gradual drop of Log P until it reached 0.5 at 1:8 molar ratio of IND to arginine 
respectively.  
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Figure 3.3.41:- IND concentrations in aqueous and octanol layers and its corresponding Log P values at 
various concentrations of lysine. 
 
Similar trend was observed upon using lysine as counter ions: this is probably because both 
arginine and lysine have very close pKa values of 12.48 and 10.53 respectively. 
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Figure 3.3.42:-  Double reciprocal plot of the apparent octanol-water distribution coefficient of IND as 
function of arginine molar concentration. 
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Figure 3.3.43:- Double reciprocal plot of the apparent octanol-water distribution coefficient of IND as 
function of lysine molar concentration. 
 
 
The double reciprocal plots of apparent octanol/water distribution coefficients of IND as 
function of the molar concentrations of arginine and lysine are shown in figures (3.3.5 and 
3.3.6) respectively. The double reciprocal plots showed weak linear relationships (R2 of 0.81 for 
arginine and R2 of 0.61 for lysine). Nevertheless, the double reciprocal plots showed strong 
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negative exponential relationships for both the amino acids suggesting that increase in the 
molar concentration of the amino acids will decrease the partitioning coefficient of IND 
exponentially. pH solubility profile studied earlier by ElShaer et al., (2011) for IND showed that 
increasing arginine concentration results in increasing the ionisation of IND and its solubility 
exponentially. The exponential increase in ionisation will result in an exponential drop in DA 
values as the ionized species cannot partition into octanol as suggested by Shore et al., (1957). 
Studies carried out by Maller et al (2010) showed linear relationship which could be attributed 
to the small range of concentration of the counter ions used in the study. The high inherent 
hydrophilicity of arginine (Log P=-4.2) and lysine (Log P=-3.02) is the main reason behind the 
drop of the DA values for IND.  
The exponential curve equations (3.3.11, 3.3.12) were used to describe the correlation 
between the DA values and the molar concentrations of arginine and lysine respectively. These 
two equations were used to work out the intrinsic octanol water partitioning (PAB) and the 
aqueous phase binding constant (K11aq).  
397.1909.11 −= xY
 
Equation 3.3.26 
084.117.3 −= xY Equation 3.3.27 
 
The K11aq was calculated for IND-arginine and IND-lysine and found to be 1084 M
-1 and 520 M-1 
respectively. The aqueous phase binding constant for IND-arginine was stronger than that of 
IND-lysine which reflects the higher intermolecular complexation between IND and arginine. 
Two major bonds are involved during ion-pair formation; ionic and hydrogen bonds. The ∆pKa 
values between IND and arginine was 8 units while that between IND and lysine was 6 units, 
which suggests that the degree of ionic bonding is higher in IND-arginine when compared to its 
lysine counterpart. Moreover, our previous studies (ElShaer et al., 2011) suggested that 
arginine has more H-donors and H- acceptors than lysine (13 vs 9) and possibly results in 
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greater H-bonding between IND-arginine. Which further explains the stronger aqueous binding 
constant for lysine. 
3.3.3.2. Permeability studies 
Prior to conducting the permeability studies, the transepithelial resistance (TEER) was 
monitored for 22 days (Fig. 3.3.7). TEER resistance for Caco-2 cells was 221±20 Ω/cm2 after 3 
days of seeding the membranes and started to increase steadily until it reached 589±26 Ω/cm2 
on day 12. TEER remained constant after 12 days of seeding which suggests the formation of 
integral monolayers.   
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Figure 3.3.44:- TEER measurements of Caco-2 cells for 22 days of seedings (n= 3). 
 
Upon formation of intact monolayers, the cells are washed and incubated with HBSS buffer. 
The effect of incubation time with HBSS on Caco-2 monolayers TEER values was also studied. It 
was noticed that incubating the cells for too long with HBSS would not have a significant effect 
the integrity of the cells (Fig. 3.3.8). For all subsequent experiments, Caco-2 cells were 
incubated for 15 minutes with the buffer prior to carrying out the permeability studies. 
 
                                                 
 
 143
0
100
200
300
400
500
600
700
800
0 5 10 15 30 45 60 70 100
Time (mins)
TE
ER
 
(Ω
/c
m
2)
DMEM
HBSS
 
Figure 3.3.45:- Effect of inoculation time with HBSS and DMEM on the TEER values of Caco-2 cells 
(n=3). 
 
The permeability profiles of IND with increasing ratio of arginine and lysine were studied and 
summarised in Fig. 3.3.9 and 3.3.11. In all the experiments the concentration of IND was 
constant and the concentration of the amino acids was changed. TEER values were measured 
before and after the run of the experiments and all the values were above 300 (Table 3.3.1) 
which demonstrates full integrity of the monolayes and their tight junctions. 
Table 3.3.30:- TEER measurements for IND formulations before and after the permeability assay (n=5) 
Formulation TEER measurements (Ω/cm2) 
Before 
TEER measurements (Ω/cm2) 
After 
Recovery (%) 
IND  555.66±12.7 421.66±28.4 71.4 
IND-arg 1:1 611.33±19.73 450.66±21.12 89 
IND-arg 1:2 571.66±31.33 438±11.5 98.15 
IND-arg 1:4 595±14.9 457.66±26.1 72.7 
IND-arg 1:8 577.66±15.04 440.66±8.1 97 
IND lysine salt    
IND-lys 1:1 387.66±10.69 337±33.45 99 
IND-lys 1:2 349±3.60 345.66±4.16 89.7 
IND-lys 1:4 410.33±59.5 352.33±49.34 80.1 
IND-lys 1:8 412±13.1 386±22.34 76 
 
Generally amount of drug absorbed increased with time, regardless of the formulations. 
Equation 3.3.5 was used to calculate the apparent permeability (Papp). The percentage of IND 
absorbed from IND free acid formulations was 5.7±0.26 % after 5 minutes and increased 
steadily to 31±3.8% after 90 minutes. Adding arginine to IND at 1:1 ratio showed no significant 
effect on the absorption profile of IND. In contrast, IND-arginine 1:2 (Papp= 24.3x10
-6 cm/sec) 
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and 1:4 (Papp= 22x10
-6 cm/sec) ratios showed a significant increase in IND permeability 
especially after 60 minutes of starting the permeability assay. 
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Figure 3.3.46:- Percentage of IND transported across Caco-2 monolayers at various molar ratios of 
arginine (n=5). One way analysis of variance (ANOVA) and pair-wise multiple comparisons method 
(Tukey test) against drug alone at each time point were used for statistical analysis and probability 
values of (P< 0.05, * and P<0.001,***) were used to determine the significant difference. 
 
 
 As discussed above, the partitioning studies showed that the log P values of IND decreased as 
arginine ratio in the formulations was increased which would suggest that there would be a 
drop in the overall IND permeability profile. However the results demonstrated unexpected 
and interesting trends with a substantial increase in permeability especially for the 1:2 and 1:4 
ratio of IND:counter ion. Two possible scenarios could explain such improvement of the 
absorption profile. Firstly, it is possible that the increase in solubility and dissolution profile 
(Fig. 3.1.8) with increasing the concentration of the cationic amino acids resulted in the drug 
being readily available in the solution faster than that of the formulations containing IND 
alone. 
*** 
* 
*** 
*** 
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Figure 3.3.47:- Papp permeability values at 60 minutes for IND alone and IND at various molar ratios of 
arginine and lysine. One way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey test) against drug alone at each time point were used for statistical analysis and 
probability values of (P< 0.05, * and P<0.001, ***) were used to determine the significant difference 
(n=3). 
 
The second scenario is that active transportation via carrier transporters for amino acids such 
as peptidyl or anionic transporters might have played a role in drug transport. Interestingly, 
IND-arginine 1:8 ratio showed a significant drop (P<0.001) in the percentage of IND permeated 
(13.5±1.76 %) when compared to formulations containing IND alone (31±3.8 %) after 90 
minutes. Although the former had a much higher dissolution profile than the latter (Fig. 3.1.8) 
the results suggest that the permeability improvement is not because of the increase in the 
dissolution profile or deterioration in the Log P values but possibly due to increase in active 
transcellular carriage of the drug. At very high concentrations of the amino acids (1:8 ratio) the 
amino acids transporters might have been saturated with the excess arginine and hence the 
over all uptake of IND was decreased.  While on the other hand, at smaller molar ratios of 
arginine, the receptors did not get saturated quickly and IND uptake is facilitated by active 
transporters. 
Studying the effect of lysine molar ratio on the permeability profile of IND showed similar 
trend. IND-lysine formulations at 1:2 ratios had a significant impact (Papp= 22.4±4)10
-6 on 
* 
* 
* 
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percentage of IND absorbed across the Caco-2 monolayers and beyond this ratio the 
permeability started to decline. 
0
5
10
15
20
25
30
35
40
45
50
5 10 15 30 60 90
Time (mins)
%
Tr
an
sp
o
rt
ed
INDLys1:1 INDLys1:2 INDLys1:4 INDLys1:8 IND free acid
 
Figure 3.3.48:- :- Percentage of IND transported across Caco-2 monolayers at various molar ratios of 
lysine (n=5). One way analysis of variance (ANOVA) and pair-wise multiple comparisons method 
(Tukey test) against drug alone at each time point were used for statistical analysis and probability 
values of (P< 0.05, * and P<0.001,***) were used to determine the significant difference. 
 
 
Conclusion 
After improving the solubility and dissolution profile of IND using cationic amino acids (Chapter 
3.1), it was interesting to evaluate the effect using IND ion-paired formulations on its 
permeability across Caco-2 cells. High solubility and dissolution of IND reflects the high 
ionisation of the salt form hence excess amount of the counter ions were added in a trial to 
shift the salt ionisation equilibrium towards the non-ionised form of the salt. Octanol/water 
partitioning studies revealed the greasy nature of IND (log P=3) and increasing the molar ratio 
of the cationic amino acids results in significant drop in the partitioning capacities of IND in 
octanol organic layer. Nevertheless permeability data showed a significant increase in IND 
absorption especially for PMs of 1:2 molar ratios. This suggests that active carrier might have 
been involved in the uptake of IND ion-paired formulations as drug partitioning has decreased. 
 
 
 
*  ***  *** 
 *** 
 *** 
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Preparation and characterisation trimethoprim salts with anionic 
counter ions 
4.1.1. Introduction 
Trimethoprim (Figure 4.1.1) [2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine], is a synthetic 
antibacterial agent belonging to a group of compounds known as diaminopyrimidines. It was 
first synthesized as a dihydrofolate reductase inhibitor (DHFR) and used mainly in combination 
with sulfonamides to treat pneumonia and urinary tract infections. TMP is administered 
through various routes including intramuscular, intravenous and oral and has high gastro-
intestinal tolerability and low side effects. However, low aqueous solubility of TMP (Manius, 
G., 1978) reduces the bioavailability from oral formulations. In order to improve TMP 
dissolution profile, a study conducted by Li et al utilised β-cyclodextrin to form a complex with 
TMP (Li et al., 2005). The study concluded that the high surface area of contact between TMP 
and the cyclodextrin along with reduction in drug crystallinity were responsible for 
improvement in TMP solubility (Li et al., 2005). Nevertheless, the solubility improvement 
achieved by this study was 2.2 fold. Besides, high doses of β–cyclodextrin are not 
recommended and can cause diarrhea and bloating as they are degraded and fermented by 
bacteria in the colon (Del Valle., 2004). Therefore, investigation of alternative approaches to 
improve the solubility of TMP would have a high impact on oral administration of the drug. 
Interestingly, TMP has a basic nature (pKa 7.3) and a soluble derivative of the antibiotic can be 
obtained by reacting TMP with acids resulting in salt formation. Around 50% of the prepared 
salts of basic drugs are hydrochloride salts. Yet, hydrochloride salts salt out easily and in turn 
reduce the optimal solubility. Furthermore, hydrochloride salts usually cause high acidity in the 
formulations and high risk of corrosion (Bastin et al., 2000), while the loss of volatile HCl could 
affect the stability of weak bases especially over the long-term (Stahl and Wermuth, 2002). 
Due to the limitations of hydrochloride salts, alternative counter ions that have been explored 
include citric acid, acetic acid, fumaric acid and maleic acid Stahl and Wermuth., 2002; 
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Hemamalini et al., 2003 ; Raj et al., 2003). Another class of counter ions that can potentially 
address the solubility of basic drugs includes acidic amino acids. Fabrizio & Vetere utilized 
aspartic acid to prepare a water soluble salt of erythromycin. The obtained salt was used to 
prepare parenteral formulations of erythromycin and was found to be highly tolerable and less 
toxic (Fabrizio and Vetere, 1973). Glutamic acid was used to prepare water soluble salts of 
chitosan and the glutamate salt was found to improve the apparent permeability of many 
drugs such as naproxen (Maestrelli et al., 2004) and rokitamycin (Gavini et al., 2010) when 
compared to chitosan alone.  
The present study aims to improve the solubility of TMP through salt formation with anionic 
amino acids, namely glutamic acid and aspartic acid and to characterize the prepared salts 
using FT-IR spectroscopy, proton nuclear magnetic resonance (1HNMR), differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA). The study also investigates the effect 
of different amino acid isomers on the salt characteristics and evaluates the inhibitory effect of 
the amino acids salts on intrinsically resistant bacteria. 
 
 
 
 
Figure 4.1.1. Trimethoprim chemical structure. 
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4.1.2. Materials and methods 
4.1.2.1. Materials 
Trimethoprim 98% TLC, L-glutamic acid, L-aspartic acid, D-aspartic acid (99%), D-glutamic acid 
(minimum 99% TLC) and Potassium bromide (99% FT-IR grade) were purchased from Sigma 
Aldrich, UK.  
D2O (99.9% min) was purchased from Goss scientific instrument Ltd (Cheshire, UK). DMSO-D6 
(98.8% min) was purchased from Merck (Darmstadt, Germany). Tryptone Soya Broth (TSB) and 
Muller Hinton Broth (MHB) were purchased from Oxoid Ltd, Hampshire, England. 
4.1.2.2. Methods 
4.1.2.2.1. Analytical technique 
The amount of Trimethoprim (TMP) dissolved in the solution samples was quantified using the 
HPLC (Dionex 1100 system) method reported by Gallego and Arroyo (Gallego and Arroyo., 
2002). HPLC was operated at 25oC on RP-C18, (Phenomenex 110A, 150x4.6 mm, 5µm) column 
using acetonitrile-NaH2PO4 buffer (10 mM) (70:30, v/v) (pH 3) as mobile phase which was 
pumped at 1.0 mL/min flow rate using gradient pump (GP50).  UV detector (UVD 170U) was 
used and the analysis was monitored at 230 nm. The retention time was 1.74±0.04 min and a 
rectilinear calibration curve was established at concentrations ranging between 10- 500µg/mL 
(R2 of 0.99). LOD and LOQ were calculated using standard deviation of response and slope and 
were found to be 0.109 and 0.364 respectively. For more details see appendix (1).  
4.1.2.2.2. Phase solubility diagram 
Phase solubility diagram was established by measuring the saturated solubility of TMP free 
base with various concentrations of acidic amino acid (L-aspartic acid and L-glutamic acid). 
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Excess TMP was added into screw-capped tubes containing serial dilutions of the amino acid 
solutions and agitated at room temperature (Stuart SB 162 stirrer) for 24 h. After equilibrium, 
the supernatant was filtered through 0.45 µm filters and analysed by HPLC to determine TMP 
concentration. The pH of amino acid solutions was monitored using an Xisherbrand  Hydrus 
500 pH meter. 
4.1.2.2.3. Salt preparation 
Equimolar amounts of TMP and the free amino acids (L-aspartic acid and L-glutamic acid) were 
solubilised in water and the solutions were mixed and stirred until equilibration was achieved. 
The filtrate was transferred into vials and freeze dried for 48 h using a Modulyo freeze dryer at 
-40oC shelf temperature and under vacuum. The samples were collected and kept in 40oC oven 
for 4h using a Gallenkamp vacuum oven. 
Despite the low yield with freeze drying, it is a preferred technique unlike organic solvent 
methods adapted by Anderson & Conradi (1985), as lyophilized products have a high degree of 
purity and are devoid of the formation of any solvates.  
4.1.2.2.4. Thermogravimetric analysis (TGA) 
A thermogravimetric analyser (Pyris 1 TGA, Perkin Elmer) was used in this study to measure 
the moisture content and decomposition temperature of TMP and its prepared salts. 5- 10 mg 
of samples were loaded on to an open pan and analysed between temperature range 30- 300 
oC at 10 oC/min scanning rate and under nitrogen stream. Pyris Manager Software (version 
5.00.02) was used to analyse the resultant thermograms. 
4.1.2.2.5. Differential scanning calorimetry 
Differential scanning calorimeter (Pyris Diamond DSC) was used to explore thermal events of 
TMP and its salts.  Approximately 2-5 mg of the samples were weighted and transferred to an 
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aluminium sample pan (50 µL capacity). Intra cooler 2P system was used to initially cool the 
samples to 50 oC and then sample heated to 300 oC at a rate of 10 oC/min. Nitrogen was used 
as a purge gas at a flow rate of 20 mL/min. Indium and Zinc were used to calibrate the heat 
flow and melting point onset (156.6 oC for Indium and 419.47 oC for Zinc). The obtained 
thermograms were analysed using Pyris Manager Software (version 5.00.02). The experiment 
was performed in triplicate and an empty aluminium pan was used as a reference cell for all 
the measurements. 
4.1.2.2.6. FT-infrared (IR) spectroscopy 
FTIR absorbance spectra of TMP and its salts were obtained with Nicolet IR 200 spectrometer 
(Thermo electron corporation) using KBr discs. Crystalline KBr was dried at 65oC over night 
before use. Samples were prepared by mixing TMP or its salts with dry KBr at 1:100 (w/w) ratio 
and pressed at 8 tonnes for 5 minutes (using a Specac tablet presser) to form KBr discs. 64 
scans were done over a wavelength range of 4000- 400 cm-1 for each sample. EZ OMNNIC 7.0 
software was used to interpret the IR spectrum. 
4.1.2.2.7. 
1
HNMR 
Samples were studied with Bruker Avance DPX-250 NMR (at 250.1 MHz) and Bruker Topspin 
software was used to analyse the data. Approximately, 1-2 mg of the salts was dissolved in 1 
mL of deuterated water (D2O) and placed in sample capillary vial. Sample vials were placed into 
the NMR machine and analysed for the presence of hydrogen atoms (1H-NMR) 
4.1.2.2.8. pH solubility profile 
pH solubility studies were determined by using the Ledwidge & Corrigan method (Ledwidge 
and  Corrigan, 1998). Saturated solutions of the salts and acids were prepared by dissolving 
excess of the drug in deionised water. The solutions were agitated constantly using a stirrer 
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(Stuart SB 162) at ambient temperature. pH was adjusted by adding NaOH or the appropriate 
acid (L-aspartic acid or L-glutamic acid). After 2 hour interval an aliquot was withdrawn and 
filtered through 0.45 µm filter, then analysed using HPLC (see section 2.2.1) 
4.1.2.2.9. Solubility and dissolution studies 
Solubility studies were carried out using Hugchi and Connor’s method (Higuchi and Connors., 
1965). An excess amount of TMP or its salts was added to capped tubes with 5 mL of deionised 
water and stirred for 24 hours at room temperature until equilibrium was reached. 
Subsequently, the suspension was filtered through 0.45μm syringe filters and suitably diluted 
and the concentration was measured by HPLC. 
Hard gelatin capsules were filled with 200 mg of TMP or equivalent amounts of the prepared 
salts for dissolution studies. USP II paddle method (ERWEKA DT-600) was used to perform the 
in-vitro dissolution studies. The prepared capsules were placed into dissolution vessels 
containing 900 mL of distilled water (pH 7.2) and the dissolution media was maintained at 
37oC±0.5oC and stirred at 50 rpm. 5mL of samples were collected at a predetermined time 
intervals (1, 5, 10, 20, 25, 30, 45 and 60 min) then filtered through 0.45 μm Millipore filters. 
The dissolution media was replaced by 5mL of fresh dissolution media in order to maintain a 
constant volume. After proper dilution samples were analysed by HPLC as mentioned above. 
4.1.2.2.10. Microbiological studies 
Two Gram-negative bacterial strains; Escherichia coli NCTC 10418 and Pseudomonas 
aeruginosa ATCC 9027 were used for this study. Freshly inoculated bacteria agar plate was 
prepared one day before the experiment by spreading colony suspension on Trypticase-soy 
agar plate and incubating for 18 to 24h.  
Zone of inhibition study was performed using Agar plates prepared using Trypticase-soy agar 
plates. Loopful of bacteria was spread gently on the surface of the agar plates. Six small holes 
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were perforated on the agar plates and filled with 20µl of 0.5mM TMP or equivalent 
concentration of TMP salts. In order to evaluate any inhibitory effect of the amino acids on the 
bacterial growth, free amino acids were used as controls for this study. 
The bacterial minimum inhibitory concentration (MIC) of TMP and its prepared salts against 
the same two species of Gram negative bacteria were performed using micro-dilution method 
and following the national committee for clinical laboratory standards (NCCLS) specifications. 
The bacterial inoculum was established by direct colony suspension method from 18 to 24h 
Trypticase-soy agar plates, standardized and counted by Pharmacia spectrophotometer 
(Pharmacia LKB, Novaspec II).  Around 5x106 CFU/mL was suspended in Tryptone Soya Broth 
and used in our study. 
50 µl of the bacterial inoculum was transferred to 100 µl of Muller Hinton Broth (MHB) at final 
concentration ranging between 0.5- 0.00024 mM prepared by two fold dilution. 
Inoculated plates were incubated at 37oC for 18- 24 h. The lowest concentration of the 
antibacterial agent that inhibits the growth of bacteria was determined by visual turbidity 
when compared against control.  
4.1.2.2.11. Statistical analysis 
Graph Pad Instat® software was used for the statistical analysis study. Data groups were 
compared using one way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey test). Standard deviation (SD) was used to report the error in the figures and 
texts. Probability values of 95% (P< 0.05) were used to determine the significant difference. 
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4.1.3. Results and discussion 
4.1.3.1. Phase solubility diagrams 
Prior to preparing TMP salts, a solubility phase diagram was first constructed between TMP 
and two acidic amino acids; aspartic acid and glutamic acid as previously discussed by ElShaer 
et al (2011). Figure 4.1.2 shows that increasing the anionic amino acid concentrations results in 
lowering of the solution pH and in turn improving the solubility of TMP. Aspartic acid has an 
acidic (-COOH) side chain with pKa of 1.88 which is 5 units lower than the pKa of TMP (pka 7.3). 
Therefore TMP could potentially act as a strong base in aspartic acid solution capable of 
deprotonating the –COOH acidic group. Interestingly, a linear relationship (R2= 0.93) between 
TMP solubility and aspartic acid concentration was observed which suggests that complete 
ionisation of TMP in aspartic acid solution was achieved suggesting the feasibility of salt 
formation. 
On the other hand, despite the slightly higher pka of the acidic side chain (-COOH) of glutamic 
acid (pKa = 2.19) a similar trend in solubility improvement was achieved possibly due to the 
ionisation of TMP in solution. These results suggest that both glutamic and aspartic acid can be 
used in preparing novel salts of TMP. 
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Figure 4.1.2. Phase solubility diagram of TMP in the presence of different concentrations of 
glutamic acid and aspartic acid at different pH (n=3). 
 
4.1.3.2. Characterization of salt form  
In order to evaluate the effect of the isomer form on the salt characteristics, D and L isomers of 
glutamic and aspartic acid were used to prepare TMP salts. The prepared salts were further 
characterised by Fourier transform infra-red, differential scanning calorimetry, thermo-
gravimetric analysis and 1H nuclear magnetic resonance. 
4.1.3.2.1. Fourier Transform Infrared Spectroscopy (FT-IR) 
FT-IR was performed in order to assess any possible interaction between TMP and the acidic 
amino acids during salt formation and to investigate any possible changes that could occur due 
to the use of different isomeric forms of amino acids. 
The FT-IR spectra of TMP, TMP L-aspartate and TMP D-aspartate are shown in Figure 4.1.3. 
TMP has characteristic bands at 1634.3 and 1594.7 cm-1 which account for deformation of NH2 
group and stretching of aromation ring respectively. Deformation of C9H2 group appeared at 
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1458.7 cm-1, while the vibration of C6=N of the aromatic primary appeared at 1263.71 cm-1. –
OCH3 aromatic groups had characteristic bands at 1128.68 cm
-1, as reported by Garnero et al. 
(2010). 
Assessment of TMP L-aspartate salt showed that TMP bands corresponding to NH2 and C-H 
aromatic stretching vibration were difficult to analyse due to overlapping with NH2 and CH 
aliphatic of the amino acid (Figure 4.1.3A). Interestingly, the C=N in the amine aromatic 
primary became very weak and a new band appeared at 1664.53 cm-1 corresponding to νC=O 
stretching which confirms that the cationic nitrogen has interacted with the carboxylic group 
of aspartic acid. In contrast, OCH3 aromatic groups did not show any changes in the formed 
salt. 
Upon comparing the FT-IR spectra of the L-aspartate and D-aspartate salt, no difference was 
spotted between the two isomers (Figure 4.1.3A & B). 
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Figure 4.1.3. FTIR spectra of (A)trimethoprim D-aspartate, (B) trimethoprim L-aspartate and (C) 
trimethoprim. 
 
Figure 4.1.4 shows the FT-IR for TMP L-glutamate and TMP D-glutamate. Similar to the results 
obtained for aspartate salts, a new band appeared at 1656.87 cm-1 and 1654.74 cm-1 for TMP 
A 
B 
C 
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L-glutamate and TMP D-glutamate respectively. This band corresponds to the νC=O of the 
amino acid carboxylic group which when deprotonated potentially interacts electro-statically 
with the protonated amino group of TMP prymidine ring. Both the L and D salts had similar FT-
IR spectra and no significant difference was observed. 
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Figure 4.1.4. FTIR spectra of (A) trimethoprim D-glutamate, (B) trimethoprim L-glutamate and 
(C) trimethoprim. 
 
4.1.3.2.2 Differential scanning calorimetry and Thermogravimetric analysis. 
Figure 4.1.5 shows the TGA and DSC scans for TMP and L-glutamic acid. TMP had one single 
endothermic peak at 204.22 oC with an enthalpy of fusion of 166.7 J/g. TGA data revealed that 
TMP starts to degrade after around 30 oC of its melting. 
TMP L-glutamate salt was found to be in the crystalline form as no crystallization exotherm 
was observed in the DSC scans (Figure 4.1.5). At around 130oC, TMP L-glutamate had an 
endothermic peak which could possibly correspond to moisture loss. Another two 
endothermic peaks appeared at 197.22 oC (ΔH = 20.22 J/g) and 233.47 oC (ΔH= 150.02 J/g). This 
data suggest that we might have two enantiotrophs or monotrophs. A second scan was run 
after cooling down and the first thermal event was found to be irreversible and hence this 
A 
B 
C 
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strongly suggests that these are monotrophs rather than enantiotrophs. Interestingly, coupling 
the DSC scans with TGA has showed a weight loss (4.03%) at 196 oC which means that this 
thermal event can not be a phase transition because polymorphic transitions are not 
associated with weight loss. 1HNMR data (discussed in details in section 3.3.3) has not picked 
up any impurities in the spectra and strongly suggest that this 4.03% weight loss is probably 
due to highly associated water molecules within the crystalline structure of the salt. The water 
2H appear at 4.7 ppm and interfering with D2O peaks (Gottlieb et al., 1997). 
On the other hand, the TMP D-glutamate salt is partially crystalline and the amorphous portion 
of the salt starts to crystallize at 140 oC. Moisture loss appeared as an endothermic hump at 
around 80 oC corresponding to 1.62%. Similar to TMP L-glutamate, TMP D-glutamate showed 
hydrate loss at 197.22 oC (ΔH= 18.16 J/g) appeared as small peak reflecting the small amount 
of the hydrate crystals formed during the freeze drying while the rest of the salt was in the 
amorphous state and crystallizes at 140 oC as discussed before. After dehydration, the salt 
started to melt at 231.74 oC (Figure 4.1.5) similar results were suggested by Sichina, (2011). 
The thermal events of TMP L-aspartate and TMP D-aspartate were studied using TGA and DSC 
(Figure 4.1.6). TMP L-aspartate showed an up drafted base line between 100- 150 oC which 
corresponds to moisture loss and the salt converted from the amorphous form to the 
crystalline form at 160 oC followed by crystal  melt at 184.22 oC. 
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Figure 4.1.5. TGA and DSC scans for L- glutamic acid and TMP free base. 
 
 
 
Figure 4.1.6. DSC and TGA scans for  TMP D-glutamate and TMP L-glutamate salts. 2- 5 mg of the 
sample was heated to 300
o
C at rate of 10 
o
C/min (n=3). 
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Figure 4.1.7. DSC and TGA scans for TMP D-aspartate and TMP L-aspartate. 2- 5 mg of the 
sample was heated to 300
o
C at rate of 10 
o
C/min (n=3). 
 
4.1.3.3.3 
1
HNMR studies 
The electronic and chemical environment of protons are affected during salt formation which 
could be reflected by the changes in δ. 1HNMR is considered  a powerful tool in studying salt 
formation as it provides insight in to  the ratio of molar interaction between the two moieties.  
Figure 4.1.8 shows the 1HNMR of TMP free base (solubilised in DMSO). At 7.53 ppm frequency 
one proton of TMP heterocyclic ring C4H appeared as singlet and the two protons on the 
aromatic ring C10H and C14H appeared at 6.56 ppm. The nine hydrogens of OCH3 groups 
appeared as two different peaks; (6H) appeared as a singlet at 3.73 ppm as they have the same 
surrounding environment, while the other (3H) appeared as a singlet at 3.63 ppm. The two 
hydrogens of aliphatic (C8H2) appeared as singlet at 3.54 ppm while two singlet bands 
appeared at 5.7 and 6.2 which correspond to N5H2 and N
7H2 respectively. The total integrated 
H count for TMP was 18 (Figure 4.1.8). 
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TMP L-aspartate salt (solubilised in D2O) showed new (3H) assignment at 2.6 corresponding to 
(C27H2) and a highly deshielded C
25H group at 3.75 ppm, which represents the aliphatic chain of 
L-aspartic acid. As D2O was used as a solvent for TMP salts, NH2 groups were masked and the 
total integration of TMP aspartate salt was 17 instead of 21. These results confirm that one 
mole of L-aspartic acid interacts with 1 mole of TMP to form the salt (i.e 1:1 ratio) as shown in 
Figure 4.1.9. 
On the other hand, TMP L-glutamate had 5 new protons representing the aliphatic chain of the 
amino acid. (C28H2, C
27H2) appeared at 1.96 and 2.2 ppm, while the third C
25H group appeared 
at around 3.6 ppm due to the deshielding by NH2 group. The total integration also shows that 1 
mole of L-glutamic acid interacts with 1 mole of TMP (Figure 4.1.10). 
1HNMR studies of TMP D-aspartate and TMP D-glutamate salts did not reveal any difference in 
the spectra between the L and D isomers (Figure A2.1& A2.2 Appendix 2). The high similarity of 
the salts formed despite using different isomers suggest that water used to solubilise the 
amino acids during the preparation step might provide free space for the rotation of the 
molecules and potentially catalyze racemisation as suggested by Feng et al., (2011). 
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Figure 4.1.8. 1HNMR spectra of trimethoprim free base solubilised in DMSO. 
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Figure 4.1.9. 
1
HNMR spectra of trimethoprim L-aspartate solubilised in D2O. 
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 Figure 4.1.10. 1HNMR spectra of  trimethoprim L-glutamate solubilised in D2O. 
 
4.1.3.3.4. Aqueous solubility and dissolution Studies 
TMP is usually used in combination with sulfonamides in various formulations such as 
suspension, tablets and solution dosage forms. Therefore TMP solubility and dissolution are 
important determinants for its bioavailability.  
Solubility studies in our laboratory have found that the saturation solubility of TMP free base 
was 0.217 mg/mL in water. Using acidic amino acids counter ions improved the solubility of the 
drug by around 280 fold when compared against the free drug. The solubility of the prepared 
salts was around 55 mg/mL with no significant difference between the L and D isomers for 
both the counter ions (Figure 4.1.11). 
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The dissolution profile of TMP and its different salts was also studied (Figure 4.1.12). 
Dissolution studies show a significant improvement of the salt form when compared to the 
free base. Around 70% of the TMP was released from aspartate and glutamate salt form after 
only 10 minutes of the dissolution experiment while only 10% release was seen from TMP free 
form (Figure 4.1.12). Such changes in the dissolution profile could be attributed to the ability of 
TMP salts to exert a self-buffering action, which yield different pH values at the dissolving 
surface in the diffusion layer (Forbes and York, 1995). No significant difference was observed 
between the two salts, which suggest that both salts might have similar buffering capacity and 
hence similar pH at the diffusion layer. 
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Figure 4.1.11. Solubility of trimethoprim and its prepared L & D aspartate and glutamate salts 
mean ±SD (n=3). 
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Figure 4.1.12. Dissolution profile for TMP free base and its salts in deionised water. Data are 
mean± SD (n=3). 
 
Table 4.1.31:- pH measurements during solubility and dissolution studies. 
  Formulation 
p
H
 
m
ea
su
re
m
en
t 
 TMP free base TMP Aspartate TMP glutamate 
Solubility study (Equilibrium) 7.7±0.05 5.075±0.06 5.2±0.11 
End of dissolution study 8.6±0.07 5.37±0.08 5.88±0.05 
 
4.1.3.3.5. pH- solubility profile 
TMP pka and intrinsic solubility are 7.3 and 0.19 mg/mL respectively. Figure 4.1.13 shows the 
pH solubility profile of TMP when TMP glutamate salt and TMP free base were used as starting 
materials for determination of solubilities. The intrinsic solubility (Bs) was first determined by 
increasing the pH of TMP solution to 11.28 using NaOH and Bs was found to be 0.266 mg/mL. 
When TMP was used as a starting material the solubility was found to increase exponentially 
upon titrating with glutamic acid (Figure 4.1.13). TMP solubility increased from 0.37 mg/mL at 
pH 7.7 (point a) to 13.8 mg/mL at pH 4.23.  
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Figure 4.1.13. pH solubility profile of TMP and TMP-glutamate salt at  ambient conditions using free 
acid (circles) and TMP-glutamate salt (squares) as starting materials. Points b and a represent the 
saturation solubility of the salt and TMP free base respectively. [Bs]= 266.35µg/mL and pKa=7.3. 
 
On the other hand, when TMP glutamate salt was used as a starting point, the solubility 
started to decrease upon titrating with NaOH.  TMP glutamate solubility was 53.6 mg/mL at pH 
5 and decreased to 0.194 mg/mL at pH 11.9. A similar trend was observed upon titrating TMP 
with aspartic acid (data not shown). Generally, a good agreement was observed between the 
experimental values (squares and circles) and the theoretical predicted values (dotted line) see 
table (2). Theoretical calculations were carried out using Kramer and Flynn (1972) (Equation 
4.1.1). 
][
]][[ 3
+
+
=
BH
OHB
Ka  
)1()( 3max
a
st K
OH
BpHpHbaseS
+
==>  
)101( pHPkasB −+=                               (Equation 4.1.28) 
Where St is the total solubility at given pH, [Bs] is the intrinsic solubility of the free base and Ka 
is the acid dissociation constant. 
b 
a 
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Table 4.1.32. Theoretical calculations of pH solubility profile using (Equation 4.1.1). [Bs]= 
266.35µg/mL and pKa=7.3. 
pH Solubility (µg/mL) 
11.28 266.35 
7.7 372.35 
6.3 2929.63 
6.1 4487.37 
5.7 10869.11 
4.9 67165.4 
 
4.1.3.3.6 Microbiology studies 
After having significantly improved both the solubility as well as the dissolution characteristics 
using the salt forms of TMP, the next stage of the work was to evaluate microbiological 
properties to study if the therapeutic effect of the drug was still retained upon preparation of 
the different salts.  
Interestingly, zone of inhibition studies showed that use of amino acid salts not only retained 
the anti bacterial activity against  TMP sensitive species; Escherichia coli but also had a 
significant increase in the total area of inhibition (Table 4.1.3). To rule out the possible effects 
of amino acids alone on bacterial growth inhibition, control experiments with the amino acids 
were performed which resulted in no inhibition of bacterial growth on the plates. Therefore, 
the higher zone of inhibition can be attributed to the significant improvement in solubility 
which potentially results in higher permeability across the agar plates resulting in larger zone 
of inhibition.  This could possibly translate into a faster therapeutic effect along with reduced 
therapeutic dose in a clinical setting. 
On the other hand, neither the drug nor the salts showed any activity against TMP resistance 
species Pseudomonas aeruginosa. This is probably due to the complex structure of 
Pseudomonas aeruginosa membrane as it is intrinsically resistant to TMP and prevents the 
entry of both the drug and amino acid salts. 
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Table 4.1.33:- Zone of inhibition studies of TMP and its prepared salts against Escherichia coli 
and Pseudomonas aeruginosa. 
 Escherichia coli Pseudomonas aeruginosa 
Area (cm
2
) % compare to the 
total plate area 
 
TMP 4.03±0.2 18.7 **** 
TMP aspartate 4.6±0.2 21.4 **** 
TMP glutamate 4.65±0.2 21.6 **** 
Bacterial minimum inhibitory concentration was carried out as well in order to accurately 
determine the MIC of the TMP and its salts. Two species were used in this study; Escherichia 
coli and the intrinsically resistant organism, Pseudomonas aeruginosa. The MIC of TMP on E. 
coli was 0.00048 mM and TMP aspartate and glutamate salt had similar MIC values which 
confirm our previous finding that salt preparation did not impair the pharmacological function 
of TMP (Table 4.1.4).  
Table 4.1.34:- MICs of TMP and its prepared salts against Escherichia coli and Pseudomonas 
aeruginosa. 
 Escherichia coli Pseudomonas aeruginosa 
TMP 0.00048 mM. > 0.5 mM 
TMP aspartate 0.00048 mM > 0.5 mM 
TMP glutamate 0.00048 mM > 0.5 mM 
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4.1.4. Conclusion  
TMP is a basic synthetic antibacterial agent which is poorly water soluble. In order to improve 
its solubility, the ability of TMP to form new salts with L and D isomers of acidic amino acids 
was investigated in this study. The study has demonstrated that TMP solubility increased 
significantly upon coupling with aspartic and glutamic acid and this increase was attributed to 
the novel salt formation which has self buffering capacity yielding favourable pH for salt 
solubility during dissolution. Moreover, the antibacterial activity of these new salts was 
investigated and no change was seen in their MIC when compared against TMP free base. 
Using different isomers; L- and D- forms did not show any significant difference in the salt 
characteristics. Our future work will investigate the effect of amino acids salts on the 
absorption characteristics of TMP across intestinal membrane using Caco-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 171
 
A systematic and mechanistic evaluation of aspartic acid as filler for 
directly compressed tablets containing trimethoprim and trimethoprim 
aspartate 
 
4.2.1. Introduction 
Oral drug delivery is considered the most common and convenient route for drug 
administration. Solid dosage formulations, especially tablets, account for the large proportion 
of dosage forms delivered orally (Sam and Fokkens, 1997; Rasenack and Muller, 2002). In 
addition to the active pharmaceutical ingredient (API), tablets comprise of various 
pharmaceutical excipients which not only support the manufacturing process but also ensure 
high quality of the final product. Therefore, appropriate selection and precise concentration of 
excipients is critical in the tableting process.  
Most commonly used excipients include fillers (diluents), binders, lubricants, glidants, 
disintegrants, colorants and flavouring modifiers (Gohel, 2005). Diluents/fillers are added to 
tablets to bulk up the formulation for processing and handling. Mannitol is a free-flowing 
powder which is widely used as diluent for tablet manufacture. It is characterised by its low 
elastic recovery, sweet taste and cooling sensation and has been reported as the best sugar for 
manufacturing directly compressed chewable tablets (Sangekar et al., 1972). Recent studies 
suggested that mannitol could reduce intestinal absorption of pharmaceutically active agents 
and in turn lower the overall bioavailability of the pharmaceutically active agents (Adkin. et al., 
1995a; Adkin et al., 1995b). Studies conducted by Adkin et al on the formulation of cimetidine 
(H2-receptor antagonist) found that the bioavailability of the drug was reduced when 
combined with mannitol even at small concentrations (Adkin. et al., 1995a). This was 
attributed to the cathartic effect of mannitol on the small intestine which results in reducing 
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the small intestine transit time (Adkin et al., 1995b). Moreover mannitol is known to be taken 
up by the cells paracellularly via the tight junctions between the transepithelial cells (Yee, 
1997). Studies conducted by Baired et al (1997) and Iga and Ogawa (Iga and Ogawa., 1997) 
concluded that incorporating mannitol in pharmaceutical formulations would reduce drug 
absorption by competing with API for the paracellular pathways especially if the API is 
transported primarily through that route. 
Another commonly used tablet filler is dicalcium phosphate dehydrate (DCPD) which is 
characterised by its low cost, low hygroscopicity and good flow characteristics (Carstensen and 
Ertell., 1990). Clarke and co-workers found that using DCPD as a filler had a negative impact on 
the dissolution profile of spiranolactone despite not affecting the overall bioavailability of the 
drug (Clarke. et al. 1977).  
Other excipients such as talc and kaolin were found to adsorb charged molecules on their 
surface and as a result reduce the membrane permeability for drugs such as chlorpromazine 
(Nakano, 1971) and benzodiazepine (Naggar, 1981). The other majority of tablet fillers are 
believed to be inert and do not chemically interact or affect the pharmacokinetics of the active 
ingredient. 
Among the new class of fillers for directly compressed tablets, amino acids have shown 
promising results. Amino acids have been used as diluents in previous studies (AlHusban et al., 
2010; AlHusban et al., 2010; Sun and Grant, 2001). However, only few studies investigated the 
densification characteristics of these amino acids. Szabo-Revesz et al (2001) prepared new 
agglomerates of aspartic acid through salting out by controlled cooling. The prepared 
agglomerates were found to have higher tensile strength (0.75±0.03 MPa) and compressibility 
values when compared to a commercially available salt (0.13±0.1 MPa). Sun and Grant (2001) 
examined the effect of lysine salt forms on the tensile strength and compaction properties of 
tablets. It was concluded that the tensile strength increases exponentially with a resultant 
decrease in the porosity of the tablets. 
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Another aspect of directly compressed tablet manufacture is the bonding force/interactions 
between the different ingredients of the tablets including the active entity itself. During 
powder compaction, particles get closer to each other and densification does not take place 
until bond formations between particles occur. It is believed that the bonding mechanisms 
include formation of solid bridges, intermolecular forces and shape related bonding 
(mechanical interlocking) (Fuhrer, 1996). Intermolecular forces can be further divided into 
electrostatic, Van der waals forces and hydrogen bonds with electrostatic interactions 
operating between oppositely charged molecules through dipole-dipole interactions (Fuhrer 
C., 1996). 
As mentioned above it is generally known that most of the pharmaceutical excipients used for 
oral drug delivery are inert. Therefore, inclusion of excipients which have multiple functions 
within the formulation will have a significant impact on the cost and quality of the 
formulations and possibly the bioavailability of the drug.   
Our previous studies (ElShaer et al., 2012) investigated the use of aspartic acid and glutamic 
acid as salt forming agents with a model basic drug trimethoprim (TMP). The results from this 
study (substantial increase in drug dissolution due to ionisation in the presence of amino acid) 
provided the basis for investigating for the first time the potential multi functionality 
(dissolution enhancement and tablet diluent) inherent with in acidic amino acids. 
Investigations in the current study focus on mechanism of compaction of individual powders 
and binary mixtures of aspartic acid, TMP, TMP aspartate with an ultimate objective of 
determining the role of surface charge and morphology on the binding properties between the 
two entities.  
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4.2.2. Materials and methods 
4.2.2.1. Materials 
Trimethoprim (98% TLC), L-aspartic acid and magnesium stearate were purchased from Sigma 
Aldrich (Dorset, UK). Ethanol was purchased from Fisher Scientific (Loughborough, U.K.) 
4.2.2.2. Methods 
4.2.2.2. Physical mixtures (PMs) and salt preparations 
PMs of TMP with various molar ratios of aspartic acid were prepared by weighing accurate 
amount of TMP and mixed by KitchenAid (Michigan, USA) at mixing speed of 3 for 5 minutes 
with the various ratios of aspartic acid. TMP aspartate salt was prepared using the method 
developed by ElShaer et al (2011). Equimolar amount of TMP and the free amino acid were 
solubilised in water. The solutions were mixed and stirred until equilibration and then filtered 
using 125 mm filter papers (Whatman®, Maidstone, UK). The filtrate was transferred into vials 
and freeze dried for 48h using a Modulyo freeze dryer (West Sussex, UK) at -40oC shelf 
temperature and under vacuum (E2M5 Edwards pump, West Sussex, UK).  The samples were 
collected and kept at 40oC for 4h using a Gallenkamp vacuum oven. The physical mixtures of 
TMP aspartate and aspartic acid (SMs) were prepared in a similar manner to PMs. 
Powder characterization 
4.2.2.2. Powder flowability (Angle of repose method) 
Powder flowability of the drug, salt, individual amino acid and physical mixtures of them was 
evaluated using angle of repose method. 25 gm of powders were poured through a funnel 
onto a glass plate. The funnel was positioned 10 cm from the glass plate and the powders were 
allowed to flow freely until the formation of a symmetrical cone. Both the base and height of 
the cone were measured and recorded. Equation (4.2.1) was used to calculate the angle of 
repose and the flow properties were interpreted as outlined in Table 4.2.1.  
b
h
5.0
)tan( =α   Equation 4.2.29 
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Where h is the cone height and b is the cone base. 
 
Table 4.2.1:- Flow properties of pharmaceutical powders according to the measured angle of repose. 
Angle of repose (degree) Flow property 
25- 30 Excellent 
31-35 Good 
36-40 Fair (aid not needed) 
41-45 Passable (may hang up) 
46-55 Poor (must agitate, vibrate) 
56-65 Very poor 
> 66 Very, very poor. 
 
4.2.2.2. Particle size analysis (laser diffractometry) 
Powder particle size analysis was performed using a laser diffractometer (SympaTC, RODOS 
T4.1, Clausthal-Zellerfeld, Germany). An R3 lens with a working range between 0- 178 µm was 
used for this study. The instrument allows the powder to circulate constantly through the 
system during the measurements. The volume of distribution was used to calculate the median 
(50% volume percentile) and the span of distribution was calculated using equation (4.2.2). All 
the measurements were done in triplicate. 
Span of distribution
50
1090
X
XX −
=  Equation 4.2.30 
 
4.2.2.2. Apparent, bulk particle density and porosity measurements 
Bulk density was determined by using 10 ml cylinder to measure the volume (V) of a pre-
weighed sample. Apparent particle density was measured using helium pycnometer 
(Multipycnometer Quantachrome Instruments, Hampshire, UK). Both bulk and true density 
values were used to determine the powder porosity according to equation (4.2.3). 
)/1(100 td ρρε −=    Equation 4.2.31 
Where ε is the porosity and ρd is the bulk density and ρt is the true density. All the 
measurements were done in triplicates. 
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4.2.2.2. Powder wettability (Contact angle) 
The Wihelmy method was used to measure the wettability profile of the free powders by 
measuring the contact angle between the powders and distilled water (Hayes et al., 1994). A 
small glass slide (24x24 mm) was first covered with double sided tape (Scotch 12*1 mm) and 
then the free powders were uniformly coated on the tapped slides. The slides were attached 
to balance loop of the tensiometer microbalance (QCT-100 Interfacial Tensiometer, Camtel 
Ltd, Herts, UK) and the samples were lowered at a speed of 0.2 mm/s to a distance of 10 mm 
after contact with the liquid medium. 75 mL of double distilled water at 25 ºC was used as the 
liquid medium. 
The Wilhelmy equation was used to calculate the contact angle at regular intervals and 
CAMTEL CDCA-100 software (version 2.01.015, Herts, UK) was used to draw a correlation 
between contact angle and the immersion depth.  
 
4.2.2.2. Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM, STEREOSCAN 90, Cambridge Instrument) was used to 
study the surface morphology of TMP and TMP aspartate. Samples were prepared by 
sprinkling the salts onto specimen stubs which were loaded onto a universal specimen holder. 
In order to enable electricity conduction, samples were coated with a fine layer of gold using a 
sputter coater (Polaron SC500, Polaron Equipment, Watford, UK) at 20 mA for three minutes at 
low vacuum and in the presence of argon gas (Polaron Equipment, Watford, UK). 
 
4.2.2.2. Tablet preparation 
Tablets of TMP, its aspartate salt and physical mixtures with excess of the amino acid 
counterions at (1:1), (1:2), (1:4) and (1:8) molar ratios were prepared to study tableting 
properties. The powders were compacted using uniaxial hydraulic press (Specac tablet presser, 
Slough, UK) and split die which prevents mechanical failure by allowing triaxial decompression. 
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Magnesium stearate in ethanol (0.5% w/v) was used to lubricate the die walls and punch 
surfaces. Powders were compressed at 10, 20, 30, 40 and 60 kN and at dwell time of 30 sec at 
ambient conditions (room temperature 20 oC and 70% relative humidity).  
The prepared tablets were cylindrical with a diameter of 13 mm and weight of around 500 mg. 
Tablets were left in desiccators for 24 h prior to performing any mechanical testing. 
Tablet characterization 
4.2.2.2. Tensile strength measurements 
The force required to crush the prepared tablets was measured using tablet hardness 
apparatus (Schleungier 4M, Thun, Switzerland). The measured force was used to determine 
the tablet tensile strength using equation (4.2.4). 
dt
Fc
pi
σ
2
=      Equation 4.2.32 
Where σ is the tablet tensile strength, Fc is the crushing force required to break the tablet, d is 
the tablet diameter and t is the tablet thickness. All measurements were done in triplicate. 
 
4.2.2.2. Disintegration time studies 
Disintegration time is the time required for tablets to disintegrate completely without leaving 
any solid residue. In vitro disintegration time was evaluated using US pharmacopoeia 
monograph (<701> disintegration). Erweka ZT3, Appartebau, GMBH (Husenstamm, Germany) 
was used in this study as a disintegration apparatus and distilled water (800 ml) as 
disintegration medium; the disintegration medium temperature was maintained at 37 °C by 
thermostat. Six tablets were placed in the basket rack assembly and covered by transparent 
plastic disks. The disintegration time was taken as the time required for tablets to disintegrate 
completely without leaving any solid residue. All the measurements were carried out six times 
and presented as mean ± standard deviation. 
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4.2.2.2. Heckel analysis 
The Heckel equation (4.2.5) was used to analyze tablets’ compression data using out-of-die 
method (Heckel R. 1961a; Heckel R. 1961b).  
AKPD +=− ))1/(1ln(   Equation 4.2.33 
Where D is the tablet relative density at pressure P, K is a material constant (slope of the 
straight line portion of Heckel plot) and is 1/3 of the yield strength. 1/K value is used to express 
the mean yield pressure. A is a function of the initial bulk volume and is calculated from the 
intercept of the straight line of The Heckel plot. 
 
4.2.2.2. Statistical analysis 
Graph Pad Instat® software (Version 3.01, CA, USA) was used for statistical analysis. Data 
groups were compared using one way analysis of variance (ANOVA) and pair-wise multiple 
comparisons method (Tukey test) by using the mean values, standard deviation (SD) and 
number of experiment (N). Standard deviation (SD) was used to report the error in the figures 
and texts. Probability values of 95% (P< 0.05) were used to determine the significant 
difference. 
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4.2.3. Results and discussion 
4.2.3.1. Powder characterization 
Prior to studying the compaction properties of binary mixtures, powder characterisation and 
densification properties of the individual powders were studied to understand the compaction 
mechanism of materials and determine the impact of inclusion of each excipient in binary 
combinations (Table 4.2.2). 
 
4.2.3.1.1. Characterisation of powder flow properties using angle of repose (
o
) 
The flow properties of TMP, aspartic acid and TMP aspartate salt were measured using angle 
of repose. Results (Table 4.2.2) show that aspartic acid has excellent flowability as the 
measured angle of repose was 26.6±2.3o while TMP (angle of repose 32.41±0.32o) had good 
flow properties. On the other hand, the flow characteristics of the prepared TMP aspartate salt 
were poor and the powder is considered passable as its angle of repose was 42.7±5.4o.   
The flowability for all PMs, prepared at various ratios of aspartic acid was good and no 
significant difference (P>0.05) was observed for the measured angle of repose for all the 
different ratios studied. 
Table 4.2.2:-  Powder characterisation of TMP, aspartic acid, TMP aspartate salt, their physical and 
salt mixtures. 
Formulations Angle of repose 
(
o
) 
Bulk density 
(gm/cm3) 
True density 
(gm/cm3) 
Porosity 
TMP aspartate 
salt 
42.7±5.4 0.10±0.00 2.90±0.69 0.96±0.01 
TMP 32.4±0.3 0.65±0.05 1.45±0.03 0.54±0.02 
L-aspartic acid 26.6±2.3 0.67±0.04 1.92±0.05 0.64±0.03 
PM 1:1 34.2±1.4 0.53±0.02 1.63±0.03 0.67±0.02 
PM 1:2 35.2±0.8 0.57±0.01 1.86±0.17 0.69±0.03 
PM 1:4 33.7±2.8 0.61±0.02 1.80±0.03 0.66±0.02 
PM 1:8 32.1±2.8 0.60±0.02 1.97±0.12 0.69±0.03 
SM 1:1 36.3±2.2 0.17±0.01 2.10±0.01 0.91±0.00 
SM 1:2 45.6±2.3 0.21±0.02 2.57±0.87 0.91±0.03 
SM 1:4 40.2±2.9 0.18±0.00 2.39±0.21 0.92±0.01 
SM 1:8 34.02±6.6 0.28±0.01 1.98±0.08 0.85±0.01 
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4.2.3.1.2. Apparent, bulk particle density and porosity measurements 
Interestingly, the true density of both the physical mixtures (PMs) and salt mixtures (SMs) 
were concentration dependent i.e. increasing the ratio of the oppositely charged aspartic acid 
resulted in an increase in the true density (Table 4.2.2). The bulk densities for the physical 
mixtures (PMs) were lower than that of the individual powders possibly due to the reduction 
of the surface charge upon using binary mixtures of the drug and aspartic acid which carry 
opposite charges. Such a reduction on the surface charge results in reducing the repulsive 
forces between similarly charged ions and lowers bulk density which was evident with increase 
in aspartic acid ratio in the powder blend (Fuhrer, 1996). However, the opposite effect was 
observed for the SMs and the bulk density increased from 0.1±0.0 for TMP aspartate salt to 
0.28±0.01 (Table 4.2.2) upon adding excess of aspartic acid. This could possibly be attributed to 
the net surface charge of zero within the salt which becomes more negative upon increasing 
the concentration of aspartic acid resulting in greater repulsive forces and higher bulk density. 
Porosity measurement for the three powders revealed that preparation of the salt yields 
powder which has low bulk density and high porosity (Table 4.2.2) which is possibly due to the 
sublimation of ice during freeze drying which leaves behind porous channels between powder 
particles (Deville et al., 2007; AlHusban et al., 2010). 
 
4.2.3.1.3. Particle size analysis  
Previous research has shown that various factors including salt form, polymorphic transition, 
crystallinity, crystal and particle size influence inter-particulate bonding in the tablets 
(Alderborn, 2002). In the current investigation, particle size analysis of the powder samples 
(Table 4.2.3) and the crystalline structure were studied (Fig. 4.2.1). Particle size analysis was 
studied using laser diffractometer and has shown that TMP aspartate salt has small particle 
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size of 28.44±1.14 µm while TMP free base and L-aspartic acid had a mean particle size of 
69.9±0.13 and 94.4±0.8 respectively. 
Table 4.2.3:-  Heckel parameters of TMP, aspartic acid and TMP aspartate salt. 
 Yield strength (Y) 
MPa 
Yield pressure (PY) σ0 d50%(µm) Span value 
TMP 107.52 322.58 273.85 69.9±0.13 1.98±0.02 
L-aspartic acid 46.9 140.84 N/A 94.4±0.80 1.26±0.02 
TMP aspartate 144.92 434.78 179.74 28.44±1.14 3.44±0.02 
 
4.2.3.1.4. Surface morphology  
Morpholgical analysis of  powder crystals was carried out using SEM. L-aspartic acid had thin 
rectangular plates with smooth surface (Fig. 4.2.1B) while TMP crystals were found to be 
hexagonal in shape with irregular edges, rough surface and more than one crystal attached to 
each other (Fig. 4.2.1A &D). Interestingly, TMP aspartate salt showed small crystals which 
formed aggregates (Fig. 4.2.1C). The agglomerates salt form was previously reported and 
studied extensively by Szabó-Révész et al., (2001). 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 182
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.49:- SEM for TMP at low magnification 500 µM (A), at high magnification µM200 (D), 
aspartic acid (B) and TMP aspartate salt (C). 
 
4.2.3.2. Tablets characterization 
4.2.3.2.1. Compressibility 
 
Having investigated powder properties, the next stage of evaluation was the preparation of 
compacts for the three different powders. The strength of the tablets is believed to be affected 
by the compressibility behaviour of the powders (Sun and Grant, 2001). Highly compressible 
powder (smaller porosity) enables the particles to get closer to each other which enhance 
interparticulate bonding resulting in the formation of stronger compacts (Alderborn and 
Nystrom, 2005). 
A 
D C 
B 
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Upon compressing TMP and aspartic acid, TMP showed the highest compressibility which was 
found to be less dependant on the compression force and remained unaffected (p> 0.05) when 
the compression force was increased (Fig. 4.2.2). On the other hand, aspartic acid porosity 
decreased by 32% upon increasing the compression force from 10 kN to 30 kN. Beyond 30 kN, 
the porosity remained constant (p>0.05). The compressibility behaviour of TMP aspartate salt 
was similar to that of aspartic acid. Powder plasticity plays an important role during the 
densification of the powder and in order to understand the mechanism of densification of 
these powders, Heckel analysis was performed and the yield strength of the three powders 
was measured (Fig. 4.2.3). 
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Figure 4.2.50:- Plots of tablet porosity against compaction pressure, showing the compressibility of 
TMP, aspartic acid and TMP aspartate salt (n= 3). 
 
 
Heckel graph was established for each powder using out-of-die method and the linear part of 
the graph with R2 values of 0.9, 0.96 and 0.96 for TMP, aspartic acid and TMP aspartate salt 
respectively was used to carry out Heckel analysis (Fig. 4.2.3). The data showed that none of 
the materials studied are brittle and that they densify via plastic deformation because of their 
high yield strength values (Table 4.2.3) as suggested by Kuny et al. (2003). In order to 
differentiate between plastic and elastic behaviour of these materials, the yield strength was 
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Compaction force kN Compaction force kN
TMP L-aspartic acid TMP aspartate salt
calculated using the Heckel equation (Equation 4.2.3) (Table 4.2.3). L-aspartic acid had the 
lowest yield strength which reflects high plasticity and low elasticity of the powder. Although, 
the lowest plasticity properties were exhibited by TMP aspartate salt (Table 4.2.3) the tablets 
survived the decompression phase and no capping was observed possibly because of the 
agglomerate form of the salt as discussed in detail below. 
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Figure 4.2.51:-  Heckel plots for TMP, aspartic acid and TMP aspartate salt using out-of-die method 
(n=3). 
 
 
Compressibility behaviour of TMP PMs and TMP aspartate SMs with various molar ratios of L-
aspartic acid was also evaluated in this study (Fig. 4.2.4).  
At low compression forces (10 kN), PMs with high amount of TMP showed better 
compressibility characteristics when compared to L-aspartic acid tablets (Fig. 4.2.4A). Yet, at 
higher compression forces, no significant difference (p> 0.05) was observed for the majority of 
the formulations. Interestingly, the compressibility behaviour of TMP:L-aspartic PM at 1:2 ratio 
was significantly higher for the all formulations (p<0.001). This behaviour might be related to 
the percloration threshold of the binary mixture (Leuenberger H., 1982). If a binary mixture 
consisting of two materials A and B (TMP and L-aspartic acid in this study) undergoes 
y = 0.0071x + 0.4401 
 
y = 0.0031x + 0.557 
 
 y = 0.0023x + 0.4967 
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compression, a lattice is formed by particles of type A or type B. At high concentration of 
substance A, many particles of A become direct neighbours and build a cluster in the lattice. 
Therefore, substance A dominates the behaviour of the system. Upon increasing the amount 
of B, substance B starts to replace A in the lattice resulting in  phase inversion, when the 
system dominated by A is replaced by substance B (Leuenberger, 1982) at critical 
concentration called percolation threshold (1:2 ratio might be the percolation threshold for 
TMP/ aspartic acid binary mixture).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.52:- Plots of tablet porosity against compaction force, showing (A) the compressibility of 
TMP and aspartic acid PMs(n= 3), (B) the compressibility of TMP aspartate and aspartic acid SMs (n= 
3). 
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Compressibility profile for the salt/acid binary mixtures was also studied (Fig. 4.2.4B). The data 
showed that there was no significant difference between majority of the formulations at low 
compaction forces. Increasing the ratio of aspartic acid deteriorated the compressibility profile 
of the SMs. The highest compressibility was exhibited by 1:1 and 1:2 ratios of salt: aspartic acid 
(Fig. 4.2.4B) and was found to be higher than that of the individual components. These results 
support the findings previously suggested by Wu et al (2005) which showed that the behaviour 
of a binary mixture is not usually linear between the two bulk components used in the system 
(Wu et al., 2005). The compressibility profile of the PMs and SMs were comparable and no 
siginificant improvement was observed upon using the salt form instead of the free drug, 
probably because of the high content of aspartic acid which in turn dominates compressibility 
characteristics of the binary mixtures. 
 
4.2.3.2.2. Compactability 
 
The ability of the pharmaceutical powder to form a tablet with sufficient strength under the 
effect of densification is known as compactability (Joiris et al., 1998). Although compression 
enables particles to come into close contact during the applied force, bond formation between 
particles is necessary to form strong tablets (Fuhrer, 1996).  
The relationship between tablet porosity and tensile strength is shown in Fig. (4.2.5). An 
exponential relationship between tensile strength and porosity was observed for both TMP 
and TMP aspartate salt with correlation of 0.96 and 0.95 respectively. This correlation was 
previously discussed by Ryshkewitch and was used to assess the tensile strength at zero 
porosity (σo) using equation 6 (Ryshkewitch, 1953) and summarized in table 4.2.3.  
εσσ be−= 0       Equation 4.2.34 
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Figure 4.2.53:- Plots of tablet tensile strength against porosity, showing (A) the compactability of 
TMP, aspartic acid and TMP aspartate salt, (B) TMP and aspartic acid PMs, (C) TMP aspartate salt and 
aspartic acid SMs (n= 3). 
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 Although the three powders showed similar compressibility beyond 30 kN, compactability 
results were significantly different. The highest compactability was exhibited by TMP aspartate 
salt which had tensile strength of 7.24±0.09 with a tablet porosity of 0.53±0.02 (data not 
shown). However, the highest tensile strength demonstrated by L-aspartic acid and TMP was 
0.25±0.094 and 0.62±0.41 at porosity of 0.55±0.03 and 0.48±0.035 respectively (Fig. 4.2.5A). 
These results suggest that the TMP aspartate salt form has 10 fold higher tensile strength than 
aspartic acid despite the latter having higher plasticity. 
As discussed above, various factors affect inter-particulate bonding within the tablets including 
salt form, polymorphic transition, crystallinity, crystal habit and particle size (Alderborn G., 
2002). Particle size analysis showed that TMP aspartate salt had a mean particle size of 
28.44±1.14 µm while SEM showed small crystals of the salt which formed aggregates. The 
agglomerate salt form was previously studied by (Szabó-Révész et al., 2001) and it was found 
to have higher tensile strength when compared to commercial salt with no agglomerates. This 
suggests that both agglomerate formation during salt preparation and the small particle size of 
these agglomerates play a major role during the densification of the salt form. 
 However, TMP free base and L-aspartic acid had particle size of 69.9±0.13 and 94.4±0.8 µm 
respectively. Besides, morphological analysis of the powders crystals showed that L-aspartic 
acid had thin rectangular plates with smooth surfaces (Fig. 4.2.1B) which would slide over each 
other and the smooth surface would prevent any mechanical bonding.  
On the other hand, the rough surface of the hexagonal crystals of TMP (Fig. 4.2.1A) could have 
played a role in mechanical interlocking during densification as it could allow enhanced contact 
and retention between different crystals.  
Intermolecular bonding is one of the major forces involved during bond formation in 
pharmaceutical compacts (Fuhrer, 1996).   Therefore, the effect of surface charge on bond 
formation was evaluated in this study by incorporating anionic amino acid (aspartic acid) with 
the cationic TMP and neutral salt form. 
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PMs compactability profile was studied and summarized in Fig. 4.2.5B. Generally, decreasing 
the porosity increases the tensile strength.  It was clear that increasing the ratio of aspartic 
acid results in decreasing the compactability profile of the PMs as aspartic acid replaces TMP 
and dominates in the system and therefore results in higher compactability. Interestingly, 
TMP:L-aspartic 1:2 showed the lowest porosity, yet the tensile strength for this binary mixture 
was lower when compare with other binary mixtures.  Although low porosity should allow 
higher interparticulate bonding area in the tablets, the tensile strength of 1:2 tablets was not 
the highest among the binary mixtures used. The highest tensile strength was exhibited by 1:1 
tablets. This is probably because of the high content of TMP, which has better compaction 
characteristics than aspartic acid as discussed before. This suggests that TMP dominates in the 
system and nullifies the effect of lower bonding area exhibited by 1:2 tablets. It was 
hypothesised that at 1:1 ratio electrostatic interaction is highest and would result in the 
formation of stronger compacts. However, upon comparing the compactability of 1:1 PM 
against TMP alone, the results showed that the free drug has higher compactability. This result 
suggests that the electrostatic interaction has lower effect during densification of TMP aspartic 
acid PM. Upon increasing the amount of L-aspartic acid, the tensile strength began to decline 
and for reasons unknown the compactability characteristics of 1:2 ratio was the lowest. 
On the other hand, all the SMs formulations showed higher compactability than that of the 
free aspartic acid (Fig. 4.2.5C). The highest compactability was shown by 1:4> 1:1 ratios> 1:8 > 
1:2.  This order was not the same as that of TMP/aspartic acid physical mixtures profiles, 
possibly because the compactability characteristics of a binary mixture are not often 
predictable from individual material characteristics (Vromans and Lerk., 1988; Veen et al., 
2000). 
Interestingly, all of the SM formulations exhibited higher compactability than the PMs, 
although the former is a mixture between neutral and anionic moieties and no electrostatic 
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interaction is expected to take place. This confirms the early finding that the surface charge 
has minimal effect during bond formation of both PMs and SMs. 
 
4.2.3.2.3. Tabletability 
 
The ability of the powder to form a tablet with sufficient mechanical properties under the 
effect of compaction pressure is known as tabletability (Joiris et al., 1998). Generally, the 
tabletability characteristics of all the three powders improved with an increase in compaction 
pressure possibly due to the reduction in tablet porosity upon increasing the compaction 
pressure (reduction in tablet porosity increases contact area between the particles and 
therefore results in higher bonding and harder tablets) (Nystrom and. Karehill., 1995). L-
aspartic acid had poor tabletability among the three powders. The highest tensile strength of 
L-aspartic acid was 0.25±0.094 at 60 kN. The tensile strength of TMP tablets was almost twice 
(0.62±0.41) that of L-aspartic acid. Interestingly, TMP aspartate salt showed a very high tensile 
strength (2.48±0.38) even at very low compaction pressures. The tensile strength of the salt 
increased to 3.9±0.68 when the compression force was doubled to 20 kN. At 30 kN the tensile 
strength rose to 7.78±0.37 and remained constant beyond 30 kN.  
Despite the similar compressibility profile of TMP and TMP aspartate salt (as they showed 
constant compressibility beyond 30 kN), the tabletability profile was significantly different 
(p<0.001). The tensile strength of TMP tablets increased even when the porosity was constant  
(p>0.05) beyond the compression force of 30 kN (Fig. 4.2.6A) which suggests that crystal 
interlocking takes place during tablet densification as mechanical interlocking is not dependent 
on the distance between the particles (Nystrom and Karehill, 1995). However, the tensile 
strength of TMP aspartate tablets did not change when the tablet porosity remained constant 
which suggests that alternative bonding mechanism is involved during the densification of TMP 
aspartate powders. Increasing the compaction force beyond 30 kN did not result in further 
decrease in tablet porosity (as discussed above) hence, particle surfaces cannot get into closer 
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proximity any more and the tensile strength remained constant. Intermolecular bonding which 
is also known as distance attraction forces is affected mainly by the surface area available for 
bonding suggesting that intermolecular bonding could be the main bonding mechanism for the 
salt forms. Hydrogen bonds play a vital role in intermolecular bonding and structure analysis of 
TMP aspartate salt shows that the salt form has a total of nine hydrogen bond donors and 
acceptors atoms which further confirm the assumption that intermolecular bonding is the 
major binding force (Nystrom and Karehill, 1995). 
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Figure 4.2.54:- Plots of tablet tensile strength against compaction force, showing the tabletability of 
(A) TMP, aspartic acid and TMP aspartate salt, (B) TMP and aspartic acid PMs, (C)TMP aspartate salt 
and aspartic acid SMs (n= 3). 
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The tabletability plots for PMs are shown in (Fig. 4.2.6B). The crushing force was very low for 
some of the mixtures compressed at 10 kN. Upon plotting the tensile strength against the 
compaction force, a linear relationship was observed for all the PMs over the range of 
compression forces used. The tensile strength of the PMs was between that of the individuals 
components. As tabletability is determined by both bonding area (compressibility) and 
bonding strength (compactability) and as the bonding area is comparable for most of the PM 
formulations at each compression force (Fig. 4.2.4A), compactability was the main determinant 
for the tabletability characteristics of the binary mixtures. Again the highest tabletability was 
observed for 1:1 ratio mixture followed by 1:4> L-aspartic acid ≈ 1:2 (Fig. 4.2.6B).  
 
Upon studying the tabletability profile of salt/aspartic acid binary mixture (Fig. 4.2.6C) it was 
found that all the SMs were significantly lower than that of the individual salt but higher than 
the individual aspartic acid and physical mixtures at all the compression forces. 1:4 salt mixture 
showed the highest tabletability followed by 1:1.  
 
4.2.3.2.4. Disintegration time 
After ingestion of a solid dosage form, the delivery system starts to disintegrate into small 
particles prior to dissolution in the gastrointestinal tract. Previous studies have suggested that 
tablet disintegration time increases as the compression forces rises (Riippi et al., 1998).  The 
effect of compression force on the disintegration time of the prepared tablets was evaluated 
(Fig. 7A, B & C). Both TMP and L-aspartic acid showed an increase in the disintegration time 
upon increasing the compaction force (Fig. 4.2.7A). Moreover, TMP tablets failed to 
disintegrate with in 30 minutes at compression forces as low as 20 kN. Nevertheless, L-aspartic 
acid showed a linear relationship between the disintegration time and the applied compaction 
force. L-aspartic acid disintegrated very rapidly (6.6±3.7 s) when low compression forces were 
used (Fig. 4.2.7A). 
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TMP aspartate salt showed an interesting disintegration profile.  The tablets disintegrated at 
304±13 s when compressed at 10 kN. The disintegration time increased upon increase of 
compression force. However, beyond 30 kN the tablets’ disintegration time started to decrease 
to 128±34 s at 60 kN. 
 
Tablet disintegration takes place by various mechanisms such as swelling, porosity and 
capillary action. Prior to disintegration, the tablet surface should be wetted by the 
disintegration media (Fukami et al., 2006) which results in tablet disintegration via one of the 
above mechanisms.  
In order to understand the mechanism of disintegration of the prepared tablets, wettability 
studies of the dry powder were performed using the protocol described in the methods 
section. Interestingly, all the three powders showed good wettability profile with zero contact 
angle. Contact angle depends on the hydrophilicity/hydrophobicity of the surface. The low 
contact angles exhibited by the three powders could be attributed to the high hydrophilicity 
for all powders. 
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Figure 4.2.55:- Disintegration time of (A) TMP, aspartic acid and TMP aspartate salt, (B) TMP and 
aspartic PMs, (C) TMP aspartate salt and aspartic acid SMs at various compression forces (n=3). 
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For all the powders, increasing the compaction force resulted in increasing the disintegration 
time possibly because of the decrease in tablet porosity at higher compaction forces. 1:1 PM 
showed the highest disintegration time at all the compression forces (Fig. 4.2.7B). At low 
compression forces of 10 kN, 1:1 tablets disintegrated at 20±7 s and the disintegration time 
increased steadily until 287±40 s at 60 kN. Interestingly, increasing the amount of L-aspartic 
acid in the PMs formulations was found to decrease the disintegration time of the tablets 
significantly and the disintegration time was even lower than that of L-aspartic acid alone.  
For instance, at 40 kN, 1:1 tablets disintegrated at 102±15.6 s and the disintegration time 
dropped significantly to around 25 s upon increasing the L-aspartic acid amount in 1:2 and 1:4 
mixtures and to 12 s for 1:8 ratio. It is known that the porous structure of the tablets has a 
large effect on the disintegration time. Nevertheless, the porosity for all the tablets was 
comparable and it could not explain the rapid disintegration for the physical mixtures at 1:2, 
1:4 and 1:8. It could be hypothesised that the use of water as disintegration media would have 
enhanced the ionisation of TMP and aspartic acid and facilitated tablet disintegration in line 
with the results reported by Ferrari et al., (1996).  
Disintegration time profiles for the SMs were similar to that of the PMs. Disintegration time 
was found to decrease as the aspartic acid ratio increases. Nevertheless, the PMs 
disintegration times were faster than that of the salt mixtures. 
 
4.2.4. Conclusion 
The current study evaluated the compaction properties of aspartic acid, TMP and TMP 
aspartate salt. Both particle size analysis and surface morphology studies revealed that TMP 
has rough hexagonal crystals that interlock mechanically during densification, while the thin 
rectangular plates of aspartic acid slide over each other instead of mechanical intercalation.  
The very high tensile strength exhibited by TMP aspartate salt was attributed to its small 
particle size and formation of agglomerates during salt preparation. Although Heckel analysis 
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revealed that aspartic acid has high plasticity, inclusion of the acid as a tablet filler did not 
enhance the compaction properties of TMP and TMP aspartate salt possibly due to the large 
particle size of its crystals. It can be concluded that aspartic acid demonstrate 
multifunctionality as a filler (with no binder property), disintegration promoting agent thereby 
ultimately enhancing bioavailability and pharmacokinetics of BCS IV drug candidates. 
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TMP permeability studies and transcriptomic changes occurring during 
its uptake across Caco-2 cells 
 
4.3.1. Introduction 
 
One of the major obstacles in oral drug delivery is the poor permeability of drugs across the 
intestinal membrane. The majority of drugs are absorbed via passive diffusion through 
paracellular and transcellular routes. Nevertheless, the physico-chemical properties of the 
drug molecules limit their uptake via passive diffusion (Martinez et al., 2002). Active drug 
uptake mediated by carrier transporters enables some molecules to circumvent the issues 
associated with poor intestinal absorption (Lipka et al., 1996; Walter et al., 1996; Amidon et 
al., 1998).  The complicated process of permeation across the intestinal membrane results in 
large numbers of new drugs  which fail to exhibit therapeutic effectiveness in-vivo;  even 
though they may have exhibited in vitro potency , as they cannot cross the cell membrane in 
the gastrointestinal tract due to their intrinsic molecular properties. Many approaches have 
been developed including prodrug formation and ion-pairing to improve the inherent physico-
chemical properties of the drug candidates to enhance permeability. 
The prodrug approach is based on formation of a covalent bond between the drug molecule 
and a lipophilic moiety in order to improve passive diffusion of the drug (Ettmayer et al., 2004). 
Although this approach has achieved success in improving drug uptake, covalently linking the 
drug with another moiety could potentially result in a new chemical entity with low or poor 
efficacy and/or increased toxicity. 
Schankier 1960, discussed a similar approach to prodrugs which exploits electrostatic 
interactions between two moieties instead of covalent bond formation; this is referred to as 
ion-pairing. After being absorbed, the ion-pairs dissociate in the blood stream via dilution. This 
approach has many advantages over prodrug synthesis as it does not need activation by 
enzymes and does not rely on disrupting the integrity of the membrane to facilitate drug 
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uptake. The majority of the investigations carried out on ion-pairing focused on improving drug 
uptake via passive diffusion (Miller et al., 2010). In the current study we investigate whether 
ion-pairing of TMP with actively transported counter ions (aspartic and glutamic acids) would 
improve the overall absorption of the drug candidate via active transporter carriers. 
Trimethoprim is a synthetic antibacterial agent belonging to a group of compounds known as 
diaminopyrimidines. It was first synthesized as a dihydrofolate reductase inhibitor (DHFR) and 
used mainly in combination with sulfonamides to treat pneumonia and urinary tract infections. 
TMP has cationic nature with a pka of 7.3. This basic drug is very slightly soluble in water (0.2 
mg/mL) and has poor intestinal absorption and hence classified as BCS IV according to the 
Biopharmaceutical Classification System (ElShaer et al., 2012). 
In order to improve TMP solubility, Li et al. (2005) utilized β-cyclodextrin as a complex forming 
agent. The increased surface area of contact between TMP and the cyclodextrin along with the 
reduction in drug crystalinity were shown to be responsible for improvement of TMP solubility. 
Previous work carried out by ElShaer et al., 2012 showed that coupling TMP with glutamic acid 
and aspartic acid improved the drug solubility by 280 fold. Despite a Log P value of 1.4, TMP 
has low oral permeability (Kasim et al., 2003). The low absorption profile is attributed to high 
efflux through P-gp (Victoria E., 2009). A study by Joseph et al., (2001) suggested that basal to 
apical flux for TMP was 3.61 times higher than its apical to basal absorption. Moreover, the 
study demonstrated that TMP activates ATPase which provides the energy required for P-gp 
activity.  Conversely, the studies carried out by Romiti et al., (2002) on human kidney-2 (HK-2) 
cells suggested that TMP does not interfere with P-gp activity nor modulate human multidrug 
resistance gene (MDR-1). Wendy et al (2002) and Jung et al (2008) studies reported that TMP is 
a substrate for human organic cation transporters (hOCT) suggesting that TMP could be 
transported actively via OCT1 and OCT2 transporters. The degree of TMP ionisation was also 
found to determine its capacity to interact with hOCT2. Jung et al., 2008 studies demonstrated 
that decreasing TMP ionisation by increasing the pH of the transport media from 7 to 8 
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resulted in lowering the binding with hOCT transporter. Nevertheless, the kinetic calculations 
based on the proportion of molecules charged at each pH value showed higher inhibitor effect 
than predicted. These results were attributed to the difference between the pH values of the 
membrane and that of the bulk of the media or the difference of TMP pKa values at the 
transport receptor region and that in the free solution (Jung et al., 2008). OCT1 and OCT2 are 
expressed predominantly in liver, kidney (Jung et al., 2008) ileum, duodenum and colon 
(Englund et al., 2006). Moreover, OCT1 transporters were also found to be expressed in Caco-2 
monolayers, 3 times higher than in ileum and duodenum (Englund et al., 2006). The major 
focus of this study is to ion-pair the poorly absorbed TMP to a highly permeable counter ion 
which has a full transporter system across the intestinal membrane. Interestingly, most of the 
living cells express a combination of common and specific transporter systems for amino acids 
as they  play a vital role in cellular activities of the living cells. Because the cationic nature of 
the drug used in this study (TMP), anionic amino acids (aspartic acid and glutamic acid) were 
selected as potential counter ions. Cellular uptake of anionic amino acids is mediated by solute 
carrier transporters known as high affinity glutamate transporters (SLC1 or X-AG). SLC1 was first 
identified in 1992 by (Kanai and Hediger) and were further characterised into five sub-families: 
SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7. X-AG  is Na
+ and K+ dependent transporters 
which mediates the uptake of glutamic acid and aspartic acid accompanied by co-transport of 
3Na+, 1H+ and  counter-transport of 1K+.  X-c is another carrier transporter which is Na
+ 
independent antiport system that transports glutamate and cystine in order to protect the 
cells against oxidation (Robert et al., 1998). X-AG and X
-
c were reported to be fully expressed in 
Caco-2 monolayers and mediate the transport of glutamic acid, aspartic acid (Mordelle et al., 
2000) and cysteine (Andy et al., 2006) during the differentiation of caco-2 cells.  
The aim of the current work is to investigate whether anionic amino acids (glutamic acid and 
aspartic acid) would ion-pair strongly with the cationic model drug, TMP and if the new ion -
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pairs would have better uptake across the Caco-2 monolayers. Both aspartic and glutamic acids 
are similar in their structure apart from an extra alkyl group in the glutamic acid side chain.  
 
4.3.2. Materials and methods 
4.3.2.1. Materials 
Trimethoprim, L-Glutamic acid (Reagent plus ≥ 99%), L-aspartic acid (≥ 98%) and ninhydrin 
reagent (2% solution) were purchased from Sigma Aldrich, UK. 
Sodium hydroxide and sodium chloride were purchased from Fisher Scientific UK. 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), Nonessential amino 
acids (NEAA), 1% pencillin-streptomycin, 2mM glutamine and Hank’s balanced salt solution 
(HBSS) were purchased from Bio Sera, UK. 1% Trypsin–EDTA was obtained from Gibco Lab. UK. 
RNeasy kit (RNA free water, buffer RLT, buffer RW1 and buffer RPE) was purchased from 
Qiagen (Hiden, Germany). Gene expression hybridization kit, low input Quick Amp labelling kit, 
RNA spike-in kit (one color) all were purchased from Agilent (Cedar Creek, Texas, USA). Agilent 
gene expression washing buffer 1 and 2 were ordered from Agilent (Wilmington, DE, USA) and 
Ethanol which was purchased from Fisher scientific (Leicestershire, UK). 
4.3.2.2. Methods 
4.3.2.2.1. Preparation of pre-saturated solution of 1-octanol and de-ionised water. 
1000 ml of de-ionised water was added to 4 mL of 1-octanol. The mixture was shaken for few 
minutes and left overnight. The de-ionised water was separated from 1-octanol using 1000 mL 
separation funnel. 
4.3.2.2.2. Octanol- water partitioning experiment 
500 µg of TMP was added to 100 mL octanol-saturated deionised water with molar excess of 
aspartic acid/glutamic acid (in ratios 1:1, 1:2, 1:4 and 1:8). 5 mL of the aqueous phase was 
allowed to equilibrate with 5mL of octanol at room temperature and stirred for 24 hours using 
magnetic stirrer. The two phases were then separated by centrifugation and TMP 
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concentration [TMPt]Aq in the aqueous phase was measured using HPLC. Mass balance was 
used to calculated TMP concentration in octanol phase [TMPt]Oct using equation (4.3.1). 
[TMPt]Oct = total drug put into the system- [TMPt]Aq   Equation 4.3.35 
 
The apparent distribution coefficient DB could be calculated using equation (4.3.2) 
DB= [TMPt]Oct/[TMPt]Aq     Equation 4.3.36 
 
4.3.2.2.3. HPLC method to study the concentration of trimethoprim 
The amount of Trimethoprim (TMP) dissolved in the solution samples was quantified using the 
HPLC (Dionex 1100 system) method reported by Gallego and Arroyo (2002). HPLC was 
operated at 25oC on RP-C18, (Phenomenex 110A, 150x4.6 mm, 5µm) column using 
acetonitrile-NaH2PO4 buffer (10 mM) (70:30, v/v) (pH 3) as mobile phase which was pumped at 
1.0 mL/min flow rate using gradient pump (GP50).  UV detector (UVD 170U) was used and the 
analysis was monitored at 230 nm. The retention time was 1.74±0.037 min and a rectilinear 
calibration curve was established at concentrations ranging between 10- 500µg/mL (R2 of 
0.99). LOD and LOQ were calculated using standard deviation of response and slope and were 
found to be 0.109 and 0.364 respectively.  
 
4.3.2.2.4. Ninhydrin analysis 
The concentrations of aspartic acid and glutamic acid in octanol/water partitioning studies 
were quantified using the ninhydrin method. In order to construct a calibration curve, serial 
dilutions of the amino acids were prepared and 1 mL of the prepared samples was mixed with 
0.5 mL of ninhydrin reagent and vortexed for 20 seconds. The samples were heated in a pre-
warmed water bath at 80 oC for 20 minutes. The samples were removed from the water bath 
and left to cool. The intensity of the coloured Ruhemann purple was analysed using a UV 
spectrophotometry at a wavelength of 560 nm. 
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Calibration curves were constructed with regression coefficients of 0.994 and 0.999 for 
aspartic and glutamic acid respectively. After constructing the calibration curves, the 
concentration of the amino acids in the aqueous layer were determined using the linear curve 
equations (4.3.3) and (4.3.4) for aspartic acid and glutamic acid respectively. 
Y=0.0695x    Equation 4.3.37 
Y=0.0895x   Equation 4.3.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.56:- Ninhydrin calibration curve for aspartic acid (A), glutamic acid (B) n=3. 
 
4.3.2.2.5. Procedure for Caco-2 cell culture 
Caco-2 cells at passage 48 were gifted from Huddersfield University and used at passages 50-
80. Cells were allowed to grow in 75cm² T-flasks and maintained using Dublecco’s modified 
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 0.5% pencillin-streptomycin, 2mM 
glutamine and 1% nonessential amino acids (NEAA). Culture medium was changed every 2 to 3 
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days and cells were grown at a temperature of 37°C and 5% CO2.  The cells were passaged 
using 5 mL trypsin-EDTA when they reached 90% confluence. A transepithelial transport assay 
was carried out using Khan et al., (2011) methods. 2 x 105cells/cm² were seeded on 
polycarbonated-coated membranes (6-well transwell plates, 24mm, 4.7cm²) and were allowed 
to grow for 21 days and the media in both apical and basal compartments was changed every 
2-3 days. The transepithelial electrical resistance (TEER) was measured at the start and end of 
every study. 
 
4.3.2.2.6. Trimethoprim permeability studies 
Caco-2 monolayers were used 19-21 days after seeding. The apical to basolateral permeability 
of TMP and its formulations was assessed. The transwells were rinsed and incubated for 15 
minutes with drug-free transport medium (Hanks balanced salt solution; HBSS). Following 
incubation, HBSS was removed and 1.5 mL of the medium containing TMP alone (500 µg/mL) 
and TMP with various molar ratios of the anionic amino acids (1:1, 1:2, 1:4 and 1:8) were 
introduced to the apical side. Sample aliquots (300μL) were taken from the basolateral side at 
given time intervals (0, 5, 10, 15, 20, 30, 60 and 90 minutes). After each sampling, an equal 
volume of fresh transport buffer (pre-warmed at 37°C) was added to the receiver 
compartment (basal side) and kept the cells at a temperature of 37°C and 5% CO2 during 
experiment. Samples were subsequently analyzed by HPLC. In order to confirm the mass 
balance, samples were taken from both apical and basolateral compartments at the last time 
point (90 mins). All experiments were performed at 37°C (n = 5). Apparent permeability 
coefficient Papp (cm/s) was calculated using (equation 4.3.5) 
0/1/ ACdtdQPapp ×=    Equation 4.3.39 
 
Where dQ/dt is the rate of appearance of the drugs on the basolateral side (nmol s-1), Co is the 
initial concentration on the apical side and A is the surface area of the monolayer (4.7 cm2). 
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The data presented were validated using HPLC measurement of drug transfer during the 
process of permeability. This included repetition of drug permeability studies in the 
preparations used for microarray analysis. 
4.3.2.2.8. Recovery 
The amounts of TMP recovered from both apical and basolateral compartments at the end of 
the experiment were calculated using equation (4.3.6). 
100(%)covRe
min0
min90min90 ×
×
×+×
=
DD
DDRR
VC
VCVC
ery
          
Equation 4.3.40
 
 
Low recovery data is attributed to entrapment of the compounds into the cell monolayers or 
adsorption to the device surface which in turn results in error calculating the transport rate 
(Aungst et al., 2000) 
 
4.3.2.2.9. RNA extraction for microarray studies 
Samples for microarrays studies was collected at 5, 30, 60 minutes for TMP, TMP:glutamic acid 
at 1:1 (PM 1:1) and 1:8 (PM 1:8) molar ratios. Caco-2 monolayers were treated with ethanol: 
phenol mixture (95:5) for 24 hours. Cell pellets were obtained by centrifugation of the 
scrubbed cells at 2000 rpm and 4 oC for 10 minutes. All pellets were stored at -80 oC until the 
RNA extraction step.  
Total RNA was extracted by using RNeasy kit (Qiagen) and quantified using the Nanodrop 1000 
spectrophotometer (Themoscientific, Wilmington, DE) and data are summarised in Table 
(4.3.1). 
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Table 4.3.35:- Quantification of total RNA using nanodrop spectrophotometer. 
 Total RNA 
Sample 
 
Conc 
(ng/µl) 
260/280 
ratio 
260/230 
ratio 
Control 5 983.1 2.02 1.57 
Control 60 842.5 2.01 1.94 
TMP,  5 min  631.3 2.04 2.05 
TMP: Glu 1:1,  5 min 952.1 1.99 1.92 
TMP :Glu 1:8 , 5 min 851.8 1.96 1.63 
TMP, 30 min 507.7 1.99 1.69 
TMP : Glu 1:1,  30 min 362.2 1.98 1.68 
TMP :Glu 1:8, 30 min 318 2.03 1.97 
TMP 60 min 889.8 2 1.78 
TMP: Glu 1:1, 60 min 614.3 1.99 1.29 
TMP : Glu 1:8, 60 min 1286.3 1.99 1.82 
 
4.3.2.2.10. Microarray study 
In order to investigate the systemic changes of the gene expression upon exposing Caco-2 cells 
to TMP and its various formulations, approximately 45,000 cDNA were hybridized with the 
microarray probe using Agilant one-color-spike procedure. Briefly, 1.5µl of 25 ng of total RNA 
was mixed with 2 µl of diluted one-color-spike mix. cDNA master mix (Agilent Technologies, 
Santa Clara, CA) was used to prepare cDNA for all the samples which were labelled using cy3-
dUTP. The yield and specific activity (Table 4.3.2) for fluroscent cDNA probes were determined 
by using equations 4.3.7 and 4.3.8 respectively, after quantifying cDNA (ng/µl) and cyanine 3 
(pmol/ µl) using the Nanodrop 1000 spectrophotometer (Themoscientific, Wilmington, DE). All 
samples were hybridized to Agilent 4x44 K whole genome array for 16 hours at 65 oC in 
hybridization oven (Sheldon manufacturer, Corneilus, OR). After hybridization, samples were 
scanned at 50n resolution and at 20 bit scan using an Agilent scanner (Agilent Technologies, 
Santa Clara, CA). 16-bit TIFF images were obtained and used as input for the feature extraction 
software (V10.7, Santa Clara, CA). 
Yield 
1000
... volumeelutioncRNAofConc ×
=        Equation 4.3.41 
 
Specific activity 1000
..
3..
×=
cRNAofConc
CyofConc
       Equation 4.3.42 
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Table 4.3.36:- Yield and specific activity of the complementary DNA used for hybridization in TMP 
studies. 
 cDNA probe 
Sample 
 
Conc 
(ng/µl) 
260/280 
ratio 
cystine dye 
pmol/ µl 
Yield 
 
specific activity 
 
Control 5 131.3 2.2 2.5 3.939 19.04 
Control 60 165.2 2.2 3.1 4.956 18.7 
TMP,  5 min  160.7 2.15 2.4 4.821 14.9 
TMP: Glu 1:1,  5 min 226.4 1.97 1.7 6.792 7.5 
TMP :Glu 1:8 , 5 min 148.5 2.15 2.6 4.4 17.5 
TMP, 30 min 348.3 2.18 2.7 10.4 7.75 
TMP : Glu 1:1,  30 min 214.1 2.29 1.7 6.42 7.94 
TMP :Glu 1:8, 30 min 144.8 2.35 1 4.34 6.9 
TMP 60 min 72.5 2.29 0.6 2.17 8.27 
TMP: Glu 1:1, 60 min 257.1 2.16 1.6 7.71 6.22 
TMP : Glu 1:8, 60 min 257.1 2.19 1.6 7.71 6.223259 
 
4.3.2.2.11. Data Processing (Image analysis and data normalization) 
The feature extraction software (V10.7, Santa Clara, CA) was used to study the quality of the 
obtained images. The image was analysed in terms of grid alignment, signal quantification and 
overall slide quality.  
Background intensities in the DNA microarray data such as optical background and non-specific 
binding (NSB) were adjusted using the R library gcrma (Boes and Neuhäuser, 2005). The gcrma 
converted the background adjusted probe intensities into expression measures (Fig. 4.3.2) 
while, the probe sequence information were used to estimate probe affinity to non-specific 
binding (NSB). The levels of probe intensities between the arrays before and after 
normalization were compared using box-plots. The middle line of the box-plot represents the 
median while the two ends of the box represent the upper and lower quartiles. Values which 
are more than 1.5 the interquartile range are outliners (small circles), while the horizontal lines 
connected to the box-plots are not considered outliners. Figure (4.3.2A) shows that the 
intensities levels for most of the arrays differ and were corrected upon normalization (Fig. 
4.3.2B). 
 
 
                                                 
 
 208
 
 
 
 
 
 
 
 
 
 
Figure 4.3.57:- Box-plots showing raw data before normalization (A), and centred distributed 
normalized microarray data (B). 
 
4.3.2.2.12. Data clustering and filtering 
Data clustering was carried out on the normalized data using TMEV software (version TM4, 
WA, USA). The genetic changes were clustered according to their similarities in the pattern of 
their expression using hierarchical clustering algorithm. The mean values were used to 
compare between the various data sets used in this study. In order to highlight the main 
variability in the multidimensional data set principle component analysis was carried out using 
TMEV software. Microsoft excel (version 2003, Toulouse, France) was used to filter out the 
non-expressed genes or the genes which do not show variation across sample types. Genes 
which were up or down regulated by two fold were selected for further analysis. Equations 
(4.3.9 and 4.3.10) were used to calculate the folds of up or down-regulation of the expressed 
genes when compared against the control (Caco-2 cells). 
 In order to investigate the changes occurring in various pathways during the absorption 
process, up and down-regulated genes were uploaded online onto Kyoto Encyclopaedia of 
A B 
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Genes and Genomes (KEGG) http://www.genome.jp/kegg/ and the expression changes 
were high- lighted in red. 
)(
)( 2
CE
CEIF
−
> =       Equation  4.3.43 
)(
)( 2
EC
CEIF
−
< −=     Equation 4.3.44 
 
 
4.3.3. Results and discussion 
 
4.3.3.1. Octanol-Water partitioning. 
In order to investigate the partitioning behaviour and hence the passive diffusion capacities of 
the cationic drug upon pairing with the anionic amino acids, octanol/water partitioning (log P) 
was carried out. For this study both the free drug and salt form were paired with the anionic 
counter ions to investigate whether the salt form has any advantage over the free TMP during 
the partitioning and absorption studies. 
 During partitioning, it is assumed that an ion-pair is formed between TMP (basic drug) and the 
acidic amino acids (aspartic/glutamic acid) in octanol-water mixture. The formation and 
destruction of ion-pairing and partitioning process between octanol-water will take place at 
equilibrium conditions. The association constant for ion-pair formation in the aqueous phase 
(K11aq) is calculated using equation (4.3.11). 
aqaq
aq
aq BA
AB
K ][][
][
11 =      
Equation 4.3.45 
 
Where [A]aq, [B]aq and [AB]aq are the concentrations of the acidic counter ion, TMP and the ion-
pair in the aqueous phase respectively. 
The total amount of TMP in octanol would exist only as an ion-pair which means that [Bt]oct will 
equal [AB]oct and the apparent octanol aqueous distribution coefficient of TMP can be 
calculated using equation (4.3.12). 
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AB
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Equation 4.3.46 
 
Where [B]aq represents the concentration of TMP free drug in the aqueous phase and [Bt]aq is 
the total concentration of TMP in the aqueous phase [Bt]aq= [B]aq+[AB]aq.  
 The intrinsic partition coefficient of the ion-pair in octanol-water, PAB is defined as the ratio 
between the ion-pair concentration in octanol to its concentration in water equation (4.3.13) 
 
aq
oct
AB AB
AB
P ][
][
=
     
Equation 4.3.47 
  
Upon combining equations (4.3.11) (4.3.12) and (4.3.13), a common equation is obtained.  
ABaqABaqB PAPKD
1
][
11
11
+=
  
Equation 4.3.48
 
 
Upon plotting the double reciprocal of the apparent octanol-water distribution coefficient of 
TMP as a function of the acidic amino acid concentration (i.e plotting 1/DB Vs 1/[A]aq) an 
exponential curve is obtained and is used to calculate K11aq  and PAB. The concentration of TMP 
in the aqueous layer was determined using HPLC method , while the concentrations of the 
anionic amino acids were calculated using ninhydrin test. 
In this study the partitioning behaviour of TMP and TMP aspartate salt at various molar ratios 
of aspartic acid were studied and summarised in figures (4.3.3 & 4.3.4). Log P value for TMP 
was calculated using the octanol/water partitioning method and was found to be 1.07 (Fig. 
4.3.3) which comes in line with the previous findings by Kasim et al., 2003. On the other hand, 
the log P value for the salt form was significantly lower than that of the free drug (log P= -1.13) 
which reflects the very high polar nature of the salt form. 
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Figure 4.3.58:- TMP partitioning in the aqueous and octanol layers and its corresponding Log P values 
at various concentrations of aspartic acid (n=3). 
 
 
Increasing the molar ratios of aspartic acid was found to decrease the partitioning capacity of 
TMP in the octanol layer and increase the migration of the cationic drug into the aqueous 
phase and hence the Log P values was found to decrease steadily as the molar ratio of the 
anionic amino acid increases (Fig. 4.3.3). TMP Log P value was halved upon incorporating 
aspartic acid at 1: 1 ratio and became 0.157 and -1.08 when aspartic acid was increased to PM 
1:2 and PM 1:8 ratios.  
For the salt form, increasing the concentration of aspartic acid resulted in very poor 
partitioning into the octanol layer as all the TMP molecules were detected in the aqueous 
phase. Although dissociation of TMP aspartate salt was expected to take place in water 
yielding the ionised form of the cationic drug and the anionic amino acid at 1:1 ratio, the 
partitioning behaviour of the salt form was different from the TMP: aspartic acid physical 
mixture at 1:1 molar ratio, probably because of the self-buffering capacity of the salt forms 
which yield different pH at the diffusion bilayer between the aqueous and oily phase as 
suggested by Forbes et al., 1995; ElShaer et al., 2011. 
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Figure 4.3.59:- TMP aspartate partitioning in the aqueous and octanol layers at various concentrations 
of aspartic acid (n=3). 
 
The difference in the buffering capacities between the salt form and the physical mixtures 
resulted in significant difference in the partitioning behaviours as suggested by Sangster, 
(1989). 
In order to calculate the K11aq and PAB, the double reciprocal plots of apparent octanol/water 
distribution coefficient of TMP at various molar concentrations of aspartic acid was evaluated 
(Fig. 4.3.5). Similar to IND studies, a strong negative exponential relationship (R2=0.94) was 
observed. Increasing the molar concentration of aspartic acid resulted in an exponential 
decrease in the partition coefficient of TMP due to the low inherent lipophilicity of aspartic 
acid (Log P= -3.89). 
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Figure 4.3.60:- Double reciprocal plot of the apparent octanol-water distribution coefficient of TMP as 
function of aspartic acid molar concentration. 
 
The equation (equation 4.3.15) obtained from figure (4.3.5) was used to calculate the intrinsic 
octanol water partitioning (PAB) and the aqueous binding constant (K11aq) 
The intercept of the curve = -1.69x Log 1.05 and equals 1/intrinsic octanol/water partitioning 
(1/PAB). Hence PAB was found to be 27.9 while K11aq equals 0.021 mM
-1 (21 M-1). 
 
698.1059.1 −= xY
   
Equation 4.3.49
 
 
 
4.3.3.2. Permeability studies of TMP aspartic acid ion-pairs 
The absorption profiles of TMP and TMP aspartate salt at various ratios of aspartic acid were 
studied and summarised in (Fig. 4.3.6). The concentration of TMP (500 µg/mL) was kept 
constant for all the experiments while the concentration of aspartic acid was changed. TEER 
values were measured before and after the run of the experiments and recorded in Table 
(4.3.3.) TEER values demonstrate the full integrity of the Caco-2 monolayers as all the values 
were higher than 300 Ω/cm2 (Miller et al., 2010).   
 
Table 4.3.37:- TEER measurements for TMP aspartate formulations before and after the permeability 
assay (n=5) 
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Formulations TEER (Ω/cm2) 
 Before After 
TMP free base 502±33 504±44 
TMP: aspartic 1:1  532±87 462±46 
TMP: aspartic 1:2 563±56 503±90 
TMP: aspartic 1:4 547±16 544±81 
TMP: aspartic 1:8 486±45 515±25 
TMP aspartate salt 552±42 556±41 
TMP asp salt: aspartic 1:1  552±67 515±30 
TMP asp salt: aspartic 1:2 627±19 561±13 
TMP asp salt: aspartic 1:4 611±8 568±10 
TMP asp salt: aspartic 1:8 572±30 552±3 
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Figure 4.3.61:- Percentage of TMP transported across Caco-2 monolayers from TMP alone 
formulations and its physical mixtures (PM) with various molar ratios of aspartic acid (n=5). One way 
analysis of variance (ANOVA) and pair-wise multiple comparisons method (Tukey test) against drug 
alone at each time point were used for statistical analysis and probability values of (P< 0.05, * and 
P<0.001,***) were used to determine the significant difference. 
 
The percentage of TMP transported across Caco-2 cells was found to increase with time. For 
instance, the percentage absorbed of TMP aspartic acid physical mixture at 1:1 ratio (PM 1:1) 
was 5.2±1.5 after 5 minutes and increased to 18.75±3.38 after 60 minutes. 
Interestingly, no significant difference (p>0.05) was observed between the percentages of TMP 
transported at various ratios of aspartic acid, apart from PM 1:8 ratio. It could be argued that 
the lack of difference in the permeability profile for the prepared ion-pairs is due to the weak 
aqueous binding constant (K11aq = 21 M
-1) between TMP and aspartic acid. Interestingly, the 
percentage of TMP transported dropped significantly (p<0.001) when aspartic acid was used at 
* 
*** 
* 
* 
*** 
* *** 
* 
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8x molar concentrations of TMP and the Papp decreased from (8.78±1.16)x10
-6 for TMP to 
(5.39±0.3)x10-6 at PM 1:8 ratio (Fig. 4.3.8) probably because of the very high increase in the 
polarity of the cationic drug brought by the significant drop of the pH of the media by  aspartic 
acid. It was suggested in chapter (3.3) that the high content of amino acid might saturate the 
amino acid or the dipeptidyl transporters which are involved in uptake of the ion-paired 
formulation but this is unlikely to occur in the current study because of the very low K11aq for 
TMP aspartic acid ion-pairing as the ion-pairs cannot be transported as one moiety through the 
membrane transport carriers. 
On studying the permeability profile of TMP aspartate salt alone and with excess of aspartic 
acid (Fig. 4.3.7), the data showed no significant difference (p>0.05) between the absorption 
profiles of the various formulations during the first 30 minutes (Fig. 4.3.7). At 60 minutes of the 
permeability assay, it was observed that the percentage permeated from the salt form 
(18.2±0.12) is significantly higher than that from TMP alone (12.18±2.3), and this percentage 
increased more at TMP aspartate: aspartic acid salt mixture (SM 1:2) to (25.35±3.95). 
Similar to the previous studies carried out on IND, at molar ratios greater than SM 1:2 and 
especially at SM 1:8, the percentage of TMP transported across the Caco-2 membrane started 
to decrease again to reach (11.13±1.6%) at 60 minutes. 
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Figure 4.3.62:- Percentage of TMP transported across Caco-2 monolayers from TMP aspartate salt and 
salt mixtures (SM) with various molar ratios of aspartic acid (n=5). One way analysis of variance 
(ANOVA) and pair-wise multiple comparisons method (Tukey test) against drug alone at each time 
point were used for statistical analysis and probability values of (P< 0.05, * and P<0.001,***) were 
used to determine the significant difference. 
 
 
 
The apparent permeability coefficient (Papp) for TMP, TMP aspartic acid physical mixtures, TMP 
aspartate salt and TMP salt mixtures with aspartic acid were calculated using equation (4.3.5). 
Papp for TMP alone was found to be (8.78±1.16) x10
-6 cm/sec; studies carried out by (Sun et al., 
2011) suggested a higher value for TMP Papp (22x10
-6 cm/sec) probably because of the low TEER 
values for the transwells used in their experiment. According to Artursson et al compounds are 
classified as highly permeable and low permeable if they have Papp >1x10
-6 and Papp<1x10
-7 
cm/sec respectively. This means that TMP is highly permeable according to Artursson et al 
classification and not poorly absorbed as suggested by Joseph et al (2001). Papp permeability 
studies for the physical mixtures and the salt mixtures showed a similar trend; the apparent 
permeability increases as the molar ratio increases up to 2x and raising the molar ratio beyond 
1:2 the apparent permeability starts to decrease again and drops to the lowest at 1:8 ratios for 
the physical and salt mixtures (Fig. 4.3.8). 
 
*** 
 *** 
 *** 
 
*** 
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Figure 4.3.63:-  Papp permeability values at 60 minutes for TMP, TMP aspartate and their mixtures with 
various molar ratios of aspartic acid. One way analysis of variance (ANOVA) and pair-wise multiple 
comparisons method (Tukey test) against drug alone at each time point were used for statistical 
analysis and probability values of (P< 0.05, * and P<0.001,***) were used to determine the significant 
difference. 
 
 
4.3.3.3. Partitioning studies for TMP glutamate formulations 
In order to investigate the effect of the side chain of the amino acid counter ion on the binding 
capacity occurring during the ion-pair formation, glutamic acid was used. Glutamic acid has a 
similar structure to aspartic acid apart from an additional alkyl side chain (-CH2-). 
Octanol/water partitioning for TMP glutamic acid physical and salt mixtures was studied and 
summarised in (Fig. 4.3.9&4.3.11). Similar to TMP aspartic acid partitioning studies discussed 
above, the ability of TMP to partition into the organic phase was found to decrease gradually 
as the molar concentration of glutamic acid increases. TMP Log P value was 1.07 and 
decreased to 0.33 at PM 1:2 with glutamic acid and -0.27 at 1:8 molar ratio of TMP to glutamic 
acid respectively. Increasing the concentration of glutamic acid results in lowering of the pH of 
the media and in turn enables the domination of cationic charge on TMP thereby influencing 
its solubility. 
*** 
 
*  
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Figure 4.3.64:- TMP partitioning in the aqueous and octanol layers and its corresponding Log P values 
at various concentrations of glutamic acid (n=3). 
 
 
Upon studying the double reciprocal plot of the apparent octanol/water distribution 
coefficient of TMP as a function of molar concentration of glutamic acid, a strong (R2=0.95) 
negative exponential correlation was observed (Fig. 4.3.10), i.e. increasing the molar 
concentration of glutamic acid resulted in an exponential decrease in TMP partitioning 
coefficient. The exponential curve equation (equation 4.3.16) was used to calculate the K11aq 
and PAB as discussed before. Interestingly, the aqueous phase binding constant (K11aq= 66 M
-1) 
was found to be three times higher than the K11aq of TMP aspartic acid ion-pairs (K11aq= 21 M
-1) 
despite the high similarity of the bond formed between the two ion-pairs. The ionic bonding 
between TMP and aspartic acid is similar to that between TMP and glutamic acid as ∆pKa value 
is very comparable; ∆pKa is 5.42 between TMP and aspartic acid and 5.11 between TMP and 
glutamic acid.  Moreover, aspartic acid and glutamic acid have similar number of H-donors and 
H-acceptors hence similar H-bonding is also expected. Nevertheless, glutamic acid has an extra 
alkly chain (-CH2-) in its structure which might have played a role during the secondary 
interactions (non-covalent interactions) taking place during ion-pair formation. This 
phenomenon is known as odd-even effect which was extensively studied in solution phases 
                                                 
 
 219
(Pistolis et al., 2005) and is believed to affect the packing of the molecules, morphology and 
physical properties (Khan et al., 2011). 
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Figure 4.3.65:- Double reciprocal plot of the apparent octanol-water distribution coefficient of TMP as 
function of glutamic acid molar concentration. 
 
 
06.185.0 −= xY
   
Equation 4.3.50 
 
Conversely, studying the partitioning behaviour of TMP glutamate salt showed that the 
partitioning of the TMP glutamate salt in the aqueous layer was very high even at the low 
concentrations of glutamic acid (Fig. 4.3.11). The log P value for the salt form was -0.738 
reflecting the high hydrophilicity of the salt. Log P value was found to decrease upon increasing 
the molar ratio of glutamic acid until it reached -1.55 at 1:8 ratio of the salt to aspartic acid (Fig 
4.3.11). 
Such a difference in the partitioning behaviour of the salt form from the physical mixture could 
be explained by the self-buffering capacity of the salt form as discussed above. 
 
                                                 
 
 220
422.8268 423.8132
494.4228 493.3571 486.305
77.17323 76.18678
5.577176 6.642857 13.69499
0
100
200
300
400
500
600
0 1 2 4 8
Molar concentration of glutamic acid
Co
n
ce
n
tr
at
io
n
 
(µg
/m
L)
-2.5
-2
-1.5
-1
-0.5
0
Lo
g 
P
Aqueous conc Octanol conc Log P
 
Figure 4.3.66:- TMP glutamate partitioning in the aqueous and octanol layers at various 
concentrations of glutamic acid (n=3). 
 
 
The double reciprocal plot of the apparent octanol/water distribution coefficient of TMP 
glutamate salt as function of the molar concentration of glutamic acid is summarised in Fig 
(4.3.12).  
From the curve equation (equation 4.3.17) the intercept was found to be (-4.8x Log 1.16) and 
equals 1/intrinsic octanol water partitioning (1/PAB), hence PAB equals 3.2. While, the slope was 
-4.8 and equals 1/K11aqPAB. Therefore K11aq will equal 64 M
-1.  
8.4163.1 −= xY
  
Equation 4.3.51
 
 
Although the partitioning behaviour of the salt form was different from that of the physical 
mixtures, the aqeous phase binding constant was the same when the salt form and the free 
drug was used in the double reciprocal studies.
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Figure 4.3.67:- Double reciprocal plot of the apparent octanol-water distribution coefficient of TMP 
glutamate salt as function of glutamic acid molar concentration. 
 
4.3.3.4. Permeability studies for TMP glutamic formulations 
The effect of various molar concentrations of glutamic acid on the absorption profile of TMP 
and TMP glutamate salt was studied (Fig. 4.3.13 & 4.3.14). All the transwells used for this study 
showed TEER values higher than 300 Ω/cm2. For all the formulations, the percentage of TMP 
transported across the Caco-2 monolayers increased with time. The percentage of TMP 
absorbed after 5 minutes of the permeability assay was 1.02±0.84 % and increased gradually 
to 14.7±1.94 % after 90 minutes. Incorporating glutamic acid with TMP at 1:1 molar ratio 
resulted in a significant increase in TMP absorption at all the time points. For instance, the 
percentage of TMP absorbed from TMP alone formulations was 12.18±2.3% after 60 minutes 
and increased to 40.3±1.71% when glutamic acid was added at 1:1 molar ratio to TMP. Further 
increase was observed at PM 1:2 which remained constant at PM 1:4 and started to decrease 
again at PM 1:8 of TMP to glutamic acid (Fig. 4.3.13). 
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Figure 4.3.68:- Percentage of TMP transported across Caco-2 monolayers from TMP alone 
formulations and its physical mixtures (PM) with various molar ratios of glutamic acid (n=5). One way 
analysis of variance (ANOVA) and pair-wise multiple comparisons method (Tukey test) against drug 
alone at each time point were used for statistical analysis and probability values of (P< 0.05, * and 
P<0.001,***) were used to determine the significant difference. 
 
 
Although octanol/water partitioning studies showed a decrease in the partitioning ability of 
TMP into the organic layer upon pairing with glutamic acid, permeability studies showed better 
absorption at PM 1:1, PM 1:2 and PM 1:4. The partitioning data suggest that passive 
absorption is reduced upon pairing the cationic drug with the anionic amino acid. However, 
the increase in the overall uptake suggests the involvement of active transporter carriers 
during the permeation process. 
TMP permeability from the salt form and the salt mixtures are shown in Fig. (4.3.14). The use 
of TMP glutamate salt resulted in a significant increase in the absorption profile of TMP despite 
having lower Log P value and partitioning capacities. The percentage of TMP absorbed was 
increased by around 6% upon using the salt form after 5 minutes of running the permeability 
experiment. The total percentage of TMP absorbed from the salt form at the end of the 
experiment was 22.99±5.74% compared to 14.7±1.94 %from the free drug. Similar to the 
physical mixture, increasing the molar ratio of the counter ion significantly (p<0.001) increased 
*** *** *** 
* * 
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the permeability profile of TMP especially at SM 1:1 and SM 1:4 which again started to drop at 
SM 1:8. 
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Figure 4.3.69:- Percentage of TMP transported across Caco-2 monolayers from TMP glutamate salt and 
salt mixtures (SM) with various molar ratios of glutamic acid (n=5). One way analysis of variance 
(ANOVA) and pair-wise multiple comparisons method (Tukey test) against drug alone at each time 
point were used for statistical analysis and probability values of (P< 0.05, * and P<0.001,***) were 
used to determine the significant difference. 
 
 
 
The Papp permeability for all TMP formulations is shown in figure (4.3.15).The data shows that 
glutamate PMs and SMs have higher Papp when compared to that of the free base and 
aspartate formulations. This may be attributed to the high aqueous binding constant between 
the glutamate counter ion and TMP base (K11aq= 64 M
-1) compared to that between aspartate 
and TMP (K11aq= 21 M
-1) i.e three times higher.  
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Figure 4.3.70:- Papp permeability values at 60 minutes for TMP, TMP aspartate, TMP glutamate and 
their PM and SM with aspartic acid and glutamic acid. 
 
 
Microarray studies 
Permeability data discussed earlier in this chapter showed a significant increase of the amount 
of TMP absorbed across Caco-2 monolayers upon ion-pairing the drug with glutamic acid. 
Therefore, three formulations were selected for the microarray study; namely TMP alone, TMP 
1:1 PM and TMP 1:8 PM and time course analysis at 5, 30 and 60 minutes was studied as 
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cellular changes are affected by the time course of exposure to therapeutic agent. The 
expression patterns for the cells at the basal state (without exposure to TMP or any other 
formulations) were used as control. After RNA extraction and quantification, around 45,000 
cDNA were hybridized with the microarray probe using Agilent one-color-spike procedure and 
microarrays slides were scanned and quality of the obtained TIFF images was analyzed prior to 
carrying out data normalization and clustering. 
 
4.3.3.5. Image analysis 
Finding spot centroids is a critical feature to ensure the quality of the microarray image. If the 
location of one or more of the spot centroids is off-centre, hybridization has to be carried out 
again using new grid. The four spot centroids in the current experiment were mapped 
accurately (Fig. 4.3.16A) for all slides which reflects the high quality of the used slides and 
successful hybridization of the probes. 
 
 
 
 
 
 
 
Figure 4.3.71:-  Microarrays image analysis showing Spot Finding of the Four Corners of the Array (A), 
Histogram of Signals Plot (B) data were generated by feature extraction software. 
 
The level of signal and shape of signal distribution were also evaluated using feature extraction 
software. A histogram of the line plot of number points in the intensity bins against the 
logarithm of the processed signal was obtained (Fig 4.3.16B). The obtained histogram showed 
that the intensity bins were normally distributed with a good bell shape (symmetric) reflecting 
A B 
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the high quality of the signals. A good correlation between the logarithmic values of the 
processed signal and the logarithmic values of the corresponding concentrations was obtained 
for most of the slides with R2 values ranging between 0.99 and 1 (Fig. 4.3.17A).  
In order to evaluate multiplicative detrending, the median of the processed signal and the 
median of the background subtracted signal (mean signal- BG used) for each column and over 
all the rows on the arrays were plotted which yielded a flat line (Fig 4.3.17B) indicating low 
multiplicative detrending (i.e. similar intensities from various replicate probes on the 
microarray slide). One-color-spike chips have number of probe replicates across the microarray 
and these replicates were used to evaluate the reproducibility of the signals. A low median 
coefficient of variation (%CV) of 3.9 was obtained reflecting the high signal reproducibility 
across the arrays. Image quality analysis was satisfactory for all the used arrays and the 
obtained data was used for normalization and further analysis. 
 
 
 
 
 
 
 
 
Figure 4.3.72:- Correlation between log signal against log Relative concentration (A) and spatial 
distribution of median signals for each column (B). 
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4.3.3.6. Data Clustering and Principle component analysis (PCA) 
The data obtained from each microarray experiment is highly complex in terms of quantity and 
dimensions. Many statistical and computational approaches (i.e. supervised learning) are 
employed in order to interpret the biological meaning of the data (Fisher, 1936). Data 
clustering or unsupervised learning is another analysis method which is used to reduce data by 
adding the observations into a cluster which can be represented by an average value. Various 
clustering computational approaches are available including; K-means clustering (Hartigan and 
Wong., 1979), hierarchical clustering (Everitt and Rabe-Hesketh, 1997; Eisen et al., 1998), self-
organizing maps (Kohonen, 1990) and artificial network (Bishop, 1996). As none of these 
methods offer any specific advantage over each other, hierarchical clustering was used in this 
study as it measures the distance between rows of various data to cluster them. After 
measuring the distance between every couple of genes, the algorithm then merges the genes 
which are close to each other (i.e. has shorter distance between them) into one cluster. The 
midpoint of the two merged genes is used to merge the distance between them and other 
genes. This iteration takes place for the all data set and final cluster is obtained showing the 
up-regulated genes in red and the down regulated genes in green (Fig. 4.3.18). 
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Figure 4.3.73:- Data clustering for TMP formulations at various time points; green clusters show down-
regulations while red clusters show up-regulations.  
 
As the experimental conditions for all the arrays are controlled, any variation in the expression 
pattern will be introduced by the conditions under investigation i.e. as a result of exposure to 
various formulations. Nevertheless, this study measured 45,000 genes at 11 different 
conditions. Therefore the obtained data could form a matrix of 11x45,000 measurements. If a 
scatter plot of 11 axes (one axis for each experimental condition) was used to plot these 
45,000 genes in muti-dimensional space, the resultant graph will be a cloud of values in the 
space. Therefore, principle component analysis (PCA) was used to identify the dimension 
where the data (cloud) is more extended. 
TMEV software was used to calculate the Eigen values for the 11 principle components and the 
highest Eigen values were shown by the first three principle components. In total 69.5% of the 
genetic changes were extended along the first, second and third principle components. Hence, 
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the first three components were selected for analysis of gene expression changes occurring 
during the uptake of TMP, TMP 1:1 PM and TMP 1:8 PM. 
First and second PCA showed that the time course had a great effect on the expression pattern 
of the genes. At the beginning of the experiment (i.e. 5 minutes) most of the genetic 
expressions were centered around the origin, suggesting minimal variations at the first five 
minutes of permeability study. Leaving the formulations for another 25 minutes (i.e. after 30 
minutes of the beginning of the permeability assay) resulted in significant changes in the 
cellular behavior of Caco-2 monolayers (Fig. 4.3.19) where the majority of the genetic changes 
occurred along the first component (40.85% as suggested by Eigen values). These changes 
returned back to the origin after 60 minutes of exposing the cells to TMP, TMP 1x and TMP 8x. 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 4.3.74:- First and second principal component analysis on the transcriptional time course for 
TMP and its various ion-paired formulations at 0, 30 and 60 minutes. The number represents the time 
points. The plot represents the data for the mean values at each time point. 
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9.2% of the genetic changes occurred at the third principle component and were attributed to 
the genetic changes that took place after 60 minutes of exposing the cells to ion-paired 
formulations (Fig. 4.3.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.75:- First and third principal component analysis on the transcriptional time course for TMP 
and its various ion-paired formulations at 0, 30 and 60 minutes. The number represents the time 
points. The plot represents the data for the mean values at each time point. 
 
 
4.3.3.7. Genetic changes of transporters pathways 
 
Cellular behavior including physiological changes in disease condition or in response to toxic 
agents or drug treatment is reflective of the pattern of gene expression. Monitoring such 
changes enables better understanding of disease progression or toxic and therapeutic effects 
of drugs which results in better targeting of disease conditions at cellular level thereby 
promoting higher therapeutic efficacy. The aim of the current study was to understand and 
study differences in gene expression profile upon exposure to different formulation types of 
                                                 
 
 231
the drug candidate during permeability across Caco2 monolayers. Results obtained from 
permeability studies showed significant increase in drug uptake of some of the ion-paired 
formulations when compared to the free form of the drug and other formulations at various 
ratios of the counter ions. Drug absorption across the gastrointestinal tract is affected by many 
variables such as drug solubility, partitioning abilities, pH of the surrounding environment and 
genetic changes along the intestinal membrane. The majority of the physicochemical 
properties of TMP and CIP that could affect their uptake were evaluated prior to studying the 
genetic changes taking place across the cells. Microarray studies were carried out to visualize 
how different genes of various pathways vary in expression upon exposure to therapeutic 
agent and various formulations with a particular emphasis on transporter carrier genes. In 
order to carry out the microarrays experiment cDNA were hybridized with approximately 
45,000 gene probes attached to the microarrays chips. After normalization and clustering 
analysis, the obtained data were filtered and only genes which were over-expressed or down-
regulated by two fold or more when compared against the control were selected for further 
investigations. 
Genetic changes that occurred after exposing Caco-2 cells to TMP alone formulations for 5, 30 
and 60 minutes were monitored (Fig. 4.3.21). One ABC transporter was over-expressed after 5 
minutes of exposure to TMP. The number of up-regulated ABC transporters increased to 5 
after 30 and 60 minutes of the permeability assay. The numbers of ABC genes down-regulated 
were 1, 10 and 7 after 5, 30 and 60 minutes respectively. 
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Figure 4.3.76:- Total number of ABC genes over-expressed (  ), suppressed (  )  and unchanged (      ) 
after 5 minutes (A), 30 minutes (B) and 60 minutes (C) of exposure to TMP. 
 
Table (4.3.4) summarises all the ABC transporters over-expressed during TMP permeability 
across Caco-2 monolayers. MRP7 was among the over-expressed genes after 5 minutes and 30 
minutes of TMP uptake across the cells. The transporter gene was over-expressed in more 
than one of the replicate probes which reflects the high involvement of MRP7 in mediating the 
efflux of TMP. MRP7 is member 7 of multiple resistance protein and is also known as ABCC10. 
MRP7 has similar topology to other ABCC members such as MRP 1, 2, 3 and 6 as it has three 
membrane binding domains and two nucleotide binding domains (Kuang et al., 2010). Various 
studies suggested that MRP7 is expressed in cancer cells and confers resistance to a range of 
chemotherapeutic agents (Naramoto et al., 2007). Drugs such as 17-β-estradiol, paclitaxel, 
vincristine, vinblastine (Chen et al., 2003; Hopper-Borge et al., 2004) and vinorelbine (Bessho 
et al., 2009) were reported to be effluxed by MRP7. Microarray results suggest that MRP7 
plays a key role in the efflux of TMP and hence decreases the overall uptake of the drug across 
the epithelial membranes. The role of MRP7 in TMP efflux was not reported before in the 
literature where majority of the previous studies reported the involvement of P-gp (Joseph et 
al., 2001; Murakami and Takano, 2008) in TMP efflux. In the current study, P-gp was not 
filtered as up or down-regulated gene and having investigated the expression changes of P-gp 
it was found to be less than 2 fold up-regulated (1.83 fold) which suggests the relatively lower 
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role of P-gp in mediating TMP efflux. These results are in consensus with Romiti et al’s (2002) 
suggestion that TMP efflux is not supported by P-gp activity in HK-2 cells even at high 
concentrations of the drug (50 µM) (Romiti et al., 2002). 
Table 4.3.38:- Summary of the over-expressed ABC transporters during TMP permeability across Caco-
2 monolayers. 
Time point probes Gene symbol Expression level 
5 minutes A_23_P215720 MRP7 2.02 
 
30 minutes A_23_P215720 MRP7 2.85 
A_32_P29703 ABCA17P 2.22 
A_24_P235429 ABCA1 2.04 
A_23_P78018 ABCA5 2.47 
A_23_P92602 ABCA11P 2.53 
60 minutes A_32_P29703 ABCA17P 2.57 
A_23_P43504 ABCA2 2.15 
A_24_P235429 ABCA1 2.02 
A_23_P78018 ABCA5 2.40 
A_23_P201918 ABCB10 2.42 
 
Another interesting finding is that many members of ABCA family -including ABCA1, ABCA5 
and ABCA17- were over-expressed upon treating the cells with TMP. The three transporter 
genes were up-regulated at 30 and 60 minutes of TMP permeability study (Table 4.3.4). The 
prototype of this family is ABCA1 which was first identified in 1994 (Luciani et al., 1994) and 
more members were identified and sequenced later on (Connors et al., 1997; Allikmets et al., 
1997). The structure of ABCA1 was studied by Santamarina-Fojo et al (2000) and the 
transporter is composed of 50 exons that encode 2261 amino acids. ABCA1 was found to be 
associated with the removal of cellular cholesterol in to plasma utilizing ATP hydrolysis as an 
energy source (Morales et al., 2008). As a result, ABCA1 mutation was reported to cause 
Tangier disease (Bodzioch et al., 1999) due to the accumulation of cholesterol esters and 
cholesterol in spleen, liver and other tissues (Francis et al., 1995). Similar functions were 
reported for both ABCA17 (Morales et al., 2012) and ABCA5 (Ye et al., 2010). From the current 
investigation, the results suggest that TMP efflux is co ordinate via multiple members of ABCA 
family. To further analyze our findings, the structure of TMP and cholesterol were compared in 
order to determine similarities between the two molecules (Fig. 4.3.22). However, no 
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similarities were observed between the two molecules. Moreover cholesterol has higher 
lipophilicity (log P= 7.17) possibly because of the long aliphatic side chain (Stanculescu et al., 
2006).  
 
 
 
 
  
 
Figure4.3. 77:- Comparison between the molecular structure of TMP (A) and cholesterol (B). 
 
 
Solute carrier transporters (SLCs) were also investigated to determine their role in TMP 
transport (Fig. 4.3.23). The data shows that the number of solute carrier transporters up-
regulated after 30 minutes was 26 and increased to 35 at the end of the experiment (Fig. 
4.3.23C). 
 
 
 
 
 
 
 
Figure 4.3.78:- Total number of SLC genes over-expressed (  ), suppressed (  )  and unchanged (    ) 
after 5 minutes (A), 30 minutes (B) and 60 minutes (C) of exposure to TMP. 
 
SLC22A4 (OCTN1) is among the over-expressed genes as its expression increased by 2.36 fold 
after 60 minutes. OCTN1 is an organic cation transporter which mediates the transport of 
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pyrilamine, quinidine and tetraethylammonium (Wu et al., 2000). Various studies 
demonstrated that OCTN1 is pH-dependent which suggests that changes in pH will change the 
level of expression of the transporter (Wu et al., 2000; Tamai et al., 1997) possibly because of 
the cationic nature of its substrates. Majority of OCTN1 substrates carry cationic nitrogen 
which also exists in TMP pyrimidine ring possibly explaining the permeation of TMP across the 
Caco-2 monolayers by active transport. It was reported in the literature that SLC22A1 (OCT1) 
and SLC22A2 (OCT2) mediate the uptake of TMP, however in this study the expression of OCT1 
and OCT2 was not affected by TMP treatment.  
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Figure 4.3.79:- Gene expression of SLC transporters of Caco-2 cells after 30 minutes of exposure to TMP. 
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The effect of ion-paired formulations at 1:1 and 1:8 molar ratios were also evaluated at the 
same time points; 5, 30 and 60 minutes. Incorporating glutamic acid into the formulations 
resulted in activation of various members of SLC1 across Caco-2 monolayers as summarised in 
Table (4.3.5).  
SLC1 is glutamate/neutral amino acid transporter which has 5 high affinity glutamate 
transporters previously described as X-AG (EAAT4/5, GLAST, EAAC1 and GLT1) and two Na+ 
dependent neutral amino acid transporters (ASC; ASCT1 and ASCT2). Glutamate transporters 
mediate the uptake of L-Asp, D-Asp and L-Glu by co-transporting 1H+/3Na+ and counter 
transport of 1K+ (Kanai and Hediger., 2003). On the other hand, ASC mainly transport alanine, 
serine and cysteine and protect the cells against glutamate excitatoxicity. SLC1 has a unique 
structure which comprises of 8-transmembrane domains and a highly conserved long 
hydrophilic chain attached to its C-terminus. Both glutamate and ASC transporters share 
similar structure and recognize common substrates (Zerangue and Kavanaugh., 1996). 
EAAT4 (SLC1A6) was over-expressed by 3.36 fold after 5 minutes of exposing the cells to TMP 
1x formulation while SLC1A1 was up-regulated at 30 minutes. At higher concentrations of 
glutamic acid (i.e. TMP 8x formulations) the two Na+ dependent ASC transporters were over-
expressed. Both ASCT1 (SLC1A4) and ASCT2 (SLC1A5) were up-regulated by 2.27 and 2.97 
respectively. It can be hypothesized that the low concentration of glutamic acid in TMP 1x 
formulations activated high affinity glutamic acid transporter SLC1A6 and SLC1A1 whereas 
increase of concentration to 8x results in the expression of ASCT1 transporters. Moreover, it is 
believed that as the pH of the media decreases (in the current study due to increase in 
glutamate concentration), glutamate uptake shifts towards ASC transporter (Utsunomiya-Tate 
et al., 1997). 
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Table 4.3.39:- Summary of SLC1 transporters up-regulated during the uptake of TMP glutamic acid ion-
paired formulations across Caco-2 monolayers. 
Formulation Probes Gene symbol Expression difference 
TMP 1x 5 minute A_24_P179467 SLC1A6 3.364774 
TMP 1x 30 minute A_24_P232252 SLC1A1 2.362158 
TMP 8x 30 minute A_24_P232252 SLC1A1 2.240894 
TMP 8x 60 minute A_23_P55998 SLC1A5 2.973543 
A_23_P91151 SLC1A4 2.276961 
 
The expression of OCTN1 is also affected by the ion-paired formulations and an interesting 
pattern was observed. OCTN1 was over-expressed by 2.2 fold during the absorption of 
TMP:glutamic acid at 1:1 molar ratio. On the other hand, the expression of this gene dropped 
to reach the basal state when the cells were treated by TMP:glutamic acid 1:8 ratio. A similar 
trend was explained by Wu et al (2000) when human retinal pigment epithelial (HRPE) cells 
were used to evaluate the uptake of tetraethylammonium at various pH. It is possible that 
increasing the ratio of glutamic acid in the ion-paired formulations resulted in increasing the 
drug uptake as discussed above in the permeability study. Such increase could be attributed to 
the activation of OCTN1 transporters by 1:1, 1:2 and 1:4 molar ratios but increasing this ratio 
further to 1:8 resulted in a drop in drug uptake. Hence it can be concluded that glutamic acid 
would have affected the pH during the uptake of TMP which in turn has affected the 
expression levels of OCTN1 as early suggested by (Wu et al., 2000). 
MRP7 was found to mediate the efflux of TMP in this study; hence it was interesting to track 
the expression changes for this upon inclusion of the ion-paired formulations. MRP7 remained 
at the basal state; as it was expressed 1.6 fold during the uptake of TMP 1x formulations. It 
was over-expressed to 2.9 and 3.02 after 30 and 60 minutes respectively. Similar trend was 
observed when TMP 8x formulations were used. Nevertheless, the expression level was 
significantly higher at 30 minutes for TMP 8x formulations as MRP7 was over-expressed by 6.4 
fold. This could possibly explain the low uptake of TMP from TMP 8x formulations. 
It can be concluded that the ratio of glutamic acid in the ion-paired formulations has a 
significant effect on the flux of TMP as it increased OCTN1 expression in a parabolic manner 
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and shifted the uptake of glutamic acid from high affinity transporters to the low affinity 
carriers. Nevertheless, no evidence exists that the ion-paired formulations are transported as 
one entity as none of the dipeptidyl carriers were over-expressed. 
 
4.3.3.8. Genetic changes of metabolic pathways and other pathways 
As mentioned before, cellular function varies in both disease state and upon exposure to 
toxins. Cells identify therapeutic agents as toxins and modify/activate functions/pathway to 
protect them as seen in transporter network changes. Those genes which were either up-
regulated or down-regulated were uploaded onto KEGG database to visualize the cellular 
changes occurring upon treating the cells with TMP and its ion-paired formulations. Multiple 
pathways were found to be affected including metabolic pathways, oxidative phosphorylation, 
cytokine-cytokine interactions and xenobiotic metabolism.  
TMP exhibits several adverse reactions since it is used in combination with sulfamethoxazole 
(Lai et al., 1999). Moreover, the use of TMP alone resulted in many idiosyncratic reactions, 
neutropenia (Hawkins et al., 1993) and hypersensitivity reactions (Carr et al., 1993) and the 
mechanism by which TMP causes these adverse effects is still not clear. Only few studies 
(Meshi and Sato, 1972; Van et al., 1992; Schwartz et al., 1970; Brooks et al., 1973) proposed 
some metabolic mechanisms for TMP and are summarised in Fig. (4.3.25). 
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Figure 4.3.80:- A scheme of the known metabolites and reactive intermediates (in brackets) of TMP 
obtained from in vitro and in vivo experiments. The figure is adapted from Damsten et al., 2008. 
 
Frisch studies suggested that TMP hepatic and cutaneous reactions are caused by immunologic 
mechanisms rather than direct toxicity (Frisch, 1973). The studies carried out by Lai et al. 
(1999) demonstrated that TMP is oxidized by both hepatic macrosomes and human 
neutrophils into reactive metabolites. In a similar way to oxidation of phenolic compounds by 
cytochrome P-450 enzymes and peroxidase, TMP was found to be oxidized into iminoquinone 
methide and pyrimidine iminoquinone (Lai et al., 1999). Microarray data shows the high 
involvement of oxidative phosphorylation reactions upon treatment with TMP as 30 reactions 
were activated (Fig. 4.3.26). Both cytochrome C oxidase (COX5B, COX6B, COX7A and COX7B) 
and NADH dehydrogenase were activated possibly to oxidise the nitrogen atom to yield TMP-
1-N-oxide and TMP-3-N-oxide as suggested by (Damsten et al., 2008). 
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Figure 4.3.81:- Various oxidative phosphorylation reactions activated upon exposing Caco-2 monolayers to TMP alone formulations for 30 minutes (over-expressed 
genes are highlighted in red). The graph was created by KEGG online database. 
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No information was available on the role of cytochrome P450 enzymes (CYP450) on the 
oxidative metabolism of TMP until 2008 when Damsten et al investigated the role of human 
CYP450 enzymes on TMP metabolism. Our microarray data proposed that at least five CYP450 
enzymes are involved in TMP metabolism as these enzymes were activated upon exposing the 
cells to TMP especially for 30 and 60 minutes (among the activated enzymes include CYP1A2, 
CYP2C9, CYP2C19 and CYP3A4). Our findings come in line with Damsten et al studies who 
reported that both CYP1A2 and CYP3A4 oxidize TMP by dehydrogenation of the terminal -NH2 
group to form an intermediate that interacts with glutathione (GSH) to form TMPG-1 and 
TMPG-2 metabolites (Damsten et al., 2008). Damsten and co-workers also suggest that CYP1A2 
oxidizes TMP to TMP-N-oxide probably by using nonspecific monooxygenase (1.14.14.1) as 
shown in Fig. (4.3.28) and as suggested by (Kranendonk et al., 2008). TMP-N-oxide converts 
into intermediates that are dehydrogenated by CYP2A3 and get conjugated to GSH (which was 
also activated; 2.5.1.18) to form TMPG-5 and TMPG-6 (Damsten et al., 2008). On the other 
hand, CYP2C19 plays a role in demethylation of two of the three methoxy groups (-OCH3) 
attached to TMP benzene ring to yield TMP-6 metabolite (Damsten  et al., 2008). 
Non specific monooxygenase (1.14.14.1), glutathione (2.5.1.18) and glucuronosyltransferase 
(2.4.1.17) were found to be over-expressed during the absorption of TMP (Fig. 4.3.28 & 
4.3.29). The role of glucuronosyltransferase in trimethoprim metabolism is still unknown and 
therefore warrants further investigation. 
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Figure 4.3.82:- Scheme showing all in vitro human metabolites and reactive intermediates (in brackets) of TMP. The role of CTYP450 isoforms involved in the 
metabolites formation is also shown in this figure. The figure is adapted from Damsten et al., 2008. 
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Figure 4.3.83:- Various metabolic pathways activated upon exposing Caco-2 monolayers to TMP alone 
formulations for 30 minutes (over-expressed CYP450 isomers and enzymes are highlighted in red). The 
graph was created by KEGG online database. 
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Figure 4.3.84:- Various enzymes activated upon exposing Caco-2 monolayers to TMP alone 
formulations for 30 minutes (over-produced enzymes are highlighted in red). The graph was created 
by KEGG online database. 
 
Investigating the metabolic profile of the ion-paired formulations, the results showed the 
involvement of oxidative phosphorylation reactions and CYP450 enzymes in the metabolism of 
TMP in addition to the activation of glutamate metabolic enzymes such as glutamate 
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dehydrogenase (1.4.1.3) which converts L-glutamate into 2-oxoglutamate and ammonia (Di 
Prisco and Garofano, 1974) and glutaminase A (3.5.1.2). 
 
Figure 4.3.85:- Various enzymes involved in glutamic acid metabolism upon exposing Caco-2 
monolayers to TMP: glutamic acid 1:8 ratio formulations for 30 minutes. glutamate dehydrogenase 
and glutaminase A (both highlighted in red) were over-produced. The graph was created by KEGG 
online database. 
 
 
4.3.4. Conclusion 
The ion-pairs formed between aspartic acid and TMP showed low aqueous binding constant, 
which was tripled when an amino acid with an extra alkyl side chain was used. The 
improvement of K11aq upon using glutamic acid resulted in a 3 fold increase in the permeability 
profile of TMP. Probably the ion-paired formulation is transported as one moiety across the 
Caco-2 monolayers. Although ion-pairing TMP with glutamic acid had a negative effect on the 
partitioning capacities of the drug, the increased overall uptake suggest the involvement of 
active transporters rather than just passive diffusion. Genetic changes across Caco-2 showed 
that MRP7 is the major efflux protein that extrudes TMP from the cells while P-gp seems to 
have a minimal role in its efflux. Our results strongly agree with the literature, that TMP is 
actively uptaken by organic cation transporters as OCTN1 was over-expressed by 2.36 fold. The 
molar ratio of glutamic acid is believed to affect the expression of OCTN1 as its expression 
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reached 2.2 fold for 1:1 formulations and dropped to the basal state for 1:8 ion-paired 
formulations. Interestingly, the microarray data revealed the involvement of many cytochrome 
P450 isomers in the metabolism of TMP. 
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Preparation and characterization Ciprofloxacin salts with anionic and 
cationic counter ions 
 
5.1.1. Introduction 
Ciprofloxacin (CIP) (1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid) is 
a member of quinolone antibiotics which are widely used due to broad spectrum of activity, 
low resistance and high tolerance (Appelbaum & Hunter, 2000). CIP is characterised by the 
presence of two types of rings in its structure (Fig. 5.1.1); napthyridine ring which contains 
nitrogen atom at position 17 and 20, the second nucleus known as quinolone nucleus 
containing one nitrogen at position 1 (Park et al., 2002). Ciprofloxacin contains keto oxygen at 
C-4 and carboxylic acid side chains at C-3 which are essential for ciprofloxacin activity. It acts 
by inhibiting bacterial DNA gyrase enzyme; this process depends greatly on the pH and 
concentration of the acid (Neuman, 1988). Moreover, CIP is classified according to the 
biopharmaceutical classification system as a class IV drug (BCS IV). Its solubility is pH 
dependent and ranges between 0.15 mg/mL to 6.19 mg/mL at pH 7 and 5 respectively (Li et al., 
2007). 
As shown in Fig. 5.1.1 CIP is a zwitterionic molecule with pKa’s of 6.09 and 8.74 and pI of 7.42 
and is an ideal candidate for salt formation with both acidic and basic counter ions. 
Complexation of CIP with multivalent cations such as Ca+2, Al+3, Fe+3 and Mg+2 was approved by 
FDA as alternative for the parent active (Susana et al., 2009). Therefore these complexes were 
commonly used with CIP and other fluroquinolones in order to improve the solubility of these 
drugs with the aim of increasing their bioavailability (Susana et al., 2009). Nevertheless, 
fluroquinolone metal complexes were found to have a negative impact on bioavailability (Sahai 
et al., 1993; Kozjek et al., 1996) as the resultant complexes were too large to be effectively 
transported across the cell membranes. As a consequence, the efficacy of fluroquinolones was 
lower (Hart et al., 1991) and the risk of developing bacterial resistance was greater. Although 
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salt formation is a commonly used approach in order to improve drug solubility, 
fluroquinolones hydrochloride (HCl) salts (most commonly and widely used for CIP) failed to 
dissolve completely at intestinal pH of 6.8 (Breda et al., 2009). Another study conducted by 
Ramanuk et al showed an improvement in CIP solubility together with taste masking for a new 
salt with saccharin (Romanuk et al., 2009).  
 
Hence, improving the solubility of fluroquinolones without impairing their permeability 
behaviour would be a challenging task which if achieved would provide CIP within a BCS 
biowaiver. 
The aim of this study was to improve the solubility and dissolution properties of CIP via salt 
formation. In addition, we investigated the role of inter- and intra molecular interaction 
between the drug and amino acids by integrating experimental and theoretical approaches.  
 
Investigation of published literature has shown that limited work has been done on theoretical 
studies on CIP complexes as listed in Table 5.1.1 (Aristilde et al., 2010; Turel et al., 2008; 
Aristilde et al., 2008; Sadeek et al., 2011).  These studies utilised the simple force field 
(COMPASS force field) and short simulation time (up to 40 ps) resulting in low precision. The 
current paper utilises all-atomic molecular dynamics simulation with general AMBER force field 
(gaff) to study the molecular interaction between CIP molecules and amino acids. 
Table 5.1.1 Computer simulation about ciprofloxacin complexes 
Complexes  Simulation details References  
Ciprofloxacin/humic substance 
complexes 
InsightII version 2000.1 software package with 
COMPASS force field, 5-A° layer of water box; up to 40 
ps 
(Aristilde et 
al., 2010) 
Mg/ciprofloxacin complexes HyperChem and the MM+ force field 
Langevin dynamics with a simulated annealing 
method 
(Turel et al., 
2008) 
Ciprofloxacin/metal complexes Cerius package with COMPASS force field, 
35 ps simulation, water box 
(Aristilde et 
al., 2008) 
Solid complexes 
[Y(CIP)2(H2O)2]Cl3·10H2O and 
[ZrO(CIP)2Cl]Cl·15H2O  
Gaussian98W package by density functional theory 
(DFT) at the B3LYP/CEP-31G level of theory 
(Sadeek et 
al., 2011) 
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5.1.2. Materials and methods 
5.1.2.1. Materials 
Ciprofloxacin, L-Arginine (non-animal source), L-Histidine (Reagent plus ™), L-Lysine, L-
Glutamic acid (Reagent plus ≥ 99%), L-aspartic acid (≥ 98%) and Potassium bromide (99% FT-IR 
grade) all were purchased from Sigma Aldrich, UK. Methanol and acetic acid were purchased 
from Fischer scientific.  
D2O (99.9% min) was purchased from Coss Scientific Instrument Ltd. 
5.1.2.2. Methods 
5.1.2.2.1. Salt preparation 
Equimolar amounts of CIP and the free amino acid were solubilised in water, and the solutions 
were mixed and stirred until equilibration was achieved and filtered. The filtrate was 
transferred into a stainless steel pan and freeze dried for 42 h using Virtis Advantage (wizard 
2.0) freeze dryer. Salts were primary dried at -40oC shelf temperature and under -55 mTorr 
vacuum for 36 h and secondary dried at 20 oC for 6 h.  
5.1.2.2.2. HPLC analysis 
The amount of ciprofloxacin (CIP) dissolved in the samples was quantified by HPLC using a 
Dionex 1100 system fitted with autosampler (AS50), gradient pump (GP50), UV detector (UVD 
170U) and RP-C18 analytical column (Phenomenex 110A, 150x4.6 mm, 5µm). Mobile phase 
consisting of methanol: water: acetic acid (840:158:2) and pumped at 1.0 mL/min was used to 
elute CIP. λmax was determined using Unicam UV-Visible Spectrophotometer  and the HPLC 
UV detector was set at λmax of 280 nm. CIP was eluted with a retention time of 1.5±0.1 min 
and a rectilinear calibration curve was established at concentration range between 10- 
200µg/mL. 
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 5.1.2.2.3. Phase solubility diagram. 
Phase solubility diagram was established by measuring the saturated solubility of CIP free drug 
with various concentrations of cationic amino acids (L-arginine, L-lysine and L-histidine) and 
anionic amino acids (L-aspartic acid and L-glutamic acid) as previously discussed by (Elshaer et 
al., 2011). Excess CIP was added into screw-capped tubes containing serial dilutions of the 
amino acids solutions and agitated at room temperature (Stuart SB 162 stirrer) for 24 h. After 
equilibrium the supernatant was filtered through 0.45 µm filters and analysed by HPLC to 
determine CIP concentration. The pH of amino acid solutions was monitored using a 
Xisherbrand  Hydrus 500 pH meter. 
5.1.2.2.4. Differential scanning calorimetry and Thermogravimetric analysis 
Thermal events such as melting point and crystallization exotherms of CIP and its prepared 
salts were measured using Differential Scanning Calorimeter (Pyris Diamond DSC).  
Approximately, 2-5 mg of the salts were weighed and transferred to an aluminium sample pan 
(50 µL capacity) then sealed with aluminium top. Intra cooler 2P system was used to initially 
cool the samples to 50 oC and then sample heated to 300 oC at rate of 10 oC/min. Nitrogen was 
used as a purge gas at a flow rate of 20 mL/min, Indium and Zinc were used to calibrate the 
heat flow and melting point onset (156.6 oC for Indium and 419.47 oC for Zinc). The obtained 
thermograms were analysed using Pyris Manager Software (version 5.00.02). The experiment 
was performed in triplicate and an empty aluminium pan, sealed in the same way of the 
samples, was used as a reference cell for all the measurements. 
Moisture content and decomposition temperature of CIP and its prepared salts were 
determined using thermogravimetric analyser (Pyris 1 TGA, Perkin Elmer). 5- 10 mg of samples 
were added to an open pan and analysed at temperature range 30- 300 oC at 10 oC/min 
scanning rate and under nitrogen stream. The resultant thermograms were analysed using 
Pyris Manager Software (version 5.00.02) 
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5.1.2.2.5. FT-infrared (IR) spectroscopy 
Nicolet IR 200 spectrometer (Thermo electron corporation) was used to measure FTIR 
absorbance spectra of CIP and its salts using the KBr disc technique. Crystalline KBr was dried 
at 65oC over night before use. Samples were prepared by mixing CIP or its salts with dry KBr at 
1:100 (w/w) ratio and pressed at 8 tones for 5 min (using Specac tablet presser) to form KBr 
discs. 64 scans were performed over wavelength 4000- 400 cm-1 for each sample. FTIR spectra 
were interpreted using EZ OMNNIC 7.0 software. 
 
5.1.2.2.6. 
1
HNMR 
Samples were analysed with Bruker Avance DPX-250 NMR (at 250.1 MHz) and Bruker Topspin 
software was used to analyse the data. Approximately, 1-2 mg of the salts were dissolved in 1 
mL of deuterated water (D2O) and placed in a sample capillary vial up to 5-10 cm height.  
5.1.2.2.7. Solubility and dissolution studies. 
The method of Hugchi and Connor (Higuchi & Connors, 1965) was used to measure the 
solubility of CIP salts. An excess amount of CIP or its salts was added to capped test tubes with 
5 mL of deionised water and stirred for 24 hours at room temperature until equilibrium was 
reached. Subsequently, the suspension was filtered through 0.45μm syringe filters and suitably 
diluted and the concentration was measured by HPLC. 
Conventional tablets weighing 500 mg and containing 50 mg of CIP or equivalent amounts of 
the prepared salts were prepared for dissolution studies. Starch was used as a tablet binder 
and anhydrous lactose was used as a diluent in 1: 8 ratio respectively. All the excipients were 
geometrically mixed with the active ingredients and compressed using (Specac tablet presser) 
at 8 tones pressure for 10 minutes. 
USP II paddle method (ERWEKA DT-600) was used to perform the in-vitro dissolution studies. 
The prepared tablets were placed into dissolution vessels containing 900 mL of phosphate 
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buffer (pH 7.2) and the dissolution media was maintained at 37oC±0.5oC and stirred at 50 rpm. 
5mL of samples were collected at predetermined time intervals (1, 5, 10, 15, 20, 25, 30 and 40 
min) then filtered through 0.45 μm Millipore filters. The dissolution media was replaced by 
5mL of fresh dissolution fluid in order to maintain a constant volume. The samples were 
analysed by HPLC as mentioned above. 
5.1.2.2.8. Simulation studies 
MD simulations were carried out using the AMBER11 software package (Case et al., 2005) with 
the general AMBER force field (gaff) for all molecules (Wang et al., 2005). All molecules were 
built by Discovery Studio Visualizer 3.1 (http://accelrys.com/products/discovery-
studio/index.html). At neutral pH (pH ~ 7), all the primary amines of amino acids were 
protonated and carboxyl groups of amino acids were negatively-charged. Using the LEAP 
module in AmberTools 1.5, the amino acids were positioned near the ciprofloxacin molecules 
(at least 3 Å for enough sampling). The electrostatic interactions were calculated using the 
particle mesh Ewald method (Darden et al., 1993; Essmann et al., 1995; Crowley et al., 1997; 
Sagui et al., 1999; Toukmaji et al., 2000; Sagui et al., 2004) and the cutoff was 10 Å. Using the 
LEAP module in AmberTools 1.5, the complex structure was immersed in a truncated 
octahedral water box with a solvation shell of 10 Å thickness using TIP3P model for water 
(Jorgensen et al., 1983). This procedure resulted in solvated water structures containing 
approximately 10 000 atoms which included 164 ciprofloxacin atoms and different numbers of 
amino acid atoms, with the remainder being water molecules.  
The minimization procedure for solvated complex consisted of two steps. In the first stage, the 
complex was fixed and positions of water and ions were minimized. The solvated structures 
were then subjected to 500 steps of steepest descent minimization followed by 500 steps of 
conjugate gradient minimization (Leach, 2001; Hans-Dieter et al., 2008). During this 
minimization process the complex was fixed in its starting conformation using harmonic 
  255
constraints with a force constant of 500 kcal/mol/Å2. In the second stage, the entire system 
was minimized by 1000 steps of steepest descent minimization followed by 1500 steps of 
conjugate gradient minimization without the restraints. 
The minimized structure was then subjected to 20 ps of MD, using a 2 fs time step for 
integration. During the MD simulation the system was gradually heated from 0 to 300 K using 
10 kcal/mol/Å2 weak positional restraints on the complex. The SHAKE algorithm was used in 
which all bonds involving hydrogen are constrained (Ryckaert et al., 1977). After the system 
was heated at constant volume with weak restraints on the complex, MD was performed for 1 
ns with a time step of 2 fs under constant pressure/constant temperature (NPT ensemble) at 
300 K with an average pressure of 1 atm without positional restraints. The random number 
seed of every restart was changed (Cerutti, 2008). Isotropic position scaling (Berendsen, 1984) 
was used to maintain the pressure and a relaxation time of 2 ps was employed. SHAKE was 
used to constrain bonds involving hydrogen and the temperature was kept at 300 K with 
Langevin dynamics (Wu & Brooks, 2003) using a collision frequency of 1.0 ps-1. 
 
5.1.3. Results and discussion 
5.1.3.1. Ciprofloxacin phase solubility profile. 
CIP is a zwitter ionic molecule as it has a positively charged nitrogen atom (N20) and negatively 
charged carboxylic group (Fig. 5.1.1). Therefore, the ability of CIP to form new salts with 
cationic and anionic amino acids was investigated in this study. 
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Figure 5.1.86. Structure of ciprofloxacin. The central structural unit is a quinolone ring with a fluorine 
atom at the 9-position, a piperazine moiety at the 8-position, a cyclopropyl ring at position 1 and a 
carboxyl group at position 3. There are two pK values, pKa;COOH = 6.09 and pKa;N20 = 8.7. 
 
Fig. 5.1.2 shows the phase solubility diagram of CIP with three basic amino acids namely; L-
arginine, L-lysine and L-histidine and two acidic amino acids; L-aspartic acid and L-glutamic 
acid. Phase solubility diagram show that both aspartic acid and glutamic acid ionised CIP to a 
greater extent while the extent of ionisation for CIP was lower with basic amino acids such as 
arginine and lysine. No ionisation was observed upon inclusion of histidine. Therefore, four 
salts were prepared in this study and further investigated by FT-IR, 1HNMR, DSC and TGA to 
confirm salt formation. 
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Figure 5.1.87:- Phase solubility diagram of CIP in the presence of different concentrations of arginine, 
lysine, histidine, glutamic acid and aspartic acid at different pH (n=3) 
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CIP solubility in water was found to be 7.22±1.02 µg/mL at 25 oC. The use of acidic amino acids 
considerably improved the solubility of CIP. CIP solubility increased significantly upon 
solubilising in L-glutamic acid solution especially at high concentrations of the counter ion. 
Around 1.2 mg of CIP was solubilised in 1 mL of 1000 µg/mL of glutamic acid. These results 
suggest that CIP acts as a strong base in glutamic acid solution possibly due to the big 
difference between the pKa values of CIP and glutamic acid (8.74 and 2.19 respectively). 
Therefore, the basic amino group is completely ionised in glutamic acid solution favouring salt 
formation between the basic group of CIP and the acidic group of the amino acid. Similarly, the 
solubility of CIP increased in L-aspartic acid solution and could be potentially due to salt 
formation between the two ionised species (these data were further confirmed using FT-IR and 
1HNMR as discussed below). 
 
On the other hand, solubilizing CIP in various concentrations of L-histidine solutions showed no 
improvement in solubility with a maximum solubility of 9.65±0.28 µg/mL at 1000 µg/mL of 
histidine solution. Poor solubilisation of CIP can potentially be due to similar pKa of basic group 
on histidine (pKa 6) and the carboxylic group of CIP resulting in no ionisation of the parent 
drug.  
Interestingly, increasing the concentration of L-arginine solution was found to improve the 
solubility of CIP. At a concentration of 10 µg/mL arginine, CIP solubility was 10.7±2.8 µg/mL 
and the solubility increased linearly upon increasing the concentration of arginine solution 
where CIP solubility was 247.8±4.2 µg/mL at 1000 µg/mL of arginine solution (Fig. 2). 
Although the pKa of the –NH2 side chain of L-arginine (12.48) is much higher than the pKa of 
CIP acidic side chain, CIP was ionised to a lower degree. A similar trend was observed when L-
lysine was used as CIP solubility increased from 11.62±5.8 µg/mL to 350.7±34 µg/mL when 
lysine concentration increased from 10 µg/mL to 1000 µg/mL.  
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Characterization of CIP salts 
5.1.3.2. Fourier Transform Infrared Spectroscopy (FT-IR) 
The phase solubility diagram has shown that CIP possibly dissociates in acidic amino acids 
solution and some of the basic amino acids. The next stage of the work was to prepare five 
salts of CIP amino acids and to investigate and characterise the salt formation using physico-
chemical methods such as FT-IR, 1HNMR and DSC. 
Fig. 5.1.3 shows the FT-IR spectra of CIP, CIP aspartate and CIP glutamate. CIP had 
characteristic absorption peaks at 3044 cm-1 which can be assigned to C-H olefinic and 
aromatic chains, 1617.8 corresponding to C4O16 keto group. Since CIP is in the zwitterionic 
form, the carboxylic group C14=OOH does not appear in CIP FT-IR spectrum (Romanuk et al., 
2009).  
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 Figure 5.1.3:- FTIR spectra of  (A)Ciprofloxacin, (B) CIP L-aspartate and (C) CIP L-glutamate 
 
Interestingly, this carboxylic group was present in CIP glutamate and aspartate salts at 1720 
and 1719 respectively suggesting that the zwitterionic nature of CIP was reverted by proton 
transference from L-aspartic acid and L-glutamic acid. These results are in line with results 
obtained by (Romanuk et al., 2010) On the other hand, FT-IR data for basic amino acids with 
A 
B 
C 
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CIP does not show the C4O16 keto group at 1617.8 but had an absorption band at 1579.55 and 
1646.4 corresponding to carboxylic group C=O of lysine (Ogura et al., 1998) and arginine 
(Petrosyan, 2007) respectively. Upon comparing CIP lysine and lysine free amino acid, similar 
spectrum was observed which support our findings (Fig. 5.1.4 C& D). Our results were further 
confirmed using 1HNMR as discussed below. 
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Figure 5.1.4:- FTIR spectra of  (A)Ciprofloxacin, (B) CIP arginine, (C) CIP lysine, (D) lysine 
 
5.1.3.3. 
1
HNMR 
To further confirm the salt formation and investigate the molar ratio of interaction between 
CIP and the counter ions, the total number of protons in the prepared salts was studied using 
1HNMR. 
Fig. 5.1.5 shows the 1HNMR data for CIP aspartate. Both C12H2 and C13H2 of the cyclopropyl 
group of CIP appeared at 1.08 and 1.3 ppm, while the C11H group was deshielded at higher (δ) 
due to the deshielding effect exerted by N1. Piperazine ring 8 protons C22H2, C21H2, C18H2 
and C19H2 appeared as multiplet at around 3.79 ppm. C2H, C7H, C10H appeared deshielded at 
A 
B 
C 
D 
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8.5, 7.4 and 7.33 respectively. The total integration of CIP was found to be 16 similar to what 
was previously reported by Wetzsein et al (1999). 
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Figure 5.1.5:-  
1
HNMR spectra for Ciprofloxacin Aspartate dissolved in D2O 
 
Two new bands appeared at 2.67 and 3.81 ppm corresponding to three protons of one 
molecule of aspartic acid (C28H and C30H2). This data shows that one molecule of CIP has 
formed a salt with one molecule of aspartic acid in 1:1 ratio.  
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Figure 5.1.6:-  
1
HNMR spectra for Ciprofloxacin glutamate dissolved in D2O 
 
Similarly, the 1HNMR spectrum of CIP glutamate (Fig. 5.1.6) showed 5 new proton assignments 
between 1.98 and 2.3 ppm which correspond to the 5 alphatic protons of L-glutamic acid. 
However, the 1HNMR data for CIP basic amino acid preparations show no salt formation and 
only protons of the free basic amino acids were detected by the 1HNMR (see figures 5.1.7 & 
5.1.8). 
These data suggest that only acidic amino acids were capable of forming salts with CIP, while 
the basic amino acids failed to form salts as suggested by the FT-IR studies above. 
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Figure 5.1.7:-  
1
HNMR spectra for Ciprofloxacin lysine dissolved in D2O 
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Figure 5.1.8:-  
1
HNMR spectra for Ciprofloxacin arginine dissolved in D2O 
 
NH2 34
33
32 31
30 28
26
NH229
OH
25
O
27
3
2
4
N
1
5
6
10
9
7
8
N
17
18
22
19
21
NH2
+
20
11
1213
F
23
O
16
14
O
24
OH
15
3
2
4
N
1
5
6
10
9
7
8
N
17
18
22
19
21
NH
20
11
1213
F
23
O
16
14
O
24
OH
15 NH2 35
34
NH
33
32
31
30
28
26
NH
36
NH229
OH
25
O
27
  263
5.1.3.4. Differential scanning calorimetry and thermogravimetric analysis. 
New salts have different physical behaviour from their parent components. Therefore, the 
melting point and degradation temperature of CIP and its salts were investigated using DSC 
and TGA. 
CIP free drug was in the crystalline form and showed an endothermic peak at 272.15 oC (ΔH= 
173.19 J/g) corresponding to its melting endotherm. TGA data showed start of drug 
degradation upon completion of its melt. On the other hand, the CIP aspartate salt had two 
endothermic peaks at 224.63 and 237.8 oC suggesting that the CIP aspartate salt has two 
forms. On the other hand, the CIP glutamate salt showed a single melting endotherm at 
203.35oC. Arginine CIP formulations melted at 227.31 oC which was found to be similar to that 
of arginine free base and the absence of CIP melting endotherm or any other new melts 
confirms the failure of salt formation between CIP and basic amino acids as discussed 
previously.  
5.1.3.5. Simulation studies 
Characterisation studies showed that anionic amino acids form new salts with CIP while the 
cationic amino acids failed to form any salts with the drug. This was contrary to the generally 
accepted hypothesis that a 3 unit difference in pKa between the parent compound and the 
counter ion results in salt formation. Therefore, the role of inter and intra molecular 
interaction between CIP and the amino acid was investigated using molecular dynamic 
simulation studies in order to gain further understanding of CIP in different solutions of amino 
acids. Two amino acid models were used in this study; aspartic acid and histidine as aspartic 
acid resulted in CIP salt formation while histidine failed. 
Figure 5.1.9 shows the interaction between CIP molecules; two CIP molecules in water 
aggregate together after 400 ps due to the hydrophobic interaction thereby further confirming 
the role of hydrophobic forces in the low solubility of CIP. The lab based experiments showed 
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that CIP solubility in aspartic acid increased significantly especially at high concentrations of 
aspartic acid solution. Thus the interaction of two CIP molecules with one aspartic acid 
molecule in water (low concentration), and the interaction of two CIP molecules with four 
aspartic acid molecules in water (high concentration) was studied using molecular simulations. 
As shown in Figure 5.1.10, the aggregation of CIP molecules is delayed until 800 ps in the 
presence of one amino acid (aspartic acid) molecule. On the other hand, aggregation of CIP 
molecules was hindered in the solution with high concentration of amino acid (four aspartic 
acid molecules) as shown in Figure 5.1.11. Data obtained from the simulation studies were in 
agreement with the results of experiments where high concentrations of amino acid solutions 
(e.g. 500 and 1000 µg/mL) resulted in significant increases in solubilisation capability, while the 
low concentration of amino acid solutions have less effect. However, it was interesting to see 
that inclusion of histidine did not prevent aggregation of CIP molecules even at high 
concentrations (with four histidine molecules), as shown in Figure 5.1.12. It further confirms 
experimental results of the solubilisation incapability of histidine. These results indicated that 
two factors influence the inter- and intra-action between CIP molecules and amino acids. On 
one hand, CIP is an amphoteric electrolyte and acts as the base in aspartic acid solution due to 
the difference between the pKa values of -NH group of CIP (8.74) and -COOH group of aspartic 
acid (3.86). The positively-charged -NH group of CIP and negatively-charged -COOH group of 
aspartic acid form the electrostatic interaction. The pKa of the basic amino group of L-histidine 
(6) is almost the same as that of the CIP carboxylic group (6.09) possibly resulting in no 
enhancement in solubility. Besides, hydrophobic interaction is also an important factor in CIP 
aggregation. When ionic interactions and/or hydrophobic interactions between CIP molecules 
and amino acid molecules are stronger than hydrophobic interaction between CIP molecules, 
the solubilisation process is accelerated. 
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Figure 5.1.9. Snapshots of two ciprofloxacin molecules in water: (A) at 0 ns, (B) after 200 ps, (C) after 
400 ps, (D) after 600 ps, (E) after 800 ps and (F) after 1 ns. (Water is only shown in A) and is ignored 
from B) to F) for clarity) 
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Figure 5.1.10. Snapshots of two ciprofloxacin molecules with one aspartic acid molecule in water: (A) 
at 0 ns, (B) after 200 ps, (C) after 400 ps, (D) after 600 ps, (E) after 800 ps and (F) after 1 ns. (Water is 
only shown in A) and is ignored from B) to F) for clarity) 
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Figure 5.1.11. Snapshots of two ciprofloxacin molecules with four aspartic acid molecules in water: (A) 
at 0 ns, (B) after 200 ps, (C) after 400 ps, (D) after 600 ps, (E) after 800 ps and (f) after 1 ns. (Water is 
only shown in A) and is ignored from B) to F) for clarity) 
 
A B 
C D 
E F 
  268
 
                                                                                       
Figure 5.1.12. Snapshots of two ciprofloxacin molecules with four histidine molecules in water: (A) at 
0 ns, (B) after 200 ps, (C) after 400 ps, (D) after 600 ps, (E) after 800 ps and (f) after 1 ns. (Water is only 
shown in A) and is ignored from B) to F) for clarity). 
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5.1.3.6. Solubility & dissolution studies 
In order to assess the saturated solubility of CIP and its prepared salts, excess amount of the 
drug and its prepared salts were stirred in 2 mL of deionised water and stirred for 12 hours 
until equilibrium was achieved. Drugs were adequately diluted and their solubility was 
measured using HPLC. The highest solubility was exhibited by the CIP glutamate salt which was 
found to be 215±13.3 mg/mL while the solubility of CIP aspartate was 185.4±8.6 mg/mL. As 
demonstrated by DSC study the melting point of CIP aspartate salt was lower than that of the 
parent drug which requires less energy to break the crystalline structure of the salt and hence 
solvate the drug. Other factors such as gravitation index, charge on the most negative atom, 
and number of hydrogen bonding acceptors might also have played a role in favour of higher 
water solubility of the salt form (Mitchell & Jurs, 1998). 
In vitro dissolution studies of CIP free drug were compared against it salts and amino acids 
physical mixtures (Fig. 5.1.13). After 10 minutes of dissolution test, only 16.09±1.15 % of CIP 
was released from CIP containing tablets while 58.3±10.37 of CIP was released from CIP 
aspartate salt tablets. More than 75% of CIP was dissolved from CIP salt tablets after 40 
minutes of the dissolution study while only 54.3±10 and 61.8±5.02 were released from CIP and 
CIP aspartic acid physical mixture respectively (Fig. 5.1.13A). 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.88:-  (A)Dissolution profile for CIP free drug, CIP aspartic acid physical mixture and CIP 
aspartate, (B) Dissolution profile for CIP glutamic acid physical mixture and CIP glutamate,  data are 
represented as mean±SD (n=3). 
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Figure 5.1.13B shows the dissolution profiles of CIP glutamate, CIP and CIP glutamic acid 
physical mixture. The highest dissolution profile was exhibited by CIP glutamate salt as 
26.7±6.7 % of CIP was released from this formulation during the first 5 minutes of dissolution 
studies. These results suggest that CIP aspartate and glutamate salts have relatively high 
buffering capacity which in turn improves the dissolution profile by increasing the pH of the 
surrounding diffusion layer. 
 
5.1.4. Conclusion 
CIP is a BCS IV drug with low solubility and permeability. Due to its zwitterionic nature the use 
of basic and acidic amino acids to formulate new CIP salts was investigated. Acidic amino acids 
formed two novel salts with high solubility when compared to CIP alone. Phase solubility 
diagrams have shown a high degree of ionisation of CIP in presence of L-aspartic and L-
glutamic acid. Characterization studies confirmed the formation of salt which was supported 
by FTIR, NMR and DSC studies. 1HNMR demonstrated that the molecular interaction between 
CIP and the acidic counter ions was a 1:1 ratio. Moreover, the molecular dynamic simulations 
have shown for the first time that the hydrophobic interactions between CIP molecules 
decrease in the presence of the acidic amino acids and in turn form a stable salt. 
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Ciprofloxacin permeability studies and the transcriptomic changes 
occurring during its uptake across Caco-2 cells 
5.2.1. Introduction 
Ciprofloxacin (CIP) is a flurinated-4-quinolone derivative which belongs to the fluoroquinolone 
antibiotic group and is structurally related to nalidixic acid. The broad spectrum synthetic 
antibiotic is used for systemic therapy against acid-alcohol resistant bacteria (Eliopoulos et al., 
1984) and is classified as a BCS IV drug with both low solubility and permeability (Wu et al., 
2005). CIP is zwitter ionic in nature with  a “U” shaped pH solubility profile exhibiting lowest 
solubility values near its isoelectric point and the highest value below pH 5 and above 10 
(Olivera, 2011). Studies reported by Bergan et al., (1987) and Neuman (1988) suggest that 55-
85% of CIP becomes bioavailable after oral administration. This percentage was found to be 
slightly lower than other fluoroquinolone compounds. The low dissolution profile from oral 
dosage forms and the first pass metabolism were believed to be the reasons behind the 
incomplete absorption of CIP. It was believed that CIP was eliminated entirely by the kidney 
until Sorgel et al (1989) found that the intestine eliminates around 10% of CIP and this 
percentage increases in patients with renal failure (Rohwedder et al., 1990). The importance of 
the intestine in the elimination of CIP was further studied by Rubinstein et al., (1994) and Metz 
& Soergel, (1990) using an ex vivo rat intestinal perfusion model. The intestinal secretion for 
most of the fluoroquinolones is mediated by efflux proteins P-glycoprotein (P-gp) and 
multidrug resistance associated protein 2 (MRP2). In 2002 Lowes and Simmons suggested that 
CIP is not a substrate for MRP2 and P-gp but secreted by an alternative pathway which was 
termed as CIP sensitive pathway. Lowes and Simmons believed that two efflux proteins located 
on the apical and basal sides of the epithelial cells control efflux of CIP. A similar phenomenon 
of active efflux of CIP was also reported in bacteria such as Streptococcus pneumoniae (Valerie 
et al., 1997) and Salmonella enterica (Etienne et al., 2000). 
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Pharmacokinetics and pharmacodynamics of CIP are also affected by the concomitant intake of 
food which has clinical implications for the bioavailability of CIP (Singh, 1999; Harris et al., 
2003). Food also affects the pharmacokinetics of the drug by altering the GI pH, gastric 
emptying rate, bile flow and physical/chemical characteristics of the drug molecule. Various 
proposed mechanisms for reduction in bioavailability by food include chelation of the drug and 
reducing solubility of basic drug upon reaching the small intestine (Leyden, 1985; Carver et al., 
1999). 
CIP bioavailability is known to decrease upon co-administration with food containing metal 
ions (Hoffken et al., 1985; Lomaestro and Bailie, 1995) which was attributed to complex 
formation with the metal ions (Wallis et al., 1996). The formed complexes have different 
geometry, size and charge from the non complexed drug and therefore have a reduced passive 
diffusion across the cell membranes and the tight junctions of intestinal epithelial cells. 
Another study conducted by Ledergerber et al., (1985) demonstrated that concomitant 
administration of CIP oral tablets with food prolongs the time required to reach peak serum 
levels without affecting the overall bioavailability. 
 
The aim of the current study was to study the ion-pair formation between the anionic amino 
acids; aspartic acid and glutamic acid and the zwitter ionic model drug (CIP) and the impact of 
ion-pairing on the permeability profile of CIP and to visualize the molecular genetic changes 
happening during the uptake of CIP and its ion-paired formulations. This study also 
investigated the effect of pH and the media composition (fed and fast state) on the absorption 
patterns of CIP. 
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5.2.2. Materials and methods 
5.2.2.1. Materials 
Ciprofloxacin, L-Glutamic acid (Reagent plus ≥ 99%), L-aspartic acid (≥ 98%), ninhydrin reagent 
(2% solution), sodium taurocholate, lecithin, glycerylmonooleate, sodium oleate and maleic 
acid were purchased from Sigma Aldrich, UK. 
Sodium hydroxide and sodium chloride were purchased from Fisher Scientific, UK. 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), Nonessential amino 
acids (NEAA), 1% pencillin-streptomycin, 2mM glutamine and Hank’s balanced salt solution 
(HBSS) were purchased from Bio Sera, UK. 1% Trypsin–EDTA was obtained from Gibco Lab. UK. 
RNeasy kit (RNA free water, buffer RLT, buffer RW1 and buffer RPE) was purchased from 
Qiagen (Hiden, Germany). Gene expression hybridization kit, low input Quick Amp labelling kit, 
RNA spike-in kit (one color) all were purchased from Agilent (Cedar Creek, Texas, USA). Agilent 
gene expression washing buffer 1 and 2 were ordered from Agilent (Wilmington, DE, USA) and 
Ethanol which was purchased from Fisher scientific (Leicestershire, UK). 
 
5.2.2.2. Methods 
5.2.2.2.1. Preparation of pre-saturated solution of 1-octanol and de-ionised water. 
1000 ml of de-ionised water was added to 4 mL of 1-octanol. The mixture was shaken for few 
minutes and left overnight. The de-ionised water was separated from 1-octanol using a 1000 
mL separating funnel. 
 
5.2.2.2.2. Octanol- water partitioning experiment 
500 µg of CIP was added to 100 mL octanol-saturated deionised water with molar excess of 
aspartic acid/glutamic acid (in ratios 1:1, 1:2, 1:4 and 1:8). 5 mL of the aqueous phase was 
allowed to equilibrate with 5mL of octanol at room temperature and stirred for 24 hours using  
a magnetic stirrer. The two phases were then separated by centrifugation and CIP 
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concentration [CIPt]Aq in the aqueous phase was measured using HPLC. Mass balance was used 
to calculated CIP concentration in octanol phase [CIPt]Oct using equation (5.2.1). 
[CIPt]Oct = total drug put into the system- [CIPt]Aq   Equation 5.2.52 
 
The apparent distribution coefficient DB may be calculated using equation (5.2.2) 
DB= [CIPt]Oct/[CIPt]Aq     Equation 5.2.53 
 
5.2.2.2.3. HPLC method to study the concentration of ciprofloxacin 
The amount of ciprofloxacin (CIP) dissolved in the samples was quantified by HPLC using a 
Dionex 1100 system fitted with an autosampler (AS50), gradient pump (GP50), UV detector 
(UVD 170U) and RP-C18 analytical column (Phenomenex 110A, 150x4.6 mm, 5µm). Mobile 
phase consisting of methanol and 1.25% acetic acid was mixed in the pump and analysis of CIP 
was done using gradient elution at 1.0 mL/min. λmax  was determined using a Unicam UV-
Visible Spectrophotometer  and the HPLC UV detector was set at λmax of 280 nm. CIP was 
eluted with a retention time of 1.5±0.1 min and a rectilinear calibration curve was established 
in the concentration range between 10- 200µg/mL. 
5.2.2.2.4. Ninhydrin analysis 
The concentrations of aspartic acid and glutamic acid in octanol/water partitioning studies 
were quantified using the ninhydrin method. In order to construct a calibration curve, serial 
dilutions of the amino acids were prepared and 1 mL of the prepared samples was mixed with 
0.5 mL of ninhydrin reagent and vortexed for 20 seconds. The samples were heated in a pre-
warmed water bath at 80 oC for 20 minutes. The samples were removed from the water bath 
and left to cool. The intensity of the coloured Ruhemann purple was analysed using a UV 
spectrophotometer at a wavelength of 560 nm. 
Calibration curves were constructed with a regression coefficient of 0.99 and 
0.99 for aspartic and glutamic acid respectively. Subsequent to the  construction 
of the calibration curves, the concentration of the amino acids in the aqueous 
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layer was determined using the linear curve equations (5.2.3) and (5.2.4) for 
aspartic acid and glutamic acid respectively. 
Y=0.0695x    Equation 5.2.54 
Y=0.0755x   Equation 5.2.55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.89:- Ninhydrin calibration curve for aspartic acid (A), glutamic acid (B) n=3. 
 
5.2.2.2.5. Procedure for Caco-2 cell culture 
Caco-2 cells at passage 48 were gifted from Huddersfield University and used at passages 50-
80. Cells were allowed to grow in 75cm² T-flasks and maintained using Dublecco’s modified 
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 0.5% pencillin-streptomycin, 2mM 
glutamine and 1% nonessential amino acids (NEAA). Culture medium was changed every 2 to 3 
days and cells were grown at a temperature of 37°C and 5% CO2.  The cells were passaged 
using 5 mL trypsin-EDTA when they reached 90% confluence. Transepithelial transport assay 
was carried out using Khan et al., (2011) methods. 2 x 105cells/cm² were seeded on 
polycarbonated-coated membranes (6-well transwell plates, 24mm, 4.7cm²) and were allowed 
to grow for 21 days and the media in both apical and basal compartments were changed every 
A 
B 
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2-3 days. Transepithelial electrical resistance (TEER) was measured at the start and end of 
every study. 
 
5.2.2.2.6. Ciprofloxacin permeability studies 
Caco-2 monolayers were used 19-21 days after seeding. Apical to basolateral permeability of 
CIP and its formulations was assessed. The transwells were rinsed and incubated for 15 
minutes with drug-free transport medium (Hanks balanced salt solution; HBSS). Following 
incubation, HBSS was removed and 1.5 mL of the medium containing CIP alone (500 µg/mL) 
and CIP with various molar ratios of the anionic amino acids (1:1, 1:2, 1:4 and 1:8) were 
introduced to the apical side. Sample aliquots (300μL) were taken from the basolateral side at 
given time intervals (0, 5, 10, 15, 20, 30, 60 and 90 minutes). After each sampling, an equal 
volume of fresh transport buffer (pre-warmed at 37°C) was added to the receiver 
compartment (basal side) and the cells maintained at a temperature of 37°C and 5% CO2 
throughout the experiment. Samples were subsequently analyzed by HPLC. In order to confirm 
the mass balance, samples were taken from both apical and basolateral compartments at the 
last time point (90 mins). All experiments were performed at 37°C (n = 5). In order to 
investigate the effect of pH on the permeability profile of CIP, the pH of HBSS was adjusted 
using 0.1N HCl solution until it reached a pH of 4.5, 5.5 and 6.8. CIP was added to HBSS and 1.5 
mL of the solutions were introduced to the apical side and the permeability profile was 
assayed as discussed above. 
Apparent permeability coefficient Papp (cm/s) was calculated using (equation 5.2.5) 
0/1/ ACdtdQPapp ×=    Equation 5.2.56 
 
Where dQ/dt is the rate of appearance of the drugs on the basolateral side (nmol s-1), Co is the 
initial concentration on the apical side and A is the surface area of the monolayer (4.7 cm2). 
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The data presented was validated using HPLC measurement of drug transfer during the 
process of permeability. This included repetition of drug permeability studies in the 
preparations used for microarray analysis. 
 
5.2.2.2.7. Fed and fasted state media preparation 
Fed (FeSSIF) and fasted state (FaSSIF) media was prepared using a method reported by 
Jantratid et al., (2008) and the composition and the properties of the media used in the 
permeability study are summarised in table (5.2.1). 50 mg of CIP was added to 100 mL of the 
simulated media and 1.5 mL of the solution was transferred to the apical side of the Caco-2 
monolayers’ transwells and permeability across the monolayers was assessed using the 
method discussed above. 
Table 5.2.40:- Composition of the media to simulate the fasted state simulated intestinal fluid (FaSSIF) 
and the fed state simulated intestinal fluid (FeSSIF). 
Composition (mM) FaSSIF FeSSIF 
Sodium taurocholate 3 10 
Lecithin 0.2 2 
Glyceryl monooleate - 5 
Sodium oleate - 0.8 
Maleic acid 19.12 55.02 
Sodium hydroxide 34.8 81.65 
Sodium chloride 68.62 125.5 
Properties   
pH 6.5 5.8 
Osmolality 180±10 390±10 
Buffer capacity (mmol/L/pH) 10 25 
Surface tension (mN/m) 54.3 40.5±0.2 
 
5.2.2.2.8. Recovery 
The amount of CIP recovered from both apical and basolateral compartments at the end of the 
experiment was calculated using equation 5.2.6. 
100(%)covRe
min0
min90min90 ×
×
×+×
=
DD
DDRR
VC
VCVC
ery
          
Equation 5.2.57
 
Low recovery data is attributed to entrapment of the compounds into the cell monolayers or 
adsorption to the device surface which in turn results in error calculating the transport rate 
(Aungst et al., 2000). 
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5.2.2.2.9. RNA extraction for microarray studies 
Samples for microarrays studies were collected at 5, 30, 60 minutes for CIP, CIP:glutamic acid 
at 1:1 (1x) and 1:8 (8x) molar ratios. Caco-2 monolayers were treated with ethanol: phenol 
mixture (95:5) for 24 hours. After scrubbing the cells, pellets were obtained by centrifugation 
at 2000 rpm at 4 oC for 10 minutes. All pellets were stored at -80 oC until the total RNA was 
extracted. Total RNA was extracted using RNeasy kit (Qiagen) and quantified using a Nanodrop 
1000 spectrophotometer (Themoscientific, Wilmington, DE). 
 
5.2.2.2.10. Microarray study 
Systemic changes of the gene expression upon exposing Caco-2 cells to CIP and its various 
formulations were evaluated using the Agilent one-color-spike procedure discussed before. 
Briefly, 1.5µl of 25 ng of total RNA was mixed with 2 µl of diluted one-color-spike mix. cDNA 
master mix (Agilent) was used to prepare cDNA for all the samples which were labelled using 
cy3-dUTP. The yield and specific activity for fluroscent cDNA probes were determined using 
equations 5.2.7 and 5.2.8 respectively; the  data obtained is summarised in (Table 5.2.2), after 
quantifying cDNA (ng/µl)and cyanine 3 (pmol/ µl). All samples were hybridized to Agilent 4x44 
K whole genome array for 16 hours at 65 oC in hybridization oven (Sheldon manufacturer, 
Corneilus, OR). After hybridization, samples were scanned at 50nm resolution and at 20 bit 
scan using Agilent scanner (Agilent Technologies, Santa Clara, CA). 16-bit TIFF images were 
obtained and used as input for the feature extraction software (V10.7, Santa Clara, CA). 
Yield 
1000
... volumeelutioncRNAofConc ×
=        Equation 5.2.58 
Specific activity 1000
..
3..
×=
cRNAofConc
CyofConc
       Equation 5.2.59 
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Table 5.2.41:-  Summary of Quantifying of total RNA, yield and specific activity of the complementary 
DNA used for hybridization in CIP studies. 
 Total RNA cDNA probe 
Sample conc 
(ng/µl) 
260/28
0 
ratio 
260/23
0 
ratio 
conc 
(ng/µl) 
260/280 
ratio 
cystine 
dye 
pmol/ 
µl 
Yield 
 
specific 
activity 
 
Control 5 983.1 2.02 1.57 131.3 2.2 2.5 3.939 19.04 
Control 60 842.5 2.01 1.94 165.2 2.2 3.1 4.956 18.76 
CIP  5 min 631.3 2.04 2.05 241.8 2.21 2.4 7.254 9.92 
CIP:Glu 1:1, 
5 min 
952.1 1.99 1.92 155.1 2.1 0.9 4.653 5.80 
CIP:Glu 1:8, 
5 min 
851.8 1.96 1.63 210.8 2.1 1.6 6.324 7.593 
CIP, 30 min 507.7 1.99 1.69 190.2 2.23 2.6 5.706 13.66 
CIP:Glu 1: 
1, 30 min 
362.2 1.98 1.68 199.8 2.21 1.6 5.994 8.00 
CIP :Glu 
1:8, 30 min 
318 2.03 1.97 132.2 2.1 1 3.966 7.56 
CIP,  60 min 889.8 2 1.78 182.4 2.19 2.8 5.472 15.35 
CIP:Glu 1: 
1, 60 min 
614.3 1.99 1.29 133.2 2.26 2.4 3.996 18.01 
CIP:Glu 1: 
8, 60 min 
1286.3 1.99 1.82 135.9 2.14 1.7 4.077 12.50 
 
5.2.2.2.11. Data Processing (Image analysis and data normalization) 
The feature extraction software (V10.7, Santa Clara, CA) was used to study the quality of the 
obtained TIFF images. The image was analysed in terms of grid alignment, signal quantification 
and overall slide quality. 
Background intensities in the DNA microarray data such as optical background and non-specific 
binding (NSB) were adjusted using the R library gcrma (Boes and Neuhäuser 2005). The gcrma 
converted the background adjusted probe intensities into expression measures while the 
probe sequence information were used to estimate probe affinity to non-specific binding 
(NSB). The levels of probe intensities between the arrays before and after normalization were 
compared using box-plots as discussed in TMP chapter. The middle line of the box-plot 
represents the median while the two ends of the box represent the upper and lower quartiles. 
Values which are more than 1.5 the interquartile range are outliners while the horizontal lines 
connected to the box-plots are not considered outliners.  
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5.2.2.2.12. Clustering analysis and filtering 
Data clustering was carried out on the normalized data using TMEV software (version TM4, 
WA, USA). The genetic changes were clustered according to their similarities in the pattern of 
their expression using hierarchical clustering algorithm. The mean values were used to 
compare between various data set used in this study. In order to highlight the main variability 
in the multidimensional data set principle component analysis was carried out using TMEV 
software. Microsoft Excel (version 2003, Toulouse, France) was used to filter out the non-
expressed genes or the genes which do not show variation across sample types. Genes which 
were up or down-regulated by two fold were selected for further analysis. In order to 
investigate the changes in various pathways during the absorption process, up and down-
regulated genes were uploaded online onto the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) http://www.genome.jp/kegg/ and the expression changes were high- 
lighted in red. 
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5.2.3. Results and discussion 
5.2.3.1. Ciprofloxacin/aspartic acid octanol/water partitioning and permeability studies 
Similar to the previous studies that were conducted for TMP and IND, partitioning studies of 
CIP and its ion-paired formulations were investigated using water and octanol system. Figure 
5.2.2 shows the partitioning behaviour of CIP at various concentrations of aspartic acid. CIP 
alone was found to have high partitioning in the organic layer with a log P value of 1.63. This 
was fairly similar to the values reported by Olivera, (2011) (log P 1.32). The octanol/water 
partitioning slightly dropped upon pairing CIP with aspartic acid as the drug concentration in 
the aqueous layer increased upon increasing the concentration of aspartic acid. The highest 
aqueous concentration was exhibited at 1:8 ratio of CIP to aspartic acid respectively and the 
log P dropped by more than one unit to 0.28. 
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Figure 5.2.90:- CIP concentrations in aqueous and octanol layers and its corresponding Log P values at 
various concentrations of aspartic acid (n=3). 
 
Ion-pairing theory assumes that pairing between the oppositely charged ions occurs during 
partitioning for basic or acidic drug with its counterpart (acidic or basic counter ion). CIP is 
zwitter ionic in nature characterised by both acidic and basic groups capable of forming ion-
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pairs. In the current investigation, anionic amino acids were used as previous studies have 
shown that stable salt forms cannot be obtained with cationic amino acids due to the lack of 
formation of inter and intra molecular bonds which was studied using molecular simulations. 
We therefore assumed that CIP will behave as a cationic molecule upon pairing with acidic 
amino acids. Equation 5.2.9 was used to plot the double reciprocal of the apparent 
octanol/water distribution coefficient of CIP and the concentration of the acidic amino acid. 
ABaqABaqB PAPKD
1
][
11
11
+=
  
Equation 5.2.60
 
 
Table 5.2.42:- pH measurements during the partitioning study for CIP aspartate (n=3). 
Formulation pH measurements 
CIP  4.46±0.03 
CIP aspartic acid PM 1:1 4.02±0.1 
CIP aspartic acid PM 1:2 3.96±0.06 
CIP aspartic acid PM 1:4 3.76±0.12 
CIP aspartic acid PM 1:8 3.61±0.026 
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Figure 5.2.91:- Double reciprocal plot of the apparent octanol-water distribution coefficient of CIP as 
function of aspartic acid molar concentration. 
 
A negative exponential relationship (R2= 0.94) was observed between the double 
reciprocal of the apparent octanol/water distribution coefficient of CIP and the concentration 
R2=0.94 
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of the acidic amino acid suggesting that an increase in the molar concentration of aspartic acid 
would result in an exponential decrease in the partitioning coefficient of the zwitter ionic drug. 
Using equation (5.2.10), the intrinsic octanol water partitioning (PAB) was calculated and found 
to be 0.56 while the aqueous binding constant (K11aq) was 1.54 mM
-1 (1540 M-1). Although the 
number of H-donor and H-acceptors for both CIP and TMP was similar (i.e. similar degree of H-
bond formation), the aqueous binding constant between CIP and aspartic acid was significantly 
higher than that between TMP and aspartic acid (21 M-1). Nevertheless, the degree of ionic 
bonding between CIP and the amino acid is higher than that between TMP and aspartic acid 
possibly because of the higher ∆pKa (6.86 in case of CIP and 5.42 in TMP). 
1681.139.35 −= xY Equation 5.2.61 
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Figure 5.2.92:- Percentage of CIP transported across Caco-2 monolayers at various molar ratios of 
aspartic acid (n=5). One way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey test) against drug alone at each time point were used for statistical analysis and 
probability values of (P< 0.05, * and P<0.001,***) were used to determine the significant difference. 
 
 
 
Figure 5.2.4 summarises the permeability profile of various formulations of CIP across Caco-2 
monolayers. 0.45±0.06% of CIP was absorbed across the monolayers after 5 minutes of start of 
the experiment. The percentage absorbed increased slightly with time to 3.1±0.67% after 90 
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minutes. The apparent permeability for CIP (Papp) was 0.81x10
-06±3.24x10-07 cm/sec which 
reflects the very low permeability of the drug. No significant difference (p> 0.05) was observed 
for most of the formulations for up to 15 minutes and the amount of CIP absorbed did not 
exceed 1%. After 30 minutes the percentage of CIP permeated began to increase for CIP 
aspartate salt (1.69±0.72%) and CIP aspartic acid PM 1:1 (3.02±0.34%) while the rest of the 
formulations showed no significant increase relative to 30 min control. Moreover, the 
apparent permeability for CIP increased in the PM 1:1 and the salt formulations to 1.28x10-
06±2.91x10-07 and 2.45x10-06±1.15x10-06 cm/sec respectively. 
 
Table 5.2.43:- Summary of the TEER measurements before and after the permeability assay (n=3), the 
percentage recovery and the apparent permeability calculations for CIP aspartic acid and glutamic 
acid formulations. 
Formulation TEER measurements 
 (Ω/cm2) Before 
TEER measurements  
(Ω/cm2) After 
Recovery 
(%) 
Apparent permeability at 
60 min (cm/sec) 
CIP free drug 452.24±11.7 420.3±26.5 86.5 8.12E-07±3.24E-07 
CIP Asp PM 1:1 440.36±18.3.73 430.6±11.2 79.2 1.28E-06±2.91E-07 
CIP Asp PM 1:2 446.5±32.3 438.5±20.5 97.1 8.80E-07±3.69E-07 
CIP Asp PM 1:4 502±15.2 460.6±28.1 82.5 1.06E-06±5.45E-07 
CIP Asp PM 1:8 420.6±10.5 412.6±12.8 96.2 1.38E-06±9.35E-07 
CIP Asp salt 455.2±23.1 420.25±13.2 75.9 2.45E-06±1.15E-06 
CIP Glu PM 1:1 390.7±12.2 387±30.45 85.2 1.15E-06±2.88E-07 
CIP Glu PM 1:2 348±32.1 337.66±5.16 89.7 9.50E-06±1.54E-06 
CIP Glu PM 1:4 412.3±20.5 352.6±38.6 95 43.2E-06±8.54E-06 
CIP Glu PM 1:8 440.4±11.5 400.1±26.2 98.1 61.1E-06±9.49E-06 
CIP Glu salt 401.2±10.2 392.66±12.6 92.3 2.19E-06±4.39E-07 
 
5.2.3.2. Ciprofloxacin/glutamic acid octanol/water partitioning and permeability studies 
The octanol/water partitioning of CIP and various concentrations of glutamic acid were studied 
and the results are summarised in Fig. 5.2.5. Similar to aspartic acid based formulations, the 
concentration of CIP in the aqueous phase increased upon increasing the concentration of 
glutamic acid which resulted in a steady decrease in the log P values until it finally reached 
0.12 at 8 molar concentration of glutamic acid. 
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Table 5.2.44:- pH measurements during the partitioning study for CIP glutamate (n=3). 
Formulation pH measurements 
CIP 4.46±0.03 
CIP glutamic acid PM 1:1 4.29±0.015 
CIP glutamic acid PM 1:2 4.21±0.012 
CIP glutamic acid PM 1:4 4.05±0.03 
CIP glutamic acid PM 1:8 3.85±0.028 
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Figure 5.2.93:- CIP concentrations in aqueous and octanol layers and its corresponding Log P values at 
various concentrations of glutamic acid (n=3). 
 
The double reciprocal plot of apparent octanol/water distribution coefficient of CIP and the 
concentration of glutamic acid showed similar trend as that of aspartic acid (Fig. 5.2.6). Upon 
using the equation (equation 5.2.11), the intrinsic octanol water partitioning (PAB) was 2.17 
while the aqueous binding constant (K11aq) was found to be 0.48 mM
-1 (480 M-1). 
96.033.0 −= xY Equation 5.2.62 
 
As discussed before in chapter 5.1, ionic  and H-bond formation are expected to be the same 
between aspartic acid and CIP ion-pairs and glutamic acid and CIP ion-pairs due to the high 
similarity between the two amino acids in terms of the pKa values and number of H- bond 
donors and H-acceptors. Nevertheless, the aqueous binding constant (K11aq) between aspartic 
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acid and CIP was higher than the K11aq of gluatmic acid and CIP. These findings are 
contradictory to our previous findings in chapter 5.1. This can be possibly due to the zwitter 
ionic nature of CIP which could result in lower kinetic energy upon ion-pairing with aspartic 
acid resulting in higher aqueous binding constant.  
 
 
 
 
 
 
 
 
 
Figure 5.2.94:- Double reciprocal plot of the apparent octanol-water distribution coefficient of CIP as 
function of glutamic acid molar concentration. 
 
The permeability profile of CIP at various molar concentrations of glutamic acid was studied 
(Fig. 5.2.7). CIP, CIP glutamate salt and CIP glutamic acid PM 1:1 showed low absorption profile 
with highest permeation from the salt form (6.99±0.48%) after 90 minutes. Interestingly, 
increasing the molar concentrations of glutamic acid beyond 1:1 for PM ratio was found to 
have a significant effect on the permeability profile of CIP. The percentage of CIP absorbed 
from PM 1:2 formulations reached 9.7±2.6% after 30 minutes and exceeded 30% and 65% for 
PM 1:4 and PM 1:8 respectively. At the end of the permeability experiment 92.57±3.29% was 
absorbed from PM 1:4 and 100% of CIP was absorbed from 1:8 formulations. 
R2=0.99 
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Figure 5.2.95:- Percentage of CIP transported across Caco-2 monolayers at various molar ratios of 
glutamic acid (n=5). One way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey test) against drug alone at each time point were used for statistical analysis and 
probability values of (P< 0.05, * and P<0.001,***) were used to determine the significant difference. 
 
 
The apparent permeability (Papp) increased by around 10, 50 and 75 fold for CIP glutamic acid 
formulation containing PM 1:2, PM 1:4 and PM 1:8 respectively (Fig. 5.2.8). Our previous 
studies conducted on IND and TMP demonstrated that increasing the molar concentrations of 
the amino acids -especially beyond 1:2 ratio has a negative effect on the permeability profile of 
the therapeutic agents. Partitioning studies showed that increasing the molar concentration of 
glutamic acid results in increasing the concentration of CIP in the aqueous layer; i.e. more 
fraction of the drug is in the ionized form and therefore lower log P values. According to the 
pH-partitioning theory only the unionized form of the drug can permeate across the cellular 
membranes, however Palm et al (1999) have demonstrated that the ionised forms of the drugs 
can also be transported across the Caco-2 cells. Moreover, it can be expected that ion-pairing 
CIP with glutamic acid supports the reversion of zwitter ionic nature of CIP by proton transfer 
(Romanuk et al., 2010) from glutamic acid resulting in an overall anionic charge on the ion-
paired molecule (Fig. 5.2.9).  
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Figure 5.2.96:-  Papp permeability values at 60 minutesfor CIP alone and CIP at various molar ratios of 
aspartic acid and glutamic acid. One way analysis of variance (ANOVA) and pair-wise multiple 
comparisons method (Tukey test) against drug alone at each time point were used for statistical 
analysis and probability values of (P< 0.05, * and P<0.001,***) were used to determine the significant 
difference. 
 
 
 
 
 
 
 
Figure 5.2.97:- structure representing the reversion of the zwitter ionic nature of CIP by the proton 
transference from the glutamic acid and hence an overall anionic charge on ion-paired molecule. 
 
5.2.3.3. Effect of fed and fasted state on CIP permeability 
As discussed above the environment in fed state in the gastrointestinal tract might affect 
solubilisation and the degree of ionisation of the drugs. Moreover, food content might interact 
with the counter ion and prevent the uptake of the ion-paired CIP amino acid for transport 
across the intestinal membrane as one unit. Therefore, this study will investigate the effect of 
fast and fed state media on the absorption profile of CIP glutamate salt. CIP glutamate salt was 
selected for this study to determine the effect of media on salt absorption as it has shown to 
*** 
*** 
*** 
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have a relatively low Papp value (2.19x10
-06±4.39x10-07 cm/sec) and any improvement in 
permeability would be significant. 
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Figure 5.2.98:- Percentage of CIP glutamate salt transported across Caco-2 monolayers from HBSS, 
FaSSIF and FeSSIF media (n=5). One way analysis of variance (ANOVA) and pair-wise multiple 
comparisons method (Tukey test) against drug alone at each time point were used for statistical 
analysis and probability values of (P< 0.05, * and P<0.001,***) were used to determine the significant 
difference. 
 
Figure 5.2.10 shows the permeability profile for CIP glutamate salt in HBSS media, FaSSIF and 
FeSSIF. During the first 15 minutes of the permeability assay, the media did not have any effect 
on the absorption profile of CIP glutamate salt and no more than 2% of the salt was 
transported across the cell lines. After 30 minutes, the percentage of CIP absorbed from the 
salt form in the FeSSIF media increased significantly (p<0.001) when compared to the salt in 
HBSS and FaSSIF media and the total percentage permeated from  FeSSIF increased to reach 
26.84±2.9% after 90 minutes. On the other hand, the FaSSIF media did not have any significant 
effect (p> 0.05) on the percentage of CIP absorbed and the percentage absorbed after 90 
minutes did not exceed 10%. Apparent permeability calculations showed a significant increase 
of CIP apparent permeability in FeSSIF media (Papp= 7.35x10
-6±0.8x10-6cm/sec) and no 
significant effect in FaSSIF (Papp= 2.49x10
-6±0.7x10-6cm/sec) when compared to Papp (2.19x10
-
06±4.39x10-07 cm/sec) of CIP glutamate salt in HBSS. 
*** 
 
*** 
 
*** 
 
*** 
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Table 5.2.45:- The percentage recovery and TEER measurements before and after the permeability 
assay of CIP glutamate salt from HBSS, FaSSIF and FeSSIF (n=5). 
Media TEER measurements 
 (Ω/cm2) Before 
TEER measurements  
(Ω/cm2) After 
Recovery 
(%) 
HBSS 401.2±10.2 392.66±12.6 92.3 
FaSSIF 440.36±18.3 380.4±15.3 89.6 
FeSSIF 446.5±32.3 172±20.5 84 
 
Interestingly, the TEER values for Caco-2 cells in FeSSIF media dropped significantly at the end 
of the permeability assay (Table 5.2.6) possibly because of the high concentration of sodium 
taurocholate (10 mM) as well as the high osmolarity of the media (390±10). Similar results 
were obtained by Ingels et al., (2002) which demonstrated that FeSSIF with 15 mM of sodium 
taurocholate affects the morphology of the cells and disrupts the cellular nuclei and the stored 
glycogen. As a result the tight junctions between the epithelial cells become loose and more 
CIP molecules were able to be absorbed across Caco-2 cells. Moreover according to  
Meyerhoffer and McGown studies the concentration of sodium taurocholate in FeSSIF is in the 
critical micile concentration range  (Meyerhoffer and McGown., 1989). However, further 
investigations is required to confirm CMC formation. 
 
5.2.3.4. Effect of pH on CIP permeability 
CIP has a zwitter ionic nature and the pH of the media affects the dissolution profile of the 
drug and might have an impact on its absorption across the intestinal membrane. pH ranging 
between 4.5 and 6.8 were selected for this study in order to mimic the gastrointestinal tract 
pH (Neuhoff et al., 2005).  
Figure (5.2.11) shows the effect of three different pH (4.5, 5.5 and 6.8) environments on the 
permeability of CIP across Caco-2 monolayers. Lowering the apical pH from 6.8 to 4.5 shows a 
significant increase in the percentage of CIP absorbed across the cells. 
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Figure 5.2.99:- Percentage of CIP transported across Caco-2 monolayers at various pHs (n=5). One way 
analysis of variance (ANOVA) and pair-wise multiple comparisons method (Tukey test) against drug 
alone at each time point were used for statistical analysis and probability values of (P< 0.05, * and 
P<0.001,***) were used to determine the significant difference. 
 
 
After 5 minutes 2.31±0.68% CIP was absorbed at pH 6.8 and the percentage slightly changed to 
2.41±0.39% and significantly increased to 4.92±0.68% when the apical pH was dropped to 5.5 
and 4.5 respectively. The percentage of CIP transported increased from the transwells with 
lower pH (4.5) until it reached 9.34±0.098% after 90 minutes, while at higher pH the 
percentage transported did not exceed 4%. The improvement in permeability at lower pH 
could be attributed to the increase of CIP solubility as suggested by Li et al., (2007); this would 
subsequently have a significant impact on dissolution profile making a higher concentration of 
CIP available for permeability. Similar findings were reported by Lee et al., (2005) who found 
that changing the apical pH of Caco-2 monolayers from 7.4 to 6.5 resulted in a five to 8 fold 
increase in the apparent permeability of acidic and basic drugs. In contrast, conducting similar 
experiments in rabbit jejunum has not shown any impact on the drug uptake at different pHs 
(Shiau et al., 1985). The study concluded that the presence of an adherent layer of mucus gel 
on the rabbit jejunum acts as a protective barrier for the epithelial cells and maintains the 
*** 
*** 
*** 
*** *** 
*** 
*** 
* 
  292
acidic microclimate by hindering the movement of hydrogen within the surrounding matrix of 
the lumen (Shiau et al., 1985). 
 
Table 5.2.46:- The percentage recovery and TEER measurements before and after the permeability 
assay of CIP at pHs of 4.5, 5.5 and 6.8 (n=5). 
pH TEER measurements 
 (Ω/cm2) Before 
TEER measurements  
(Ω/cm2) After 
Recovery 
(%) 
4.5 427.3±48.01 370±13.28 90 
5.5 481.3±10.26 380.3±4.16 79.8 
6.8 456.6±15.2 390±22.24 87.2 
 
Microarrays studies 
5.2.3.5. Image analysis, data clustering and principle component analysis (PCA) 
According to our permeability studies, significant increase of the amount of CIP absorbed was 
observed. Hence, three formulations were selected for the microarray experiment namely CIP 
alone, CIP PM 1:1 and CIP PM 1:8 with glutamic acid. in order to visualise the genetic changes 
occurring during exposing the cells to the therapeutic agent and its ion-paired formulations 
with glutamic acid, three time points were selected 5, 30 and 60 minutes. Genetic changes that 
occur for Caco-2 cells without application of any therapeutic agents were selected as a control 
for this study (basal state). Prior to data normalization and clustering, the quality of the TIFF 
image obtained from the scanner was assessed for its quality. Spot centroids were located for 
each corner of the slides and only slides with correctly located spots were used in this study. A 
symmetric histogram of number of points against the logarithm of the processed signals was 
obtained for the used slides. Besides, all the slides used showed low multiplicative detrending 
and median coefficient of variation ranging between 3.6 and 7.01 which reflects the high 
reproducibility of the signals of the arrays. 
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Figure 5.2.100:- Microarray image analysis; spot finding for four corners (A), correlation between log 
signal against log Relative concentration (B) histogram of signals plot (C),  and spatial distribution of 
median signals for each column (D). Data were generated by feature extraction software. 
The data obtained from each microarray experiment is highly complex in terms of quantity and 
dimensions. In order to interpret the biological meaning of the obtained data, clustering and 
principle component analysis were carried out. After clustering the data using hierarchal 
clustering, PCA was studied in to identify the dimension of extension of the data as discussed 
earlier in TMP chapter. Eigen values were calculated using TMEV software and the data 
showed that 24.12% of the changes occur along the first component and 56.27% occurs along 
the first three components. Therefore, the principle component 1, principle component 2 and 
principle component 3 were used to describe the changes of the molecular state of the cell 
and to determine the dynamic trends during the absorption of CIP and its ion-paired 
formulations with glutamic acid. 
A B 
D C 
  294
Figure 5.2.13 shows that some of the data are gathered around the origin and these samples 
show minimal variation in gene expression over the time course of the experiment. 
Interestingly, significant variations were observed at 30 minutes at principle component 1. And 
it seems that the formulations have played a significant role in such variation as CIP alone, CIP 
1x (i.e. CIP: glutamic acid at 1:1 molar ratio) and CIP 8x (i.e. CIP: glutamic acid at 1:8 molar 
ratio) were separated from the rest of the samples (Fig. 5.2.13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.101:- First and second principal component analysis on the transcriptional time course (0, 
30 and 60 minutes) for CIP and its various ion-paired formulations. The number represents the time 
points. The plot represents the data for the mean values at each time point. 
 
 
On the other hand, principle component analysis for component 2 and 3 has showed a 
maximum variation based on the duration of the experiments. In another word, expression 
changes at 5 minutes varied from expression changes occurred at 30 minutes and both varied 
from the changes occurred at 60 minutes (Fig. 5.2.14).  
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Figure 5.2.102:- Second and third principal component analysis on the transcriptional time course (0, 
30 and 60 minutes) for CIP and its various ion-paired formulations. The number represents the time 
points. The plot represents the data for the mean values at each time point. 
 
 
 
5.2.3.6. Genetic changes of transporters pathways 
 
Approximately 45,000 cDNA were hybridized with the microarray chip probes in order to 
investigate the systemic changes of the gene expression occurring during CIP transportation 
study. Genes which were over-expressed or down-regulated by at least two fold when 
compared against the control were selected for this study. Equations 5.2.12 & 5.2.13 were 
used to calculate the level of up or down regulation of the expressed genes when compared 
against the control (Caco-2 cells). 
)(
)( 2
CE
CEIF
−
> =     Equation 5.2.63 
)(
)( 2
EC
CEIF
−
< −=   Equation 5.2.64 
 
The results showed that a total of 104 genes including 2 genes that code for drug transport 
were over-expressed after 5 minutes of exposing the cells to CIP alone when compared to 
control (Caco2 cells). On the other hand, 248 genes were down-regulated at the same time 
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point. Exposing the cells to CIP alone formulations for longer time (30 minutes) resulted in 
activation of  1790 genes (over-expressed by at least 2 fold), while 229 genes were down 
regulated suggesting that a turnaround time between 5 and 30 minutes is essential to 
determine any significant gene expression changes when studying drug transport. The total 
number of both over-expressed and down-regulated genes began to drop again after 60 
minutes as shown in Fig. (5.2.15). 
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Figure 5.2.103:- Total number of genes up and down-regulated upon exposing the cells to CIP alone 
formulation at different time courses. 
 
The next stage of data evaluation was focused on identifying various genes that are involved in 
drug transport from the total set of  genetic changes (Fig. 5.2.15) and Table (5.2.8) summarises 
the genes over-expressed upon exposing Caco-2 cells to CIP alone formulations for 5, 30 and 
60 minutes.  
As data analysis using PCA indicated that major changes in expression profile occur after 30 
minutes, genes exhibiting significant variations were uploaded onto KEGG to determine their 
role in various cellular pathways. Pathway analysis of significant genes showed that 15 
different pathways including metabolic pathways, cytokine-cytokine interactions, pathways in 
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cancer, neuroactive ligand receptor interaction and regulation of actin cytoskeleton were 
affected. 
Table 5.2.47:- Summary of the over-expressed transporter genes upon exposing Caco-2 cells to CIP 
alone formulations for 5, 30 and 60 minutes. 
Time point Probes Gene symbol Expression level 
5  
minutes 
A_23_P307570 ABCC13 3.163352 
A_23_P159851 SLC7A3 4.083838 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
minutes 
A_23_P215720 CFTR 2.01546 
A_24_P222291 ABCC4 2.32746 
A_23_P82523 ABCB1 3.996312 
A_23_P28246 SLC23A3 2.223539 
A_32_P130630 SLC16A7 5.549221 
A_24_P131880 SLC10A7 2.940933 
A_23_P355377 SLC12A5 2.028348 
A_24_P382467 SLC39A3 2.702885 
A_32_P381593 SLC26A7 15.35347 
A_24_P342829 SLC16A14 2.441215 
A_23_P137097 SLC16A2 3.813012 
A_23_P388900 SLC22A15 23.0606 
A_24_P910660 SLC6A2 4.799098 
A_32_P812442 SLC36A3 2.250099 
A_24_P270688 SLC38A7 2.482864 
A_23_P13725 SLC6A15 9.024523 
A_23_P77653 SLC12A3 2.828382 
A_23_P388170 SLC39A3 4.650775 
A_23_P159076 SLC17A8 2.137794 
A_23_P418562 SLC6A11 5.915653 
A_24_P191312 SLC1A4 4.691002 
A_23_P389799 SLC25A42 3.16615 
A_23_P431734 SLC25A37 4.422084 
A_24_P21829 SLC22A24 8.132694 
A_24_P913210 SLC11A2 2.042913 
A_24_P397435 SLC6A3 10.85624 
A_24_P101941 SLCO4C1 2.927174 
60 
minutes 
A_23_P166297 ABCG1 -2.29228 
A_23_P143309 SLC4A11 -2.68538 
 
By looking at ATP-binding cassette (ABC) transporter network (Fig. 5.2.16) it was observed that 
among the all ABC carriers only three (ABCB1, ABCC4 and CFTR) were over-expressed 
significantly after treating Caco-2 cells with CIP alone for 30 minutes as outlined in  (Fig. 
5.2.16). 
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Figure 5.2.104:- Graph high-lightening the over-expressed ABC transporters during the absorption of 
CIP across Caco-2 cells. The graph was generated by KEGG online database. 
 
 
ABCB1 which is also known as MDR1 or P-gp is an ATP-binding cassette transporter belonging 
to subfamily B (member 1) was 3.99 fold over-expressed when compared against the basal 
state of the cells (control; Caco-2 cells without drug treatment). These findings come in line 
with the results suggested by Park et al., (2011). Park and co-workers demonstrated that 
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MDCK1 and MDCK1-MDR1 cells over-express P-gp upon exposure to CIP and the basal/apical 
flux of CIP decreases if P-gp inhibitors such as ketoconazole, vinblastine and verapamil are 
used. The fourth member of the ATP-binding cassette subfamily 4 (ABCC4) is another over-
expressed gene upon treating the cells with CIP alone for 30 minutes as it was up-regulated by 
2.3 fold. ABCC4 is a multidrug resistance-associated protein and also known as MRP4 and plays 
a role in transporting organic anions. Marquez et al (2009) believed that the efflux of CIP is 
mediated by one of the multidrug resistance associated proteins. The study showed that MRP2 
and MRP4 are up-regulated in CIP resistance cells with the expression of MRP4 
overwhelmingly predominant than MRP2 (Marquez et al., 2009). 
 
CFTR or cystic fibrosis transmembrane conductance regulator is another ABC transporter that 
was over-expressed by 2.01 fold in CIP alone formulations. CFTR is the 7th member of MRP 
family and functions as a chloride channel. The mutation of this gene was associated with an 
autosomal recessive disorder known as cystic fibrosis. No studies have evaluated the role of 
CFTR in the transport of CIP apart from Marquez et al (2009) who suggested that CFTR (MRP7) 
plays no role in the efflux of CIP. 
 
Interestingly, treating Caco-2 cells with CIP alone formulations for 30 minutes resulted in 
triggering various signalling pathways which are involved in the tight junction (TJs) assembly. 
TJs define the boundaries between the apical and basolateral plasma membrane as they work 
as paracellular barriers that limit the uptake of solutes across the intercellular space (Salama et 
al., 2006). TJs are assembled by cascade of biochemical events in the cells which lead to the 
formation of various elements of the TJs which have only been partially characterized (Tsukita 
and Furuse, 1999). They are mainly composed of three proteins: occludin, claudin and 
immunoglobulin as adhesion protein (Matter and Balda, 2003). Assembly of TJ components is 
mediated by signalling pathways such as protein kinase A (PKA) and protein kinase C (PKC) 
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which regulates the junction pore size and cell polarity. Partition defective genes (PAR) are 
other signalling modulators that have two members; PAR3 and PAR6. PAR3 binds with PAR6 
and PCKs to form PKC-PAR3-PAR6 complex that form TJ and build epithelial polarization 
(Matter and Balda, 2003). 
Among the up-regulated PKC genes were protein kinase C beta (PRKCB) and protein kinase 
cGMP (PRKG1) which were over-expressed by 6.4 and 8.09 fold respectively (Fig. 5.2.17). From 
the partitioning defective genes, PAR6 was over-expressed by 13.9 fold (Fig. 5.2.17). Moreover, 
various genes associated with myosin light chain regulation such as MYO16, MYL7, MYL2 and 
MYO3B were over-expressed by 3.22, 2.4, 3.33 and 3.94 fold respectively. These genes activate 
myosin formation which serves as a link to the plasma membrane (Anderson et al., 1995). 
These results suggest that CIP would play a significant role in modulating the assembly of tight 
junctions across the epithelial cells and this could be another barrier that hinders CIP influx 
besides the efflux proteins. 
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Figure 5.2.105:- The activated signalling pathways involved in tight junction formation. Activated 
mediators are highlighted in red. The graph was generated by KEGG online database. 
 
The genetic changes that occur upon exposing the monolayers to the ion-paired formulations: 
CIP PM 1:1 and CIP PM 1:8 on Caco-2 cells were also investigated. Majority of the changes that 
took place for the transporter network were observed for solute carrier transporters and only 
few changes were recorded for ATP-binging cassettes (Fig. 5.2.18). CIP: glutamic acid PM at 1:1 
molar ratio did not stimulate the over-expression of ABCB1 (P-gp) nor ABCC4 (MRP4) genes 
during the entire time course of the experiment. Moreover, the expression profile of P-gp and 
MRP4 were down regulated by 2.6 and 2.59 fold after 30 minutes of exposure to the 1:1 ion-
paired formulations (Fig. 5.2.18). These results suggest that ion-paired formulations mask the 
triggering effects of CIP on the efflux protein and that both P-gp and MRP4 failed to identify 
CIP when it was formulated as an ion-pair with glutamic acid.   
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Besides, comparing the expression patterns of some of the genes as listed in Fig. 5.2.18 and 
(Table5.2.8) the results show that the genes up-regulated upon exposure to CIP were down-
regulated to their basal state when the ion-paired formulations were used. For instance, 
ABCC13 and SLC7A3 were over-expressed by 3.16 and 4.08 fold respectively when the cells 
were exposed to CIP alone formulations but were down-regulated by 2.03 and 3.65 fold 
respectively when 1:1 molar ratio of ion-paired formulations were used which further confirms 
the inability of the transporters to identify CIP when it is ion-paired. 
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Figure 5.2.106:- Gene expression of ABC and SLC transporters of Caco-2 cells after 5, 30 and 60 minutes of exposure to CIP : glutamic acid formulations at 1:1 ratio. 
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Permeability data showed that increasing the molar concentration of glutamic acid in the 
formulations results in an increase in the overall uptake of CIP (Fig. 5.2.7). Nevertheless, 
partitioning studies have demonstrated that there is a steady decline of drug partition upon 
increasing the counter ion concentration (Fig. 5.2.5). Permeability data coupled with 
partitioning studies suggest that CIP fails to permeate across the lipid bilayers of Caco-2 cells 
and it is possible that there are cellular mechanisms responsible for the differences in 
permeability profile.  
The genetic changes that occurs upon using CIP:glutamic acid 1:8 formulations were 
investigated and summarised in (Fig. 5.2.19) and table (5.2.9). 
 During the first 5 minutes 7 transporter genes were over-expressed; all of the over-expressed 
genes belong to solute transporter carriers (Fig. 5.2.19A). 
 
 
 
 
 
 
 
 
Figure 5.2.107:- Up-regulated (   )   and down-regulated(    ) genes after exposing Caco-2 cells to CIP: 
glutamic acid at 1:8 molar ratio after (A) 5 minutes, (B) 30 minutes and (C) 60 minutes. 
 
Among the over-expressed solute carriers genes were amino acid transporters; SLC6A15 and 
SLC6A1. It can be hypothesised that the high content of glutamic acid in 1:8 formulations 
results in the over-expression of these transporters. Both the transporters belong to family 6 
(Fig. 5.2.20) of the solute carrier transporters which play a significant role in transport of  a 
broad range of amino acids across the epithelial cells and also remove any neurotransmitters 
7
2 6
26
3
2
A B C 
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from brain cells (Broer et al., 2006; Takanaga et al., 2005). SLC6A15 was first isolated by Uhl 
and co-workers in 1992 and is a Na+ dependent and Cl- independent transporter. Later it was 
found that it has affinity to alanine, glutamine, proline, leucine isoleucine and methionine.  
SLC6A1 on the other hand (also known as GAT1) is considered the predominant transporter for 
γ-amino butyric acid (Chen et al., 2004). 
SLC6A15 and SLC6A1 were over-expressed by 2.12 and 2.56 respectively upon treating the cells 
with 1:8 molar ratio of CIP: glutamic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.108:- Phylogenetic tree of various members of the human SLC6 transporter family adapted 
from Takanaga et al., 2005. 
 
Interestingly, SLCO1A2 -an organic anion transporting polypeptide (OATPs)- was also over-
expressed after 5 minutes (Table 5.2.9). The first member of OATPs was isolated in 1994 from 
rat liver and is believed to transport a variety of organic compounds in a sodium independent 
manner (Geyer et al., 2004). SLCO1A2 (also known as OATP1A2) was up-regulated  2.13 fold, 
and is possible that  the loss of the zwitter ionic nature of CIP upon ion-pairing with glutamic 
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acid results in the up-regulation of SLCO1A2 as the ion-paired complex carries a net negative 
charge as discussed earlier. 
Another up-regulated solute carrier transporter was SLC15A2 which belongs to a peptide 
transporter family and mediates the uptake of dipeptides and tripeptides (Rubio-Aliaga and 
Daniel., 2002). Two peptide transporters SLC15A1 (PEPT1) and SLC15A2 (PEPT2) have been 
identified in mammalian cells. Both PEPT1 and PEPT2 have similar function but differ in affinity 
and capacity. The two peptide transporters have been reported as potential targets for 
prodrug absorption. The uptake of L-DOPA L-Phe prodrug (Tamai, et al. 1998) and acyclovir L-
valyl ester (Ganapathy, et al. 1998) was increased by several fold as their uptake was mediated 
by PEPT1 and PEPT2. It is possible that besides the organic anionic transporter, PEPT2 
(SLC15A2) also mediates the uptake of the ion-paired formulations and hence results in the 
increase of CIP uptake across the Caco-2 monolayers. 
 
Table 5.2.48:- Over-expressed genes upon exposure to CIP:glutamic acid at 1:8 molar ratio. 
Time point Probes Gene symbol Expression level 
5 
 minutes 
A_23_P131111 SLC27A1 2.037017 
A_24_P307653 SLC6A15 2.124151 
A_23_P13820 SLCO1A2 2.129753 
A_24_P268685 SLC6A1 2.564218 
A_23_P160159 SLC2A5 68.07858 
A_23_P22625 SLC9A6 6.909355 
A_24_P208345 SLC45A3 17.85949 
30 
 minutes 
A_23_P43504 ABCA2 2.777874 
A_23_P133694 SLC29A1 2.365923 
A_24_P79153 SCAMP4 2.263806 
A_23_P77049 SLC25A29 2.148496 
A_23_P316960 GRINA 2.094572 
A_23_P210521 SLC2A10 2.780049 
60 
 minutes 
A_24_P74508 SLC25A18 2.632616 
A_23_P92107 SLC15A2 2.270138 
A_23_P212379 SLC6A20 2.991979 
 
Moreover, the efflux transporter genes; P-gp and MRP4 were down-regulated by 3.3 and 2.2 
fold respectively upon using the ion-paired formulations at 1:8. The genetic profiling of the 
transporter genes demonstrated that the efflux transporters were down-regulated to their 
basal state upon the ion-pairing the formulations. The data also showed that ion-pairing has 
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resulted in new routes for uptake of CIP across the membrane which explains the increase in 
permeability profile despite the decrease in partitioning capacities of the drug upon pairing 
with the anionic counter ion. 
 
5.2.3.7. Genetic changes of metabolic pathways and other pathways 
Microarray data analysis has also revealed that other pathways in addition to transporter 
pathways were significantly affected during the time course of the experiment upon ion-
pairing CIP formulations.  
Cellular metabolism was among the most affected pathways during drug uptake. Four 
metabolic pathways were up-regulated when the Caco-2 cells were exposed to CIP for 5 
minutes. The number of metabolic pathways increased to 36 when the drug was left to 
permeate for 30 minutes. The majority of the up-regulated pathways were involved in Glycan, 
carbohydrates and lipid metabolism (Fig. 5.2.21).  Metabolism of glycan and carbohydrates is 
considered the major carbon and energy source for living cells. During glycan metabolism, 
oxidative processes are involved which utilize the produced electrons to form ATP which is 
considered as a fast energy source for the cells. It can be hypothesised that the high glycan 
metabolism was stimulated by the cells in order to produce more ATP which is required by the 
efflux transporters (MRP4 and P-gp). On the other hand, using the ion-paired formulations 
showed a significant drop in the pathways involved in glycan and carbohydrates metabolism 
(Fig. 5.2.22) again re iterating that the presence of oppositely charged ions masks the 
identification of CIP and that alternate pathways are used for drug permeation.   
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Figure 5.2.109:- Glycan synthesis and metabolism after 30 minutes of exposure to CIP alone formulations. The graph was generated by KEGG online database. 
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Figure 5.2.110:- Amino acid metabolic pathways activated after 30 minutes of exposure to CIP:glutamic acid at 1:1 molar ratio formulations. The graph was generated 
by KEGG online database. 
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Calcium signalling was another pathway that was found to be affected by exposing the cells to 
CIP. Calcium is essential to trigger the activity of nitric oxide synthase (NOS) in order to 
produce nitric oxide (NO).   Nitric oxide is a universal intracellular messenger that modulates 
the normal activities, blood flow and also plays a role in protecting the cells against pathogens 
as it works as non-specific host defence (Pacher et al., 2007). Interestingly, CIP was found to 
deactivate NOS which could be because of the high ability of CIP to chelate with calcium 
(Susana et al., 2002) which in turn reduces Ca+2 concentration and NOS production. In order to 
decrease the Ca+2 flux into the mitochondria, voltage dependent anion channel (VDAC) was 
deactivated (Fig. 5.2.23) in a trial to decrease the calcium flux into the mitochondria as 
suggested by Tan and Colombini (2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.111:- Down-regulated mediators (highlighted in red) involved in calcium signalling 
pathways during CIP uptake across Caco-2 cells and after 30 minutes of the permeability assay. The 
graph was generated by KEGG online database 
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Calcium signalling pathway was reverted to the normal state upon coupling CIP with glutamic 
acid which reflects the stability of the formed ion-pair over complex formation with 
intracellular calcium. 
 
5.2.4. Conclusion 
CIP is a BCS IV drug that has low solubility and low permeability and it is believed that the small 
intestine plays a major role in its excretion. Despite showing high partitioning capacities in the 
organic phases, CIP permeability across Caco-2 monolayers was very low and did not exceed 
10% after 90 minutes of the permeability assay. Microarray data showed that P-gp and MRP4 
were over-expressed when the cells were exposed to CIP and they are believed to mediate the 
efflux of the drug. Moreover, tight junction formation was stimulated by CIP and this could be 
another barrier for CIP uptake. On the other hand, ion-pairing CIP with glutamic acid resulted 
in a significant improvement of CIP absorption as the apparent permeability increased by 10, 
50 and 75 fold for PM 1:2, PM 1:4 and PM 1:8 respectively. Two solute carrier transporters 
(SLCO1A2 and SLC15A1) were up-regulated upon using the ion-paired formulations. It seems 
that these two carriers mediates the uptake of the ion-paired formulation especially SLCO1A2 
because the ion-paired CIP carries anionic charge which might have stimulated the organic 
anion transporters. In conclusion, the improved uptake of CIP ion-paired formulations could be 
due to the reduced efflux by ABC transporters or increased entry and transport via new solute 
carrier transporters. 
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Conclusion 
Biopharmaceutical properties of drug candidates have a great impact on their bioavailability as 
it was recognised that both the rate and extent of oral drug bioavailability is controlled by the 
aqueous solubility and gastro-intestinal permeability of the therapeutic agents (Amidon et al., 
1995). Therefore a new biopharmaceutical classification system was introduced in 1995 and 
accepted by FDA in 2000. Various physical and chemical techniques were adapted in order to 
improve aqueous solubility and intestinal uptake. Solid dispersion, cyclodextrins and prodrugs 
were among the commonly used techniques for this purpose. The theory behind prodrug 
synthesis is binding additional functional groups onto the structure of the poorly water soluble 
drug molecule to enhance its solubility. This functional group splits from the drug molecule in 
vivo by enzymes. Interestingly scientists managed to use prodrugs to mask polar groups on 
therapeutic agents and hence improve the drugs ability to partition across membranes (Weller 
et al., 1993). Despite their great success, prodrugs have shown low solubilities which self limit 
their use as bioavailability enhancers (Majumdar et al., 2004). Moreover, prodrugs are new 
chemical entities and they may be inert and/or toxic. Therefore, looking for alternative 
methods that can improve drug bioavailability in a safe way became a must. 
 
Counter ions were first introduced to improve solubility of low water soluble drugs until Irewin 
et al demonstrated that the rate and efficacy of isopropamide was improved upon ion-pairing 
with trichloroacetate. Since their introduction many studies tried to propose their mechanism 
of action as permeability enhancers. Quintanar-Gueerrero et al (1997) suggested that ion-pairs 
could lower the interfacial tension of the gut wall by binding to mucosal membrane.  
 
In the current study, the use of amino acids as solubility and permeability enhancers for three 
model drugs was investigated. The first drug candidate is a weak acidic drug classified as BCS II 
as it solubility was found to be 0.244 µg/mL at pH of 4.95. This low solubility was found to 
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improve upon adding arginine and lysine at increasing concentrations as suggested by phase 
solubility diagram. Therefore, it was believed that both arginine and lysine could form highly 
soluble salts with IND. FT-IR confirmed salt formation as the spectrum of the carbonyl 
stretching of acidic group of IND disappeared due to the loss of proton and the involvement of 
the carboxylic group in the salt formation with the basic amino acids. Moreover, because salts 
have different physical properties from their components, IND arginine and IND lysine salts 
showed new melting endotherms at 209.73 oC and 223.26 oC respectively. Failure of histidine 
to bind strongly with IND was attributed to the low difference between their pka values. The 
aqueous solubility of IND improved by 2x103 and 104 fold for IND arginine and IND lysine salts 
respectively. 
Similarly, the solubility of TMP and CIP were enhanced by forming new salts with acidic amino 
acids. Although CIP is zwitter ionic in nature the drug only managed to form new salts with 
anionic amino acids; glutamic acid and aspartic acid resulting in increasing the solubility to 
215±13.3 mg/mL and 185.4±8.6 mg/mL respectively. Simulation studies demonstrated that CIP 
hydrophobic interaction between its molecules decrease in the presence of acidic amino acids 
and in turn form stable salts, these interactions were not affected in the presence of arginine 
or lysine.  
 
Results from chapters 3.1, 4.1 and 5.1 demonstrate high solubility and dissolution of IND, TMP 
and CIP salts reflecting the high ionisation of the salt form. Therefore, excess amounts of the 
counter ions were added in a trial to shift the salt ionisation equilibrium towards the non-
ionised form of the salt. Octanol/water partitioning studies revealed that increasing the molar 
ratio of the counter ions results in a significant drop in the partitioning capacities for all the 
drugs in octanol organic layer. Nevertheless permeability data showed a significant increase in 
drug absorption especially for PMs of 1:2 molar ratios suggesting that active carrier might have 
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been involved in the absorption process of the ion-paired formulations as the drugs passive 
uptake is deteriorated by the presence of the counter ions. 
 
Therefore, we believed that looking at the genetic changes occurring at the cellular levels of 
Caco-2 cells could enable better understanding about the involvement of any transporter 
carriers. DNA microarrays were used for this purpose as it enables visualising the systemic 
changes of 45,000 genes in one experiment. During TMP uptake across the monolayers, MRP7 
were over-expressed significantly in more than one replicate probe across the array chip 
reflecting the high involvement of MRP7 in extruding TMP out of the cells. Although majorities 
of previous studies (Joseph et al., 2001; Murakami and Takano 2008) reported the involvement 
P-gp in TMP efflux, the current study showed a minimal role played by P-gp in mediating TMP 
efflux. Interestingly, TMP uptake was found to be mediated by organic cation transporters 
such as OCTN1 which was up-regulated by 2.36 fold during TMP absorption. The molar ratio of 
glutamic acid was found to affect the expression of OCTN1 as it expression reached 2.2 fold for 
1:1 formulations and dropped to the basal state for 1:8 ion-paired formulations and hence the 
parabolic permeability profile was observed for TMP uptake. 
 
Nevertheless, looking at the genetic changes that accompanied CIP uptake showed that P-gp 
and MRP4 were over-expressed when the cells were exposed to CIP and they are believed to 
mediate the efflux of the drug. Besides, tight junction formation was stimulated by CIP and this 
could be another barrier for CIP uptake. It seems that the anionic nature of the ion-paired CIP-
glutamic acid stimulated the expression of SLCO1A2 transporters, while the high aqueous 
binding constant for their ion-pair (480 M-1) allowed them to get absorbed as one entity 
through dipeptidyl transporters (SLC15A1). 
Besides showing the high involvement of transporter carriers in the uptake of free drugs and 
their ion-paired formulations, microarrays showed the involvement of various metabolic 
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pathways on drug pharmacokinetics and the pharmacodynamic effects of the drug on the 
cellular signalling pathways.  
In conclusion, amino acids could be used as a successful tool to improve the biopharmaceutical 
properties of drug candidates upon ion-pairing. Microarrays could be used as a powerful tool 
to screen new chemical entities’ metabolic, toxic and absorption pathways. 
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A1.1. Validation of the HPLC method for indomethacin 
Indomethacin was eluted using Acetonitrile (60%) and 0.1 M acetic acid (40%) as a mobile 
phase and pumped at 1.0 mL/min flow rate.  
Indomethacin was first solubilised in the mobile phase and λmax was determined using 
scanning spectrophotometer over wavelength ranging between 200-400 nm. The maximum 
absorbance was 248 nm, therefore the HPLC detector was set at 248 nm to analyse 
indomethacin concentration. 
HPLC was used as the analysis method and was validated using ICH guidelines; HPLC specificity, 
precision and linearity were evaluated. 
Specificity was evaluated by injecting solution of the free bases (without indomethacin) into 
the HPLC and absence of any interference peaks at indomethacin retention time (6.5±0.12 
min) was demonstrated see figure A1.1. 
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Figure A1.112:- Typical HPLC chromatogram of IND (Concentrations 50 and 100 µg/mL at 248 nm) 
 
  345 
Repeatability (Instrumental and method precision) was also evaluated; method precision was 
demonstrated by preparing indomethacin samples (in concentration range between 10- 
500µg/mL) in triplicate and injecting them into the HPLC. The peak area R.S.D (%) ranged 
between 0.5- 1% which is considered acceptable. Instrumental precision was also 
demonstrated by injecting 100µg/mL indomethacin three times and the R.S.D (%) was 1.06% 
Inter-day precision was estimated from analysis of freshly prepared samples after few days 
and no significant difference was observed. The limit of detection (LOD) and limit of 
quantification (LOQ) were estimated in accordance to standard deviation of response and the 
slope and calculated using (Equation A1.1) 
 
S
LOD σ3.3=  Equation A1.65 
where σ is the standard deviation of response (0.025) and S is the slope of the calibration 
curve (1.54). LOD was found to be 0.05 µg. 
Where as LOQ was calculated using equation (A1.2) and the LOQ was found to be 0.15 µg.  
 
S
LOQ σ10=  Equation 66 
Indomethacin calibration curve was constructed by plotting the peak area against 
indomethacin concentration over a concentration range between 10-500 µg/mL. Beer-Lambert 
plot was obtained with curve equation y= 1.511 x and correlation factor R2 = 0.9994 which 
indicates the good linearity of the curve (Fig. A1.3). Therefore, the curve equation can be used 
to get any unknown concentration by measuring its peak area. 
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Figure A1.113:- indomethacin calibration curve (n=3) 
 
 
A1.2. HPLC validation for trimethoprim 
HPLC was operated at ambient temperature on RP-C18, (Phenomenex 110A, 150x4.6 mm, 
5µm) column using acetonitrile-NaH2PO4 buffer (10 mM) (70:30, v/v) (pH 3) as mobile phase 
which was pumped at 1.0 mL/min flow rate using gradient pump (GP50).  λmax was determined 
by Gallego and Arroyo (2002) to be 230 nm , therefore the HPLC detector was set at 230 nm to 
analyse TMP concentration. HPLC was used as the analysis method and was validated using 
ICH guidelines; HPLC specificity, precision and linearity were evaluated as mentioned above in 
section (A1.1). 
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Figure 114:- Typical HPLC chromatogram of TMP (Concentrations 20, 50 and 100 µg/mL at 230 nm) 
 
LOD and LOQ were calculated using standard deviation of response and slope using equation 
(A1.1 & A1.2). The standard deviation of response (σ) was found to be 0.043 and the slope of 
the calibration curve (S= 1.54). Applying these values to the equation above LOD and LOQ 
were found to be 0.109 and 0.364 respectively.  
TMP calibration curve was constructed by plotting the peak area against TMP concentration 
over a concentration range between 10-500 µg/mL. Beer-Lambert plot was obtained with 
curve equation y= 1.2 x and correlation factor R2 = 0.9992 (Fig. A1.4) which indicates the good 
linearity of the curve. Therefore, the curve equation can be used to get any unknown 
concentration by measuring its peak area. 
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Figure A1.115:- TMP standard calibration curve (n=3) 
 
A1.3. HPLC optimization and validation for Ciprofloxacin 
CIP was assayed using HPLC method adapted from (Kmetec et al., 1999). According to Kmetec 
et al, the mobile phase consists of methanol: 0.02 M phosphate buffer (pH 7) at flow rate of 
1mL/min. CIP was found not to be soluble in the mobile phase even at very low concentration. 
Therefore another method was adapted from (Husain et al., 1995) in which the mobile phase 
consisted of methanol: water: acetic acid (84:15.9: 0.1) with flow rate of 1 mL/min and λmax of 
254 nm. CIP was soluble in the mobile phase, yet a front tailing was observed (Fig. A1.5).  
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Figure A1.116:- HPLC chromatogram of CIP (concentration 20 and 50 µg/mL at 254 nm) 
In order to reduce such tailing, λmax was measured by UV scanning sprctrophotometer and was 
found to be 280 nm. The UV detector of HPLC was adjusted into the new λmax and a single peak 
was retained at 1.24 min corresponding to CIP. 
A calibration curve was constructed between 10 µg/mL to 200 µg/mL with curve equation of 
y= 1.57x+13.59 and correlation factor R2 = 0.996. 
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Figure A1.117:- Typical HPLC chromatogram of CIP calibration (Concentration 50µg/mL eluted at 1.24 
min using methanol:water: Acetic acid (840:159:1) at 1 ml/min flow rate). 
 
Upon studying CIP saturation solubility in water, a peak tailing was observed (Fig. A1.7). 
Therefore, it was a must to change the composition of the mobile phase in order to improve 
the affinity of CIP to the mobile phase and improve the drug retention peak characteristics. 
Acetic acid ratio has doubled and the new composition of the mobile phase became methanol: 
water: acetic acid (84:15.8: 0.2). 
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Figure A1.118:- Typical HPLC chromatogram of CIP samples solubilised in water (Saturated solubility, 
samples were eluted by methanol:water: Acetic acid (840:159:1) at 1 ml/min flow rate). 
 
CIP was solubilised in the new mobile phase and a calibration curve was constructed between 
10 and 200 µg/mL with curve equation of y=1.53x+18.9 and R2 of 0.998. HPLC was used as the 
analysis method and was validated using ICH guidelines; HPLC specificity, precision and 
linearity were evaluated as mentioned above in section (A1.1). 
LOD and LOQ were calculated using standard deviation of response and slope using equation 
(A1.1 & A1.2). The standard deviation of response (σ) was found to be 0.056 and the slope of 
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the calibration curve (S= 1.57). Applying these values to the equation above LOD and LOQ 
were found to be 0.107 and 0.356 respectively. 
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Figure 119:- CIP calibration curve (samples were eluted by methanol:water: Acetic acid (840:158:2) at 
1 ml/min flow rate and λmax  of 280 nm). 
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Appendix 2 
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Figure A2.1:-
1
HNMR spectra of trimethoprim D-glutamate solubilised in D2O. 
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Figure A2.2:- 
1
HNMR spectra of trimethoprim D- aspartate solubilised in D2O. 
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